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Chapter 1General introduction and outline of the thesis
DUCTAL CARCINOMA IN SITU
Breast cancer is the most common cancer in women worldwide.1 In the Netherlands, 
1 out of 7 women are diagnosed with breast cancer during her life and this incidence 
is still rising.2 Although the prognosis improved over the last decades, it is still the 
deadliest cancer in women worldwide.1 Ductal carcinoma in situ (DCIS) is regarded 
as a non-obligate precursor of invasive breast cancer (IBC).3 DCIS is characterized 
by an intraductal proliferation of neoplastic epithelial cells within the mammary 
ductal-lobular system (Figure 1).4,5 There is an intact myoepithelial cell layer and 
basement membrane without invasion in the surrounding stromal tissue. Risk factors 
for DCIS are similar as described for IBC such as older age, family history of breast 
cancer, null parity or an older age at first pregnancy.6-8 The detection rate of DCIS has 
rapidly increased over the last decades as a result of the increased use and improved 
resolution of mammographic screening.9 Currently, DCIS accounts for approximately 
15-30% of all breast carcinomas detected in the well-screened population.
Male breast cancer is rare, representing <1% of all breast cancer cases worldwide.10 
Despite its low prevalence, male breast cancer is associated with a worse outcome 
than female breast cancer patients due to a more advanced stage at presentation.10-12 
In this group of patients, breast precursor lesions are poorly described and 
understood. Improved understanding of carcinogenesis in the male breast could 
therefore result in earlier detection of these lesions.
Figure 1. Neoplastic cells initially arise and grow inside milk ducts. Normal breast ducts with luminal and 
myoepithelial cells, surrounded by a basement membrane. DCIS shows intraluminal growth of neoplastic 
cells with an intact myoepithelial layer and basement membrane. Invasive carcinoma is characterized 
by neoplastic cells in the surrounding stroma with no myoepithelial layer and basement membrane.
DCIS subtypes
Based on nuclear grade, DCIS can be categorized as low, intermediate or high 
grade.13 Various growth patterns are recognized, based on the arrangement of the 
intraductal neoplastic cells, i.e. solid, cribriform, micropapillary and papillary. DCIS 
is a heterogeneous disease and can also be classified into several subtypes that 
are originally described for IBC.14-17 Originally, these subtypes are based on gene 
expression patterns, but each subtype has an immunohistochemical surrogate 
based on ER, PR, HER2, and Ki-67 index18 :luminal (ER+ with or without HER2+), basal 
(triple negative (ER-, PR- and HER2-) and HER2-driven (ER-, HER2+). These subtypes 
are strongly associated with clinical outcome and therapeutic decisions. There is a 
strong correlation between histological grade and molecular subtype: ER+/HER2- 
tumors are more likely to be low grade whereas ER-/HER2+ and triple negative tumors 
are more likely to be high grade.19,20 In addition, comparative genomic hybridization 
(CGH) studies reported a strong correlation between specific copy number alterations 
1
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and histological tumor grade, in which high grade lesions demonstrated complex 
genomic alterations.
Biological behavior of DCIS
DCIS is regarded as a precursor of IBC, as mentioned above.3 This is supported by 
remarkable similarities between DCIS and adjacent paired IBC at the morphological 
and molecular level.3,21,22 Molecular concordance was initially demonstrated by 
CGH and gene expression studies. In line with this, known breast cancer mutations, 
including TP53 and PIK3CA, were also observed at the in situ stage by in-depth 
sequence studies.23,24 Currently, it is generally accepted that there are multiple parallel 
pathways of breast carcinogenesis, rather than a linear progression from low grade 
to high grade: low grade carcinomas arise from low grade DCIS and have a good 
prognosis while high grade carcinomas arise from high grade DCIS, which is associated 
with a worse prognosis.25-27 However, data is limited regarding the treatment-naive 
behavior of DCIS, since most patients are treated. Untreated, a subset of DCIS cases, 
estimated around 40-50%, will progress to invasive disease, while others remain 
indolent, although exact numbers are unknown.28-30
Several studies reported a different distribution of DCIS subtypes in series including 
patients with pure DCIS (without an invasive component) as compared to studies 
restricted to IBC.21 In studies restricted to pure DCIS cases, the prevalence of HER2+ 
DCIS is higher compared to IBC studies (15-49% versus 5-14% respectively).21,31,32 In 
contrast, the frequency of triple negative pure DCIS is low (6-8%) compared to IBC 
studies (11-13%).21,31,33-35 With respect to ER+/HER2- cases, reported frequencies do 
not differ between pure DCIS series and IBC series.20,21,31,33,34 Furthermore, HER2+ IBC 
has a relative high frequency of an extensive adjacent DCIS component, compared 
to other IBC subtypes.35,36 Overall, these data imply a different biological behavior 
according to DCIS subtypes. This is supported by clinical studies reporting that DCIS 
subtype is an independent predictor for ipsilateral recurrence.16,37
Molecular evolution of DCIS
Gene expression and CGH analysis of DCIS and synchronous IBC have been performed 
to identify changes that are specific to each stage (DCIS and IBC) of breast cancer 
progression.3,38 However, these analyses could not differentiate between both 
components due to remarkable similar signatures between DCIS and paired IBC. 
With the development of novel molecular techniques, genomic in-depth studies of 
synchronous DCIS and IBC reported intra-tumoral genetic heterogeneity and genetic 
differences between the in situ and the invasive component.24,39 Some authors 
proposed the Darwinian evolution model, also named evolutionary bottleneck model, 
as an explanation for this phenomenon.3,40,41 According to this hypothesis (Figure 
2A), only distinct subclones with specific genetic changes are selected during the 
transition from DCIS to invasive disease, which leads to differences in the prevalence 
of specific mutations between the DCIS and the paired IBC component. In contrast to 
this model, a multiclonal evolution theory has been proposed, which assumes that 
multiple subclones in DCIS co-migrate during the transition from DCIS to IBC (Figure 
2B).3,38 Additional in-depth sequence techniques as next generation sequencing (NGS) 
of synchronous DCIS and IBC might provide additional information regarding the 
prevalence of subclones, and therefore unravel the clonal evolution of breast cancer 
at the in situ stage. This technique also allows a more detailed overview of specific 
genomic alterations that might play an important role in the transition from DCIS to 
IBC.42 However, previous genomic in-depth studies of synchronous DCIS and IBC faced 
several limitations, including the lack of fresh-frozen samples, low tumor volume 
and intra-tumoral genetic heterogeneity.38 Consequently, the underlying genomic 
mechanism of DCIS progression to IBC remains unclear. Beside genetic alterations, 
micro-environmental changes seem to contribute to invasive progression of DCIS.43,44 
This is based on gene expression analysis that reported substantial stromal changes in 
the transition from pre-invasive to invasive growth. This was observed in various cell 
types, including fibroblasts, myoepithelial cells and inflammation cells.45 In addition, 
based on the absence of known mutations in myoepithelial cells and fibroblasts 
surrounding DCIS and IBC, it is suggested that epigenetic changes (methylation and 
microRNAs) play an important role in these events.19
1
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Figure 2. Evolutionary models of DCIS progression: according to the evolutionary bottleneck theory (A), 
there is an accumulation of subclones, of which only a single subclone is selected to become invasive. 
In contrast, according to the multiclonal invasion theory (B), there are several combinations of genetic 
aberrations that result in progression. In this model, all DCIS clones become invasive.
Risk stratification to optimize individualized therapy
Since we cannot accurately predict which cases of DCIS are likely to progress to IBC, 
clinicians are faced with a major challenge when treating patients with DCIS. Ideally, 
DCIS with a high malignant potential would be subjected to aggressive therapy 
whereas indolent DCIS would benefit from an active surveillance (Figure 3). However, 
since lesions with a high malignant potential are largely indistinguishable from lesions 
with a low malignant potential, the majority of patients currently undergo relatively 
extensive local treatment (wide local excision followed by radiation or mastectomy).46 
This leads to overtreatment for a substantial number of patients with DCIS. Therefore, 
there is a high need for improved risk stratification for DCIS patients. For this purpose, 
reliable markers are needed to discriminate DCIS cases with a low invasive potential 
from cases with a high invasive potential. Currently, although several studies reported 
risk factors for DCIS progression, none of them are considered reliable enough to 
safely select patients that can avoid adjuvant therapy.19 Some progress has been 
made with gene expression assays including Oncotype DX, in order to predict local 
recurrence risk (invasive or DCIS) of DCIS.47 This test allows some risk prediction, but 
its clinical implementation is still limited.
Recent data indicate that apolipoprotein B mRNA editing catalytic polypeptide-
like 3B (APOBEC3B) is a key molecular driver inducing mutations in several type of 
cancers, including breast cancer. Its overexpression and aberrant activation result 
in increased mutation load and poor clinical outcome in IBC.48,49 Several studies 
showed promising results for APOBEC enzymes as a strong candidate for targeted 
intervention.49,50 No data is available regarding expression levels of this enzyme at 
the pre-invasive stage. Increased knowledge with respect to the role of APOBEC3B 
during breast carcinogenesis could contribute to the development of targeted treated 
at a very early non-invasive stage of breast cancer.
Figure 3. Desired stratification model of DCIS treatment: no/limited treatment for patients with an indo-
lent variant of DCIS and a more aggressive approach restricted to patients with high-risk DCIS.
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OUTLINE
Since DCIS is a heterogeneous disease, a better understanding of its behavior is needed 
to achieve personal treatment strategies in order to avoid over- or undertreatment. 
This thesis aims to unravel the underlying mechanisms of the transition from DCIS 
to IBC and to identify potential biomarkers to discriminate DCIS with a low invasive 
potential from DCIS with a high invasive potential. Further, we studied characteristics 
of precursor lesions in a large cohort of males with breast cancer in order to increase 
our understanding of carcinogenesis in this group of patients.
Patients with pure DCIS have no metastatic potential and therefore nodal staging is 
not necessary. However, a substantial proportion of patients with a pre-operative 
needle biopsy diagnosis of DCIS shows upgrading to IBC after surgical excision, and 
consequently, a potential indication for lymph node staging.51-53 This leads to the 
clinical dilemma whether or not to conduct a sentinel node biopsy (SNB) in patients 
with a pre-operative diagnose of DCIS. Chapter 2 describes novel predictors of 
invasion in patients with a needle-biopsy diagnosis of DCIS. These predictors could 
select patients that may benefit from a SNB.
Chapter 3 is a large national cohort study that describes the presence and extent 
of a DCIS component according to IBC subtypes. These data provide information 
regarding differences in biological behavior of DCIS subtypes including their clinical 
relevance (surgical margin status, which is important to achieve optimal local control). 
Chapter 4 preludes further on the biological behavior of DCIS. For this study, we 
hypothesized that patients with extensive involvement of the breast with pure 
DCIS (without invasion) have a limited invasive potential. On the other hand, we 
hypothesized that patients with a limited amount of DCIS adjacent to an invasive 
component have a high invasive potential. In this chapter, we report several 
differences between these two groups at the transcriptional level by using robust 
quantitative real-time polymerase chain reaction (RT-PCR). These differences might 
point towards important molecular alterations of DCIS progression. In chapter 5, we 
describe the levels of APOBEC3B expression in the DCIS component and paired IBC 
at the mRNA level by quantitative RT-PCR assays. Upregulation of APOBEC3B in the 
pre-invasive stage might in the future allow early targeted treatment by inhibition 
of APOBEC3B.
With the development of technologies as NGS, a great opportunity has been created 
to answer questions regarding the clonal evolution of neoplastic cells during the 
transition from DCIS to IBC. Chapter 6 provides results of whole exome and targeted 
sequencing on a subset of synchronous DCIS and paired IBC lesions.
Chapters 7, 8 and 9 provide results of cancer precursor lesions of the male breast. 
Data regarding these lesions is sparse and mainly based on case reports or small 
single center studies. Chapter 7 provides information regarding the presence 
of breast cancer precursor lesions in a large series of male breast cancer. For this 
evaluation we used data from The International Male Breast Cancer Program, a 
worldwide collaborative effort to collect male breast cancer cases. In addition, this 
chapter presents NGS data on a subset of male breast cancer and early precursor 
lesions, which could determine their clonal relation. Chapter 8 elaborates further on 
this question by using copy number profiling in synchronous male DCIS and IBC and 
on a subset of pure DCIS lesions of the male breast. Chapter 9 discusses the results 
of this thesis and provides an overview of ongoing research and future prospects. 
Chapter 10 includes the appendices.
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ABSTRACT
Background
A substantial proportion of women with a pre-operative diagnosis of pure ductal 
carcinoma in situ (DCIS) has a final diagnosis of invasive breast cancer (IBC) after 
surgical excision and, consequently, a potential indication for lymph node staging. 
The aim of our study was to identify novel predictors of invasion in patients with a 
needle-biopsy diagnosis of DCIS that would help us to select patients that may benefit 
from a sentinel node biopsy (SNB).
Patients and Methods
We included 155 patients with a needle-biopsy diagnosis of DCIS between 2000 
and 2014, which was followed by surgical excision. Several pre-operative clinical, 
radiological and pathological features were assessed and correlated with the presence 
of invasion in the excision specimen. Features that were significantly associated with 
upstaging in the univariable analysis were combined to calculate upstaging risks.
Results
Overall, 22% (34/155) of the patients were upstaged to IBC. The following risk 
factors were significantly associated with upstaging: palpability, age ≤40 years, 
mammographic mass lesion, moderate to severe periductal inflammation and 
periductal loss of decorin expression. The upstaging-risk correlated with the number 
of risk factors present: e.g. 9% for patients without risk factors, 29% for patients 
with 1 risk factor, 37% for patients with 2 risk factors and 54% for patients with ≥3 
risk factors.
Conclusion
The identified risk factors may be helpful to predict the upstaging-risk for patients 
with a needle-biopsy diagnosis of pure DCIS, which facilitates the performance of 
a selective SNB for high-risk patients and avoid this procedure in low-risk patients.
INTRODUCTION
Ductal carcinoma in situ (DCIS) is regarded as a non-obligate precursor of invasive 
breast cancer (IBC).1 The detection rate of DCIS has dramatically increased over the last 
decades as a result of breast screening and improved resolution of mammography.2 
Currently, DCIS accounts for approximately 20% of all breast carcinomas detected in 
the well-screened population.3,4 Pure DCIS has no metastatic potential and therefore 
lymph node staging is not indicated. However, a substantial proportion (13-48%) of 
patients with an initial needle-biopsy diagnosis of pure DCIS is upstaged to IBC after 
final breast surgery.5-8 These patients with a final diagnosis of IBC may benefit from 
lymph node staging. So, if we could pre-operatively identify patients with a high risk 
of upstaging after surgery, we would be able to select patients that may benefit from 
a sentinel node biopsy (SNB) in the same session as the breast surgery.
So far, several risk factors have been reported to be associated with IBC in the 
final surgical specimen. These predictive factors included clinical features (age, size 
of lesion and palpable mass), radiological features (number and type of biopsies, 
density on mammography, signal intensity curves and large size on MRI) and 
histopathological features (high grade DCIS, Her2 positive DCIS, comedonecrosis, and 
solid growth pattern).9-21 However, as the interpretation of these predictive features 
in daily practice is equivocal, it results in inadequate prediction of invasion, and 
consequently, a suboptimal use of nodal staging in patients with a biopsy-diagnosis 
of pure DCIS. This obviously results in increased costs and complications without a 
clinical benefit.22-23
Several studies reported that the microenvironment of DCIS might play an 
important role in the progression of DCIS to IBC.24-32 The role of inflammation in DCIS 
progression has not been elucidated yet. Angiogenesis increases with the malignant 
transformation of benign ducts to DCIS and IBC.29,30 Therefore, microvessel density 
in needle biopsies with DCIS could be a predictive factor for upstaging. Decorin is a 
protein of the extracellular matrix and is a potent inhibitor of tumor cell proliferation .31 
A reduced expression of periductal decorin expression in the excision specimen of 
patients with DCIS has been reported to be associated with an increased risk for 
ipsilateral locoregional recurrence, either in situ or invasive.32 However, data is limited 
regarding the significance of stromal changes in needle biopsies with pure DCIS. We 
hypothesize that analysis of the microenvironment in needle biopsies with pure DCIS 
could identify better predictors of upstaging after final excision. Therefore, the aim of 
our study is to combine several known pre-operative clinical and radiological features 
2
24 25
Chapter 2Ductal carcinoma in situ diagnosed by breast needle biopsy
with novel pathological features in order to build a prediction model for upstaging, 
which may facilitate the selective use of a SNB for high-risk patients only.
PATIENT AND METHODS
Patients
In this retrospective study, patients with a breast needle-biopsy diagnosis of pure 
DCIS were consecutively selected from the histopathology files of the Erasmus MC 
Cancer Institute. These patients were diagnosed and treated between 2000 and 
2014. Only cases with a subsequent surgical excision within 3 months after diagnosis 
were included. The following exclusion criteria were applied: history of ipsilateral 
BC or suspicion of invasion on needle biopsy. Patient characteristics included age, 
palpability of the lesion and history of mantle field radiation for non-Hodgkin disease.
Radiology
In all patients a mammography was performed before breast needle biopsy, with or 
without ultrasound and/or MRI. The following imaging features were documented: 
type of image guidance (stereotactic, ultrasound or MRI), number of biopsies, type of 
biopsy (vacuum-assisted biopsy (VAB) or automated core biopsy (ACB)) and needle 
size. The number and size of biopsies were categorized in 2 groups: low number (≤ 10) 
vs. high (>10) and small size (14- and 18- gauge) vs. large size (10- gauge) respectively.
The pre-operative mammogram and/or ultrasound and/or MRI were reviewed by 
a dedicated breast radiologist (CM) regarding the presence, type and size of a lesion. 
Lesions were categorized according to the BIRADS classification.33 Imaging features 
for mammography included breast composition as defined by the ACR reporting 
system.33 Type of mammographic lesion was categorized as microcalcifications 
only or mass (± microcalcifications). The enhanced MRI features included type 
of enhancement (mass vs. non-mass) and late enhancement-time curves. Late 
enhancement-time curves were recorded as type 1 (slow and persisting curve), type 
2 (curve with plateau), and type 3 (curve with washout).
Pathology
Needle biopsy samples were reviewed by two pathologists (CvD and CD), blinded 
for outcome. Several histologic features of DCIS were reported, including the 
predominant growth pattern, grade34, presence or absence of comedonecrosis, 
microcalcifications and lobular cancerization. Stromal changes included the intensity 
of peri-tumoral inflammation (minimal to mild or moderate to severe) and stromal 
architecture (sclerotic or myxoid). Inflammation intensity was scored according 
to the method previously described for IBC, as illustrated in Figure 1 of the study 
published by Lee et al.35 Examples of a case with minimal inflammation and a case 
with moderate to severe inflammation are provided in Figure 1 (A and B). Myxoid 
stroma was defined as “loose”, pale-to-lightly basophilic peritumoral stroma.36 In 
case of mixed patterns, the predominant pattern was recorded.
Oestrogenreceptor and Progesteronreceptor were considered positive when at 
least 10% of the tumor cell nuclei were positive, according to Dutch guidelines for 
scoring of IBC.37 Her2 expression was scored according to international guidelines.38 
The proliferation index of DCIS was estimated by the percentage of Ki-67- positive 
tumor cells. The cut-off value for high proliferative index was a percentage of 20%, 
according to the St. Gallen criteria for IBC.39 The number of CD31 positive microvessels 
were counted with a 40-time magnification in 5 HPF of periductal lesional stroma.40 
Microvessel density was arbitrarily categorized in 2 groups: low density (≤75 vessels 
per 5 HPF) and high density (>75 vessels per 5 HPF). The intensity of periductal stromal 
decorin expression was scored semiquantitatively, using normal stroma outside the 
DCIS area as an internal reference, as either normal expression (comparable to normal 
stroma), slightly decreased expression (weak loss of intensity as compared to normal 
stroma) or highly decreased expression (strong loss of intensity as compared to 
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Fig 1. Microscopy (magnification 200x) showing Hematoxylin & Eosin (A, B) and immunohistochemical 
staining of decorin (C, D). Minimal inflammation (A) in comparison with moderate to severe inflammation 
(B) in peritumoral stroma. Normal staining of periductal decorin (C) in comparison with loss of periductal 
decorin (D).
Surgical excision
Several features of the final surgical excision were recorded including type of surgery 
(BCS or mastectomy, presence/absence of lymph nodes), number of sampled tissue 
blocks and final diagnosis (pure DCIS or IBC). The extent of DCIS and, if present, the 
invasive component was recorded. Nodal status was recorded for those patients that 
underwent nodal staging.
Statistics
Statistical analysis was performed using SPSS version 21.0. Two groups of patients 
were created: patients with invasion and patients without invasion in the subsequent 
excision. Chi-square tests were used to analyze the correlation between categorical 
variables and presence of invasion in the surgical excision. All variables that were 
associated with upstaging in the univariable analysis were tested as potential 
predictors in a multivariable logistic regression analysis. P-values < 0.05 were 
considered to be statistically significant.
RESULTS
A total number of 155 biopsies, derived from 153 patients (two patients had bilateral 
lesions) with a pre-operative diagnose of DCIS were included. DCIS was confirmed in 
121 (78%) women after surgery. The remaining 34 cases (22%) were upstaged to IBC.
Clinical factors associated with upstaging
In the univariable analysis the following clinical features were significantly associated 
with IBC at final diagnosis: age ≤ 40 years (P= 0.013) and the presence of a palpable 
mass (P= 0.017). Table 1. provides an overview of all clinical variables analyzed in this 
study population.
Table 1. Comparison of clinical features of patients with a final diagnosis of DCIS versus patients upstaged 
to IBC.
Variables DCIS (n=121) IBC (n=34) Univariable P-value
Age Median 54 (range 28-84) 52 (range 26-74)
≤40 years 12 (10%) 9 (27%) 0.013*
>40 years 109 (90%) 25 (73%)
Palpability No 98 (87%) 22 (69%) 0.017*
Yes 15 (13%) 10 (31%)
Unknown 11 2
Post mantle field 
radiation
No 114 (94%) 33 (97%) 0.510
Yes 7 (6%) 1 (3%)
*P <0.05
Radiological factors associated with upstaging
All radiologic features assessed in this study are listed in Table 2. In univariable 
analysis, the presence of a mass lesion on mammography was the only feature that 
was significantly associated with upstaging (P= 0.009). The following features showed 
a trend with upstaging, but were not statistically significant: a smaller needle biopsy 
size (P= 0.062), BIRADS classification 4 or 5 based on ultrasound (P= 0.057), mass 
enhancement (P= 0.060) and type 3 late enhancement on MRI (P= 0.060).
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Table 2. Comparison of pre-operative radiological features of patients with a final diagnosis of DCIS 
versus patients upstaged to IBC.
Variables DCIS (n=121) IBC (n=34) Univariable 
P-value
Type of biopsy ACD 39 (32%) 15 (44%) 0.199
VAB 82 (68%) 19 (56%)
Size of CNB 14-,18-gauge 31 (33%) 15 (52%) 0.062
10-gauge 64 (67%) 14 (48%)
Unknown 26 5
Number of cores ≤ 10 89 (82%) 25 (86%) 0.627
> 10 19 (18%)  4 (14%)
Unknown 13 5
Mammography
Performed No 28 (23%) 10 (29%)
Yes 93 (77%) 24 (71%)
Lesion No 6 (7%) 4 (17%) 0.111
Yes 87 (93%) 20 (83%)
Size (mm) Median 16 (range 2-110) 16 (range 5-121)
≤ 20mm 49 (56%) 13 (62%) 0.642
> 20mm 38 (44%) 8 (38%)
Breast composition (ACR) 1 6 (7%) 2 (8%) 0.842
2 36 (395) 8 (33%)
3 31 (33%) 7 (29%)
4 20 (21%) 7 (29%)
BIRADS 1+2 6 (7%) 3 (13%) 0.611
3 4 (4%) 1 (4%)
4+5 83 (89%) 20 (83%)
Type of lesion Microcalcification only 73 (92%) 15 (71%) 0.009**
Mass (± microcalcifications) 6 (8%) 6 (29%)
Unknown 14 3
Ultrasound
Performed No 71 (59%) 17 (50%)
Yes 50 (41%) 17 (50%)
Lesion No 32 (64%) 7 (41%) 0.100
Yes 18 (36%) 10 (59%)
Size (mm) Median 10 (range 3-50) 11 (range 5-29)
≤ 10mm 9 (60%) 3 (33%) 0.206
> 10mm 6 (40%) 6 (67%)
BIRADS 1+2 32 (64%) 7 (41%) 0.057
3 11 (22%) 3 (18%)
4+5 7 (14%) 7 (41%)
MRI
Performed No 57(47%) 31 (27%)
Yes 64 (53%) 13 (73%)
Size (mm)  Median 39 (range 7-113) 23 (range 8-79)
≤ 20mm 14 (36%) 3 (27%) 0.594
> 20mm 25 (64%) 8 (73%)
Table 2. Continued.
Variables DCIS (n=121) IBC (n=34) Univariable 
P-value
Suspicious enhancement No 16 (28%) 2 (15%) 0.345
Yes 41 (72%) 11 (85%)
Unknown 7 1
Type of enhancement Mass 8 (20%) 3 (27%) 0.060
Non-mass 30 (75%) 5 (46%)
Combination 2 (5%) 3 (27%)
Unknown 24 5
Late enhancement
Type 1 curve Yes 32 (60%) 10 (83%) 0.133
Type 2 curve Yes 29 (55%) 9 (75%) 0.198
Type 3 curve Yes 24 (45%) 9 (75%) 0.060
BIRADS 1+2 21 (37%) 2 (17%) 0.185
3 3 (5%) 0 (0%)
4+5 33 (58%) 11 (85%)
Missing cases 7 1
**P <0.01
Pathological factors associated with upstaging
The following pathologic features were significantly associated with upstaging to 
IBC: moderate to severe periductal inflammation (P= 0.040) and periductal loss of 
decorin expression (P= 0.028).
None of the other morphological DCIS features was associated with upstaging to 
IBC. ER, PR and Her2 expression, either analyzed separately or combined with Ki-67 
as immunohistochemical surrogates for molecular subtypes, did not significantly 
correlate with upstaging. Table 3 provides an overview of all pathological variables 
analyzed in this study.
2
30 31
Chapter 2Ductal carcinoma in situ diagnosed by breast needle biopsy
Table 3. Comparison of pathological features on needle biopsies of patients with a final diagnosis of 
DCIS versus patients upstaged to IBC.
Variables DCIS (n=121) IBC (n=34) Univariable 
P-value
Nuclear grade Low 12 (10%) 2 (6%) 0.754
Intermediate 53 (45%) 16 (50%)
High 53 (45%) 14 (44%)
Missing cases 3 4
Growth pattern Micropapillary 3 (2%) 1 (3%) 0.158
Papillary 2 (2%) 3 (10%)
Cribriform 41 (35%) 9 (28%)
Solid 72 (61%) 19 (59%)
Missing cases 3 2
Comedonecrosis No 42 (36%) 17 (53%) 0.072
Yes 76 (64%) 15 (47%)
Missing cases 2  2
Microcalcification No 32(27%) 11 (34%) 0.421
Yes 86(73%) 21 (66%)
Missing cases 2 2
Cancerization of lobules No 80 (68%) 22 (69%) 0.918
Yes 38 (32%) 10 (31%)
Missing cases 2 2
Inflammation Minimal to mild 82 (70%) 16 (50%) 0.040*
Moderate to severe 36 (30%) 16 (50%)
Missing cases 3 2
Stromal architecture Sclerotic 102 (86%) 26 (81%) 0.462
Myxoid 16 (14%) 6 (19%)
Missing cases 3 2
Immunohistochemistry
ER Negative 15 (14%) 7 (25%) 0.149
Positive 94 (86%) 21 (75%)
Missing cases 12 6
PR Negative 26 (24%) 9 (32%) 0.415
Positive 80 (76%) 19 (68%)
Missing cases 15 6
HER2 Negative 77 (72%) 19 (68%) 0.670
Positive 30 (28%) 9 (32%)
Missing cases 19 6
Proliferation index ( Ki-67) Low 78 (76%) 18 (67%) 0.299
High 24 (24%) 9 (33%)
Missing cases 19 7
Microvessel density (CD31) Low (≤75 vessels/5 HPF) 48 (47%) 16 (59%) 0.260
High (>75 vessels/5 HPF) 54 (53%) 11 (41%)
Missing cases 19 7
Decorin expression Normal to slightly decreased 97 (92%) 21 (78%) 0.028*
Highly decreased 8 (8%) 6 (22%)
Missing cases 16 7
*P <0.05
Prediction of upstaging by combining risk factors
A multivariable adjustment, including all variables that were significant in the 
univariable analyses, was performed to identify independent risk factors for upstaging 
to IBC. The presence of a palpable mass (OR 4.26 [1.14; 15.94], P= 0.030) remained the 
only significant independent risk factor for upstaging.
The probability of upstaging was further estimated by combining risk factors 
that showed a significant correlation with upstaging in the univariable analysis. The 
probability of invasion was more likely with an increasing number of risk factors 
present. In patients without any risk factors (n=75), the probability of upstaging was 
9% as compared to 29%, 37% and 54% for patients with one (n=50), two (n=19), or 
three or more risk factors (n=11) respectively. In-depth analyses of combined risk 
factors (e.g. palpability AND inflammation or mass lesion AND young age) were not 
informative due to small group sizes.
Final excision specimen, correlation with imaging and treatment
The majority of patients (56%) underwent BCS, the remaining patients underwent 
mastectomy. The median number of sampled tissue blocks/specimen was 21 (range 
4-58 blocks). The median pathological DCIS size was 29 mm (range 0.5-170 mm).
A total number of 34 cases (22%) were upstaged to IBC, including micro-invasion 
in 4 patients and multifocal IBC in 4 patients. The median size of the invasive 
component was 5.0 mm (range 0.9- 29 mm).
A SNB was performed in 57% (88/155) of all cases, either pre-operatively 
(n=10), concurrent with the breast surgery (n=64) or as a secondary procedure 
after breast surgery (n=14). The SN showed presence of tumor cells in 15% (13/88), 
including isolated tumor cells (ITC) in 61% (8/13), micrometastasis in 8% (1/13) and 
macrometastasis in 31% (4/13). SNB was performed in the majority (74%; 25/34) of 
patients upstaged to IBC. Of these cases, a secondary SNB was performed in 28% 
(7/25) due to upstaging after breast surgery. A total number of 7 patients upstaged to 
IBC underwent an axillary lymph node dissection (ALND), including four patients with 
a previous positive SNB containing either micrometastasis (n=1) or macrometastasis 
(n=3). Of these 4 cases, only one patient with a macrometastasis in the SNB had 
additional nodal involvement in the ALND. The remaining 3 patients underwent an 
ALND without a prior SNB due to upstaging after surgery, of which 2 patients had nodal 
involvement. In the remaining (6/34), neither a SNB nor an ALND was performed. All of 
these six patients had a tumor diameter of less than 0.3 cm, including micro-invasive 
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disease in two patients. No recurrent disease was reported after long-term follow up 
(follow-up range of 6-15 years).
In the group of 63 patients with a final diagnosis of pure DCIS that underwent 
a SNB, 8 patients had ITC and one patient had a pre-operative SNB with a 
macrometastasis. This patient underwent a subsequent ALND, which showed no 
additional lymph nodes involved.
DISCUSSION
A substantial proportion of patients with a pre-operative diagnosis of DCIS are 
upstaged to IBC after surgery. Several previous studies reported predictive factors for 
upstaging after a biopsy-diagnosis of DCIS, but the application of these results in daily 
practice is still suboptimal. This results in a large number of SNBs that are performed 
in DCIS-patients without clinical benefit and, on the other hand, in a second surgical 
procedure for upstaged patients who did not undergo a SNB during the first surgical 
excision.
In our series, the underestimation rate for IBC was 22%, which is in line with 
underestimation rates reported in literature.5-10 Palpability, age ≤ 40, mass lesion 
on mammography, periductal inflammation and loss of decorin expression were 
significantly associated with IBC at final excision. In our study, about half of the 
patients had no risk factors for upstaging and consequently, since the risk for 
upstaging is only 9% for these patients, nodal staging could be avoided for those 
patients undergoing BCS. In patients with one or more risk factors on the other hand, 
primary nodal staging by a SNB could be considered. Our study also supports the lack 
of indication for nodal staging for patients with a final diagnosis of pure DCIS, since 
only one patient had a macrometastasis and the remaining patients had only ITCs 
without local recurrences.
In literature, multiple studies reported that palpability is a strong clinical risk 
factor for upstaging17,18, which is consistent with our findings. The presence of a 
mammographic mass lesion (with or without associated microcalcifications) is also 
known to be associated with invasive disease.41-43 In our study, however, there was no 
significant difference in upstaging-risk according to type and size of needle biopsies, 
which is in contrast with some previous studies.10,18 This could partly be explained by 
study size, since we reported a trend towards increased upstaging risk after taking 
smaller biopsies.
Histologically, we observed a significant correlation between periductal 
inflammation and upstaging. In patients with IBC and DCIS, there is growing interest 
in the role of inflammation in relation to prognosis and therapy-response.44,45 The 
exact role of inflammation in the progression of DCIS remains to be elucidated, but our 
data suggest that inflammation might play an important role. Besides, we observed a 
significant correlation between loss of periductal decorin expression and upstaging. 
Although this is the first study assessing decorin expression in this context, this 
result is in line with a previous study that showed loss of decorin in DCIS-associated 
stroma as compared to normal glandular tissue.31 Similar results have been reported 
in colorectal tumors, with a lower expression of stromal decorin in adenomas as 
compared to normal and hyperplastic tissue.46 The lowest decorin expression was 
detected in adenocarcinomas, which supports the hypothesis that downregulation of 
decorin expression is associated with carcinogenesis. Further research is warranted 
regarding the potential function of decorin in cancer progression.
In conclusion, we reported several risk factors, including a novel pathological 
factor regarding stromal changes, associated with upstaging to IBC after a biopsy-
diagnosis of pure DCIS. Besides, the risk of upstaging increased with the number of 
risk factors present in a patient. These factors may be helpful to predict the upstaging-
risk for individual patients, which facilitates the performance of a selective SNB for 
high-risk patients and avoid this procedure in low-risk patients.
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ABSTRACT
Ductal carcinoma in situ (DCIS) is a precursor of invasive breast carcinoma (IBC). The 
DCIS component is often more extensive than the invasive component, which affects 
local control. The aim of our study was to analyze features of DCIS within different 
IBC subtypes, which may contribute to the optimization of personalized approaches 
for patients with IBC. Patients with IBC reported according to the synoptic reporting 
module in the Netherlands between 2009 and 2015 were included. Data extraction 
included characteristics of the invasive component and, if present, several features 
of the DCIS component. Resection margin status analyses were restricted to patients 
undergoing breast-conserving surgery (BCS). Differences between subtypes were 
tested by a Chi-square test, spearman’s Rho test or a one-way ANOVA test. Overall, 
36.937 cases of IBC were included. About half of the IBCs (n = 16.014; 43.4%) were 
associated with DCIS. Her2+ IBC (irrespective of ER status) was associated with 
a higher prevalence of adjacent DCIS, a larger extent of DCIS and a higher rate of 
irradicality of the DCIS component as compared to ER+/Her2- and triple-negative 
subtypes (P < 0.0001 for all variables). The prevalence of DCIS in triple-negative IBC on 
the other hand was lowest. In this large population-based cohort study, we showed 
significant differences between the prevalence and extent of DCIS according to IBC 
subtypes, which is also reflected in the resection margin status in patients treated 
with BCS. Our data provide important information regarding the optimization of local 
therapy according to IBC subtypes.
INTRODUCTION
Invasive breast cancer (IBC) is a heterogeneous disease which can be categorized 
into several histologic or intrinsic subtypes that differ in their biological behavior 
and clinical outcome.1–3 Intrinsic subtypes are most precisely categorized based on 
multigene expression assays, although each subtype has an immunohistochemical 
surrogate based on ER, PR, Her2, and Ki-67 index.4–7 Ductal carcinoma in situ (DCIS) 
is seen as a nonobligate precursor of invasive ductal carcinoma (IDC). In the last 
decades, the detection rate of DCIS increased markedly in the age group of 50–75 
years, as a result of the increased use and improved resolution of mammographic 
mass screening.8,9 Synchronous DCIS and adjacent IDC show a high degree of 
concordance regarding morphology and genetic profiles.10–15 The concordance of 
receptor expression of ER, PR, and Her2 in DCIS and coexisting IDC is high, with 92% 
for ER, 93–97% for PR, and about 98–10 % for Her2.10–12
Data regarding the process of progression of DCIS to IBC is limited. Several 
studies reported frequencies of pure DCIS subtypes based on immunohistochemical 
surrogates originally described for IBC.5,13,14,16 In these pure DCIS studies, the 
distribution of subtypes differs from studies including IBC. In pure DCIS studies, 
frequencies of Her2-positive subtypes are higher as compared to reported frequencies 
in IBC; about 15–32% of pure DCIS cases are Her2 positive, while this frequency is 
lower in IBC, about 6–14%.5, 13, 14, 16–18 Reported frequencies of triple-negative pure 
DCIS on the other hand are lower than reported frequencies in IBC, 6–8 % in pure 
DCIS versus 11–13% in IBC.5,13,14,16,17 Regarding the Luminal A and Luminal B subgroups, 
the reported frequencies for pure DCIS and IBC are overlapping (38–63% in pure 
DCIS versus 38–73% in IBC for luminal A and 7–28% in pure DCIS versus 5–26% in IBC 
for luminal B).5,13,14,16,17,19 Based on these prevalences, a mathematical, hypothetical 
model has been built, suggesting different speeds of progression according to breast 
cancer subtypes.20 This model suggests that Her2+ DCIS has the slowest progression 
to IBC, while triple-negative DCIS has the fastest progression.
Since the last decades, the proportion of patients undergoing mastectomy 
decreased and the majority of patients with localized DCIS are treated with breast-
conserving surgery (BCS), followed by breast irradiation.21 Overall, the local 
recurrence rate (LRR) for patients with DCIS treated with BCS followed by breast 
irradiation is about 10–17% within the first 15 years after treatment, of which 50% 
concerns IBC.22–24 Recent studies reported that DCIS subtype was an independent 
predictor for ipsilateral recurrence after treatment by breast surgery alone (BCS or 
3
42 43
Chapter 3Extent of ductal carcinoma in situ according to breast cancer subtypes
mastectomy) or breast surgery followed by breast irradiation.25–28 The overall LRR in 
patients with pure DCIS was the highest in Her2-positive and luminal B subgroups 
(10–48% and 25–42% recurring within 10 years of follow-up, respectively) and the 
lowest in the luminal A subgroup (9–21%).25–27 Regarding triple-negative DCIS, no 
firm conclusion could be drawn from the reported LRRs due to limited numbers of 
patients. Nevertheless, based on LRRs per subtype, Her2-positive DCIS seems to have 
an increased risk for LR after breast surgery as compared to Her2-negative DCIS. In line 
with this, the highest LRR was also observed for Her2-positive IBC following breast 
surgery and irradiation (LRR of 8–21% within 10 years of follow-up), as compared to 
Luminal A and Luminal B type IBC (LRR 1–8% and 2–10% respectively).29–31 These data 
suggest that adjustment of current treatment guidelines according to breast cancer 
subtypes, e.g., aggressive local therapy restricted to patients with a high LRR, could 
result in reduction of complications and costs for low risk patients.
Subtyping of DCIS has the potential to study progression-related features and to 
identify patients at high risk for LR. However, in daily practice, pure DCIS cases are not 
routinely analyzed for ER, PR and Her2 status, which limits the opportunity for large-
scale retrospective studies. Patients with IBC on the other hand are routinely studied 
for ER, PR, and Her2 status. This provides the opportunity to indirectly assess adjacent 
DCIS features, which, as mentioned above, share receptor expression pattern in the 
vast majority of cases. The aim of this study was to analyze features of DCIS within 
different IBC subtypes, including the resection margin status in patients treated 




In the Netherlands, all pathology reports are archived in the Dutch Pathology Registry 
(PALGA).32 Since 2009, synoptic reporting modules for reporting several common 
tumor types including breast cancer became available. In these modules, the 
parameters are captured in numerous variables instead of free text fields. This offers 
the unique opportunity to analyze all reports created with the module simultaneously.
Patient and tumor characteristics
For this study, we included all patients with IBC reported according to the protocol 
module in the Netherlands between January 1, 2009 and September 1, 2015 
(n = 36.937 cases). Patients with missing ER, PR, and/or Her2 status; pure DCIS; and 
patients with IBC after previous treatment (irradical resection, neoadjuvant therapy) 
were excluded.
Patients with bilateral IBC were included as two cases. In case of multiple IBCs in 
one breast, the largest IBC was included for analysis of tumor characteristics, except 
for resection margin status, which was assessed for all tumors. Clinicopathologic 
characteristics included age, type of surgical procedure (BCS or mastectomy), tumor 
size (≤2 cm, >2 to ≤ 5 cm or > 5 cm), histological type (according to WHO), grade 
(according to the modified Bloom and Richardson grading system),33 ER status, PR 
status, Her2 status, presence of angioinvasion, presence of DCIS, and nodal status. 
ER status and PR status were defined as positive in case more than 10 % of the cancer 
cells that showed nuclear staining, irrespective of density, according to the Dutch 
Guideline for breast cancer treatment.34 Her2 status was scored according to the 
international guidelines.35
Based on immunohistochemistry, tumors were divided according to the surrogate 
definitions of intrinsic subtypes as reported in the St Gallen International Expert 
Consensus 2013.36 Low PR expression was defined as ≥20 %.37 However, the absence of 
information regarding Ki-67 indexes in our dataset limited the ability to differentiate 
between Luminal A and Luminal B (Her2-) subtypes, so based on the available 
information, our cases were subtyped according to the following 5 categories:
3
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1. ER+/PR high/Her2-,




In case DCIS was present, the following features were documented: relation to the 
invasive component (restricted to invasive component or not), diameter, nuclear 
grade, and presence of microcalcifications.38 The overall resection margin status 
was reported, as well as the margin for both the invasive component and the DCIS 
component as either free, focally irradical, or more than focally irradical, according 
to the Dutch Guideline for Breast Cancer Treatment.34 Focally irradical is defined as 
tumor (either invasive or DCIS) reaching the ink in a small area (≤4 mm). In case the 
tumor (either invasive or DCIS) reaches the ink in a larger area or multiple smaller 
areas, it is defined as more than focally irradical. This distinction has important 
clinical consequences in the Netherlands, since patients with a focally positive 
resection margin of IBC or adjacent DCIS do not undergo second surgery (since 
radiation with a boost dose results in adequate local control), while patients with 
a more than focally positive resection margin undergo reexcision, according to the 
Dutch Guideline for Breast Cancer Treatment 2002.39 However, these definitions are 
not applied in most other European and North American countries.40 Therefore, in 
this study, we use the term irradicality to describe either focally or more than focally 
irradical resection margins.
Statistical Analysis
Differences between IBC subtypes were tested by means of a chi-square test 
(categorical variables) or a one-way ANOVA (continuous variables). Missing values 
are included in the tables but excluded in the analyses. Furthermore, the correlation 
between grade of the invasive component and the DCIS component was tested with 
chi-square. The correlation between the extent of the DCIS-component and resection 
margin status of the DCIS component was tested with a spearman’s correlation 
coefficient. All analyses were performed with SAS Enterprise Guide 7.1.
RESULTS
Baseline characteristics
Overall, we included 36.937 consecutive cases of IBC reported between January 1, 
2009 and September 1, 2015. The median age of our patient cohort was 62 years 
(range 18–100). The majority of patients (60.4%) underwent BCS. Table 1 provides an 
overview of clinicopathologic data of all patients. About half of the IBCs (n = 16.014; 
43.4%) were associated with DCIS, either restricted within or outside the invasive 
component (45.3 and 54.7%, respectively). Table 2 provides details of all patients 
with IBC and adjacent DCIS. Overall, there was a strong correlation between grade 
of the DCIS component and grade of the invasive component (p<0.0001, Chi-square 
test). Both the extent of DCIS and DCIS extending beyond the invasive component 
correlated with irradicality of the DCIS component (spearman’s rho = 0.3, p<0.0001 
and p<0.0001, Chi-square test, respectively). The frequency of multiple IBCs was 
significantly higher in IBC cases with adjacent DCIS (10.2%) as compared to IBC cases 
without adjacent DCIS (7.4%) (p<0.0001, Chi-square test).
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Table 1. Baseline characteristics of all patients with IBC (n=36937).
Characteristic N (%)
Age at diagnosis, years, mean, median (range) Mean: 61.0
Median: 62.0 (18-100)
Type of surgery







≤ 2 cm 24359 65.95
> 2 cm-≤ 5 cm 11117 30.10























Presence of DCIS component
Yes 16014 43.35
No 20923 56.65
Overall resection margin status (invasive component and/
or DCIS component) *  
Free 18552 83.09
Focally irradical 2286 10.24
Table 1. Continued.
Characteristic N (%)
More than focally irradical 1490 6.67
Resection margin status of invasive component only *
Free 19755 88.48
Focally irradical 1621 7.26





*Analysis restricted to patients with BCS (n=22328)











Diameter of DCIS, cm, mean, median (range) Mean: 2.08
Median: 1.50 (0-20)





Resection margin status of DCIS component only *
Free 8323 83.67
Focally irradical 1168 11.74
More than focally irradical 456 4.58
Missing  34
*Analysis restricted to patients with BCS (n=9981)
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Clinicopathologic features according to breast cancer subtypes
Based on immunohistochemical stainings, IBCs were categorized in the following 5 
categories: ER+/PR high/Her2- (n=21315; 57.7%), ER+/PR- or low/Her2- (n=7541; 20.4%), 
ER+/Her2+ (n=2806; 7.6%), ER-/PR-/Her2+ (n=1334; 3.6%) or ER-/PR-/Her2- (n=3941; 
10.7%) . Table 3 provides an overview of patient and tumor characteristics according 
to different IBC subtypes.
Overall, regarding the invasive component, the ER-/Her2+ and triple-negative 
subgroups showed the most aggressive biological features. The ER+/Her2- subgroups 
showed the most favorable biological features while the ER+/Her2+ subgroup showed 
intermediate results. Regarding the ER+/Her2- subgroups, the presence of a high PR 
expression was associated with more favorable tumor characteristics as compared 
to those cases with absence or low PR expression.
In general, patients with Her2+ (irrespective of ER status) and triple-negative IBC 
were younger as compared to patients with ER+/Her2- IBC (P<0.0001). Besides, median 
tumor size of these subtypes was larger (P<0.0001), which was in line with the higher 
proportion of patients undergoing a mastectomy (P<0.0001). Histologically, these 
tumors were more often of ductal type (p<0.0001) and of higher grade (P<0.0001). 
The frequency of angioinvasion and nodal involvement was the highest in the ER-/
Her2+ subgroup (P<0.0001).
Table 3. Clinicopathologic characteristics according to different subtypes of IBC (n=36937).
Characteristic ER+, PR high, 
Her2- 
(n=21315)
ER+, PR- or low
Her2-
(n=7541)










Age at diagnosis, years, mean, 
median and range
mean: 61.1  
median: 62 
range: 18-99 
mean: 63.4  
median: 64 
range: 21-97
mean: 57.6  
median: 57 
range: 19-100
mean: 59.3  
median: 59 
range: 24-97




Type of surgery, no (%) 
Breast-conserving surgery 13507 63.37 4476 59.36 1514 53.96 599 44.90 2232 56.64 <0.0001
Mastectomy 7808 36.63 3065 40.64 1292 46.04 735 55.10 1709 43.36
Tumor type, no (%)
<0.0001Ductal 16695 78.33 5753 76.29 2548 90.81 1255 94.08 3379 85.74
Lobular 3130 14.68 1319 17.49 147 5.24 20 1.50 87 2.21
Other 1490 6.99 469 6.22 111 3.96 59 4.42 475 12.05
Tumor size, no (%)
<0.0001≤ 2 cm 14849 69.66 4931 65.39 1719 61.26 729 54.65 2131 54.07
> 2 cm-≤ 5 cm 5771 27.07 2267 30.06 964 34.35 528 39.58 1587 40.27
> 5 cm 695 3.26 343 4.55 123 4.38 77 5.77 223 5.66
Tumor grade, no (%)
<0.0001
1 6513 35.17 1786 27.41 203 8.63 29 2.62 91 2.77
2 9559 51.62 3379 51.86 1018 43.28 273 24.66 665 20.21
3 2445 13.20 1351 20.73 1131 48.09 805 72.72 2534 77.02
Missing 2798 1025 454 227 651
Multiple invasive tumors, 
no (%)
<0.0001Yes 1624 9.02 510 8.25 216 9.45 106 9.97 194 5.97
No 16296 90.94 5671 91.75 2070 90.55 957 90.03 3057 94.03
Missing 3395 1360 520 271 690
Angio-invasion, no (%)
<0.0001Yes 1734 11.20 727 13.46 427 21.72 267 29.28 560 20.52
No 13747 88.80 4673 86.54 1539 78.28 645 70.72 2169 79.48
Missing 5834 2141 840 422 1212
Overall resection margin 
status (invasive and/or DCIS 
component)*
<0.0001Free 11243 83.24 3676 82.13 1205 79.59 459 76.63 1969 88.22
Focally irradical 1366 10.11 492 10.99 178 11.76 92 15.36 158 7.08
More than focally irradical 898 6.65 308 6.88 131 8.65 48 8.01 105 4.70
Resection margin status of
invasive component*, no (%) 
<0.0001Free 11879 87.95 3910 87.35 1344 88.77 540 90.15 2082 93.28
Focally irradical 1028 7.61 356 7.95 112 7.40 41 6.84 84 3.76
More than focally irradical 600 4.44 210 4.69 58 3.83 18 3.01 66 2.96
Nodal status, no (%)
<0.0001Negative 6717 62.17 2293 59.19 774 53.20 359 47.61 1285 61.45
Positive 4087 37.83 1581 40.81 681 46.80 395 52.39 806 38.55
Missing 10511 3667 1351 580 1850
*Analysis restricted to patients with BCS (n=22328)
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There was a strong correlation between the presence of DCIS and breast cancer 
subtype (P<0.0001). Table 4 provides an overview of all DCIS-characteristics according 
to the different subtypes of IBC. DCIS was most often present adjacent to IBCs with 
overexpression of Her2 (irrespective of ER status) with a frequency of 59.1% in the 
ER+/Her2+ subgroup and 57.4% in the ER-/Her2+ subgroup. The frequency of a DCIS 
component was the lowest in the triple negative subgroup (34.1%).
Besides a higher prevalence of DCIS in the Her2+ groups, DCIS was more often 
located outside the invasive component and the DCIS component was more extensive 
(P<0.0001 for all variables). DCIS-associated microcalcifications were most often seen 
adjacent to Her2+ IBC, while the frequency was the lowest in the triple-negative group 
(p<0.0001).
Analysis of resection margin status was restricted to patients treated with BCS. 
Overall, the frequency of irradicality (of either the invasive or the DCIS component) 
was the highest in the Her2+ subgroups and the lowest in the triple negative subgroup 
(P<0.0001). Analysis of irradicality of the invasive component separately showed the 
highest frequency of irradicality in the ER+/Her2- subgroups and the lowest in the 
triple-negative subgroup (P<0.0001). Analysis of irradicality of the DCIS component 
however showed another distribution as compared to the irradicality of the invasive 
component; the frequency of irradicality of the DCIS component was the highest in 
the Her2+ subgroups (P<0.0001).
Table 4. DCIS-characteristics according to different subtypes of IBC (n=16014).
Characteristic ER+, PR high, 
Her2-
(n=21315)
ER+, PR- or low
Her2- 
(n=7541)










Presence of DCIS, no (%)
<0.0001Yes 9168 43.01 3078 40.82 1658 59.09 766 57.42 1344 34.10
No 12147 56.99 4463 59.18 1148 40.91 568 42.582597 65.90
DCIS grade, no (%)
<0.0001
1 1983 21.77 512 16.72 61 3.70 4 0.53 38 2.86
2 5310 58.32 1613 52.66 572 34.73 106 13.93294 21.11
3 1813 19.91 938 30.62 1014 61.57 651 85.55998 75.04
Missing 61 15 11 5 14
Presence of DCIS-associated 
microcalcifications, 
no (%)
<0.0001Yes 2464 48.21 876 52.02 512 59.26 240 60.91308 40.90
No 2647 51.79 808 47.98 352 40.74 154 39.09445 59.10
Missing 4057 1394 794 372 591
DCIS restricted to invasive 
component, no (%)
<0.0001Yes 2774 48.52 823 43.82 383 39.24 127 29.13345 41.97
No 2943 51.48 1055 56.18 593 60.76 309 70.87477 58.03
Missing 3451 1200 682 330 522
Diameter of DCIS, cm, mean, 
median and range
mean: 1.9;  
median: 1.4 
range: 0-20
mean: 1.9;  
median: 1.4 
range: 0-19
mean: 2.6;  
median: 2.0 
range: 0-20
mean: 3.2;  
median: 2.3 
range: 0-20




Resection margin status of 
DCIS component* 
Free 5103 85.33 1622 83.44 707 78.82 251 71.10 640 82.79
 <0.0001Focally irradical 640 10.70 245 12.60 127 14.16 73 20.68 83 10.74
More than focally irradical 237 3.96 77 3.96 63 7.02 29 8.22 50 6.47
Missing 22 5 2 0 5
*Analysis restricted to patients with BCS and presence of DCIS 
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DISCUSSION
Our national registration system for pathology reporting provided a unique 
opportunity for this large-scale population- wide cohort study describing the 
presence and extent of DCIS according to breast cancer subtypes, in relation to other 
clinicopathologic features.
In our study, we showed substantial differences between immunohistochemical 
breast cancer subtypes regarding age, type of surgery, histology, tumor grade, and 
tumor size, which is consistent with literature.41,42 Briefly, Her2+ and triple-negative 
tumors are associated with younger age, larger size, and higher grade compared 
to luminal subtypes. However, on the other side of the spectrum, ER+/Her2- IBC 
showed the most favorable tumor characteristics, especially in the case of a high 
PR expression. This is in line with recent work of Prat et al. in which they concluded 
that the addition of a PR expression of more than 20 % adds prognostic value within 
the current immunohistochemical-based luminal A definition by improving the 
identification of IBCs with a good prognosis.37 The ER+/Her2+ group seems to be an 
intermediate subgroup.
Regarding DCIS, we showed that Her2+ IBC is associated with a higher prevalence 
of adjacent DCIS and a larger extent of DCIS as compared to other IBC subtypes. In line 
with this, we reported a relatively high rate of irradicality of the DCIS component in 
Her2+ IBC. These findings are consistent with previous studies reporting a relatively 
high rate of Her2 positivity in pure DCIS cases, presence of extensive DCIS adjacent to 
Her2+ IBC, and a high LRR after BCS for Her2+ IBC.13,29,30,42,43 Since the risk of an irradical 
resection is higher for IBCs that are associated with an extensive DCIS component 
as compared to those with a limited in situ component,41,44 it seems likely that the 
DCIS component adjacent to Her2+ IBC is responsible for the high LRR. Therefore, 
preoperative knowledge regarding the extent of DCIS according to breast cancer 
subtypes may result in adjustment of local therapy and consequently local control. 
This may reduce undertreatment in those patients with a large DCIS component, 
including fewer secondary surgeries and local recurrences. On the other hand, it may 
result in less overtreatment in those patients with a low prevalence and/ or limited 
extent of DCIS, e.g., by reduction of excision volume which affects cosmetic outcome. 
In recent years, there is an increased number of pathology laboratories performing 
the ER, PR, and Her2 status on preoperative needle biopsies on a routine basis, 
mainly as a result of the increased use of neoadjuvant treatment, which provides 
a better understanding of tumor growth patterns preoperatively. The presence of 
DCIS-associated microcalcifications adjacent to the majority of Her2+ IBCs, as shown 
in this study, may provide important preoperative information regarding imaging by 
mammography. Besides, since the DCIS component adjacent to Her2+ IBCs is mainly 
of high grade, a preoperative MRI could be beneficial for these patients, particularly 
for those without microcalcifications, since this imaging technique is considered to 
be the most sensitive modality in detecting the presence and extent of intermediate- 
and high-grade DCIS.45,46
According to our knowledge, our study includes the largest series of patients 
ever published regarding the presence and extent of DCIS adjacent to breast cancer 
subtypes, thanks to our national protocolled registration of breast cancer pathology 
reports. However, our study also has several weaknesses including the missing data 
regarding receptor expression of the DCIS component. However, since several studies 
reported a very high concordance (90–100%) of ER, PR, and Her2 expression between 
DCIS and adjacent IBC, it is highly unlikely that this has affected our results. The 
second limitation is the lack of information regarding proliferation, because Ki-67 
is not routinely performed in our pathology laboratories. This limited an accurate 
categorization of luminal A versus luminal B subtypes, which is partly based on a low 
versus a high Ki-67 index. A third limitation of our study is the lack of clinical follow-
up regarding local control. In this study, we used data from 2009 (in this year we 
started registering according to standard pathology protocols) until 2015, resulting 
in inadequate follow-up time.
In conclusion, in this large population-based cohort study, we showed significant 
differences between the prevalence and extent of DCIS according to breast cancer 
subtypes. Her2+ IBC was associated with the highest prevalence and extent of DCIS, 
while on the other side of the spectrum, triple-negative IBC had the lowest prevalence 
of DCIS of all IBC subtypes. Since the extent of DCIS was also reflected in the resection 
margin status in patients treated with BCS, these data provide important information 
regarding the optimization of local therapy.
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ABSTRACT
To understand the molecular alterations driving the progression of ductal carcinoma 
in situ (DCIS), we compared patients with pure DCIS and patients with DCIS and 
synchronous invasive breast cancer (IBC). Twelve patients with extensive pure DCIS 
were included as a representation of indolent lesions with limited invasive capacity. 
These cases were matched with 12 patients with a limited DCIS component and 
IBC, representing lesions with a high invasive potential. Matching included age and 
surrogate DCIS subtypes. Gene expression profiling was performed on DCIS cells to 
identify transcriptional differences between these two groups. The identified genes 
were validated by immunohistochemistry. Nine genes showed significantly different 
expression. Most of these genes were highly expressed in DCIS samples with IBC, 
including PLAU (P = 0.002), COL1A1 (P = 0.006), KRT81 (P = 0.009), S100A7 (P = 0.015), 
SCGB1D2 (P = 0.023), KRT18 (P = 0.029), and NOTCH3 (P = 0.044), whereas EGFR and 
CXCL14 showed a higher expression in cases with pure DCIS (P = 0.015 and P = 0.028, 
respectively). This difference was only significant for SCGB1D2 (P = 0.009). Hierarchical 
clustering revealed distinct clustering of patients with and without invasion. Patients 
with pure DCIS have a different gene expression pattern as compared to patients with 
DCIS and synchronous IBC. These genes may pinpoint to driver pathway(s) that play 
an important role in DCIS progression.
INTRODUCTION
Ductal carcinoma in situ (DCIS) is a nonobligate precursor lesion of invasive breast 
cancer (IBC).1 In the past decades, the detection rate of DCIS increased dramatically as 
a result of the increased use and improved resolution of mammographic screening.2 
Nowadays, DCIS accounts for 15% to 30% of all new breast cancer cases detected in 
a well-screened population.1,2
The mechanism behind progression of DCIS to IBC remains to be elucidated. In 
daily practice, most patients with pure DCIS are treated with local resection with 
or without radiation. Therefore, data are limited regarding the biological behavior 
of DCIS. Only a few small retrospective studies reported on the frequency of 
progression of untreated patients with a biopsy diagnosis of pure DCIS.3,4 In these 
series, approximately 40% to 50% of cases progressed to IBC after a follow-up of 20 
to 30 years, whereas the other cases remained indolent.
There is much debate regarding the optimal treatment of DCIS. Because DCIS 
is a noninvasive disease, current local treatment protocols result in overtreatment 
for many patients, which is associated with increased costs and morbidity without 
clinical benefit. On the other hand, a substantial proportion of DCIS cases progress to 
IBC and, obviously, these patients may benefit from prevention and early treatment.
Paired comparative genomic assays have widely been performed on cases 
with DCIS and synchronous IBC, showing a high genomic resemblance.5-7 However, 
comparative genomic assays of pure DCIS versus DCIS with progression to IBC are 
sparse and partly biased by the inclusion of different DCIS subtypes.8-10 Recent 
studies reported differences in the behavior of DCIS according to DCIS subtypes, 
based on immunohistochemistry or gene expression patterns.11-17 These reported 
features allow some recurrence risk prediction, but they are not widely used to select 
individual patients who can avoid adjuvant therapy.15 The identification of novel 
genetic alterations and molecular pathways underlying the transformation from 
DCIS to IBC may help to establish biomarkers that have the potential to distinguish 
low-risk patients who do not require aggressive treatment and high-risk patients who 
are likely to progress to IBC.
In daily practice, a proportion of patients presents with extensive involvement 
of the breast with DCIS without any signs of invasion. Although one cannot exclude 
that these cases would progress over time, the DCIS growth pattern suggests that 
these cases have a limited invasive potential. On the other hand, other patients have a 
limited amount of DCIS adjacent to an invasive component or multiple foci of invasion, 
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suggesting a high invasive potential. These differences in biological behavior of DCIS 
imply different alterations at the molecular level. On the basis of these observations, 
we attempted to identify molecular differences at the transcriptional level with robust 
quantitative RT-PCR assays. For this purpose, we compared breast tissues of patients 
with extensive DCIS (representing a group with limited invasive potential) with breast 
tissues of patients who presented with a limited DCIS component and synchronous 
IBC (as a surrogate for a DCIS subtype with a high invasive potential). On the basis of 
these data, we aimed to increase our understanding regarding molecular alterations 




In this retrospective study, two groups of patients were selected from the 
histopathology files of the Erasmus MC Cancer Institute. The first group included 
patients with extensive pure DCIS, which was defined as DCIS with a diameter of ≥ 5 
cm, to represent a group of DCIS with a biologically indolent behavior with limited 
invasive capacity. The second group included patients with a limited amount of 
DCIS (defined as DCIS with a diameter of ≤ 1 cm) with adjacent IBC. This latter group 
was selected as a representation of a biologically aggressive type of DCIS with 
high invasive capacity. Patients from the first group were matched with patients 
from the second group to correct for potential confounders. Matching included 
age (categorized from 30-40 years, 40-50 years, 50-60 years and 70-80 years) and 
surrogate DCIS subtypes, as described below. Patients with a history of breast cancer, 
ipsilateral breast irradiation or a BRCA mutation were excluded.
We used coded leftover patient material in accordance with the Code of Conduct 
of the Federation of Medical Scientific Societies in the Netherlands (http://www.
federa.org/codes-conduct, last accessed January 10, 2017). According to institutional 
and national guidelines, no informed consent was needed for this study.
Pathologic evaluation
Formalin-fixed-paraffin-embedded (FFPE), hematoxylin and eosin (H&E) stained 
whole sections of excision specimens were collected and reviewed by two 
pathologists (C.H.D, S.C.D). Cases of pure DCIS were extensively sampled according 
the national Dutch guidelines with a minimum of 10 tissue blocks of the lesion (Dutch 
national guideline breast cancer 2012, https://richtlijnendatabase.nl/en/richtlijn/
breast_cancer/pathology/criteria_for_dcis.html, last accessed January 10, 2017). 
Histopathological features of DCIS included grade according The Dutch Guidelines 
Database18 and surrogate subtyping based on immunohistochemistry, as originally 
described for IBC.19 According to these criteria, DCIS was categorized as luminal A 
[estrogen receptor (ER)+, progesterone receptor (PR) high, Her2-, Ki-67 low], luminal 
B Her2- (ER+, Her2-, PR-, or low and/or Ki-67 high), luminal B Her2+ (ER+, Her2+, any 
PR, any Ki-67), or nonluminal Her2 positive (ER-, PR-, Her2+). A cutoff of 20% Ki-67 
(MIB-1; Dako, Glostrup, Denmark) positive cells was used to distinguish cases with a 
low versus high proliferative index. Low progesterone (PR 1E2; Ventana, Tucson, AZ) 
expression was defined as ≤20%.20
Immunohistochemical evaluation was performed on FFPE whole slides (4 mm 
thick) using the Ventana Benchmark Ultra automatic stainer. ER (ER SP1; Ventana) was 
considered positive when at least 10% of the DCIS cells were positive, irrespective 
of intensity (https://www.gov.uk/government/ collections/breast-screening-
professional-guidance, last accessed January 10, 2017). Immunohistochemical HER2 
expression (Her2 4B5; Ventana) was scored on all cases, according to international 
guidelines.21 Equivocal cases were evaluated by silver in situ hybridization.
We also stained for P53 (BP53-11; Ventana), which was considered aberrant in case 
of a confluent negative staining or a strong diffuse positive staining. An intermediate 
expression of any intensity was considered to be normal.22
RNA extraction, cDNA synthesis, Pre-Amplification and gene expression evalu-
ation (RT-qPCR)
Areas composed of at least 50% DCIS cells were microdissected from 10 to 15 
hematoxylin and eosinestained sections (6 mm thick) of FFPE tissue. Microdissection 
was performed with a sterile needle under a stereomicroscope (Zeiss, Oberkochen, 
Germany). On the basis of this method, contamination of other cell types (myoepithelial 
cells, stroma, lymphocytes) cannot completely be avoided. However, the estimated 
tumor cell percentage in our series was high (75% to 90% in the group of patients with 
pure DCIS and 70% to 85% in the group of patients with DCIS and synchronous IBC). 
RNA was extracted from these cells using the Qiagen (Hamburg, Germany) AllPrep 
DNA/RNA FFPE Kit, according to the manufacturer’s instructions. Concentrations were 
measured with a Nanodrop 1000 system (Thermo Fisher Scientific, Waltham, MA). 
cDNA was generated from a total of 100 ng RNA for 30 minutes at 48°C with RevertAid 
H minus (Thermo Fisher Scientific). Gene-specific preamplification was performed 
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for 96 genes (93 tumor-specific genes and 3 reference genes, including GUSB, HMBS, 
and HPRT1), using the TaqMan PreAmp Master mix (ThermoFisher Scientific) for 15 
cycles. This was followed by TaqMan probeebased real-time PCRs, according to the 
manufacturer’s instructions, in an MX3000P Real-Time PCR System (Agilent, Santa 
Clara, CA).
These 93 tumor-specific target genes were selected based on their reported 
involvement in tumorigenesis and/or mutagenesis.23 Gene expression levels were 
quantified relative to the average expression of GUSB, HMBS, and HPRT1 using the 
2^(average Cq reference genes - Cq target gene) method. Samples with an average 
reference gene expression of Cq >25 were considered to be of insufficient RNA quality 
and were excluded from further analysis. In one of our previous studies, we compared 
the expression levels of 55 of our 93-gene panel between paired freshly frozen and 
FFPE samples and reported high levels of concordance (data not shown).24
Immunohistochemistry and Gene Function
Genes with a significantly different expression level between pure DCIS and DCIS with 
synchronous IBC were validated by immunohistochemistry. Antibodies and scoring 
methods are described below.
We used the DAVID Gene Functional Classification tool to evaluate the gene 
function of the differently expressed genes according to Gene Ontology (GO).25,26
Statistical Analysis
We used a paired samples t-test (IBM SPSS statistics 23) to compare the expression 
levels of the 93 genes in matched pure DCIS and DCIS with synchronous IBC.
To evaluate whether pure DCIS cases could be distinguished from cases with DCIS 
and synchronous IBC, a DCIS index-score was calculated to evaluate the impact of 
significant differences between the matched samples. For this DCIS index-score, the 
paired-samples t-test was used in the following equation:
SUM1-9 (t-test value gene X1 * ΔCq of gene transcript X1 + t-test value gene X2 * ΔCq 
of gene transcript X2 + ….t-test value gene X9 * ΔCq of gene transcript X9).
The X2 test was used to analyze immunohistochemical differences between 




In total, 24 patients were included, divided into two matched groups of 12 patients 
each. The overall median age was 56 years (range, 31 to 80 years). The median age in 
the group of patients with pure DCIS was 55 years (range, 31 to 76 years); in the group 
with an adjacent invasive component, it was 58 years (range, 32 to 80 years). The 
median follow-up of patients with pure DCIS was 37 months (range, 24 to 76 months). 
No invasive recurrences or distant metastases were reported. In the pure DCIS group, 
the median DCIS size was 7 cm (range, 5 to 13 cm). The DCIS lesions of both groups 
were graded as grade 2 or grade 3. On the basis of immunohistochemical subtyping, 
nine matched pairs were categorized as luminal A subtype and three matched pairs as 
luminal B subtype. None of the cases showed an aberrant P53-staining pattern. Table 1 
provides an overview of the clinicopathological features of the 12 matched pairs.
Table 1. Clinicopathological features of patients with pure DCIS and matched patients with DCIS and 









ER PR HER2 Ki67 DCIS subtype
1 Pure DCIS 56 3 + - - Low Luminal B
DCIS+IBC 51 2 + + - High Luminal B
2 Pure DCIS 56 2 + + - Low Luminal A
DCIS+IBC 58 2 + + - Low Luminal A
3 Pure DCIS 61 2 + + - Low Luminal A
DCIS+IBC 67 2 + + - Low Luminal A
4 Pure DCIS 76 2 + + - Low Luminal A
DCIS+IBC 77 2 + + - Low Luminal A
5 Pure DCIS 51 2 + + - Low Luminal A
DCIS+IBC 59 2 + + - Low Luminal A
6 Pure DCIS 71 2 + + - Low Luminal A
DCIS+IBC 80 2 + + - Low Luminal A
7 Pure DCIS 53 2 + + - Low Luminal A
DCIS+IBC 51 2 + + - Low Luminal A
8 Pure DCIS 54 2 + + - Low Luminal A
DCIS+IBC 58 2 + + - Low Luminal A
9 Pure DCIS 53 3 + - + Low Luminal B
DCIS+IBC 51 2 + + + Low Luminal B
10 Pure DCIS 57 3 + - - Low Luminal B
DCIS+IBC 59 2 + - - Low Luminal B
11 Pure DCIS 31 2 + + - Low Luminal A
DCIS+IBC 32 3 + + - Low Luminal A
12 Pure DCIS 49 2 + + - Low Luminal A
DCIS+IBC 42 2 + + - Low Luminal A
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Gene expression profiles of matched cases with pure DCIS and DCIS with 
synchronous IBC
On the basis of the 93 selected genes, 9 showed a significant different expression 
between patients with pure DCIS and patients with DCIS and synchronous IBC. In 
total, 4 of 93 genes (AURKA, CD133, MAGEA3, and SNAPC2) were not expressed at 
all. Supplemental Table S1 provides an overview of the remaining 89 genes. The 
differently expressed genes included COL1A1, CXCL14, EGFR, KRT81, KRT18, NOTCH3, 
PLAU, S100A7, and SCGB1D2 (Table 2). Most of these nine genes were significantly 
highly expressed in DCIS samples with synchronous IBC as compared to pure DCIS 
cases: PLAU (P = 0.002), COL1A1 (P = 0.006),=KRT81 (P = 0.009), S100A7 (P = 0.015), 
SCGB1D2 (P = 0.023), KRT18 (P = 0.029), and NOTCH3 (P = 0.044). The remaining two 
genes, EGFR and CXCL14, showed a significantly higher expression in cases with pure 
DCIS as compared to cases with DCIS and synchronous IBC (P = 0.015 and P = 0.028, 
respectively).
Supplemental Table 1. Analysis of 89 tumor specific-genes in twelve paired samples. 
 Paired differences    




Lower Upper T Df P-value 
(2-tailed)
PLAU 1.178 1.021 0.295 0.530 1.827 3.998 11 0.002*
COL1A1 2.164 2.179 0.629 0.779 3.549 3.44 11 0.006*
KRT81 2.347 2.564 0.740 0.718 3.976 3.171 11 0.009*
EGFR -1.076 1.289 0.372 -1.895 -0.257 -2.891 11 0.015*
S100A7 2.918 3.519 1.016 0.682 5.154 2.873 11 0.015*
SCGB1D2 3.228 4.224 1.219 0.544 5.911 2.647 11 0.023*
CXCL14 -1.482 2.026 0.585 -2.769 -0.195 -2.534 11 0.028*
KRT18 0.499 0.689 0.199 0.062 0.937 2.511 11 0.029*
NOTCH3 0.868 1.318 0.380 0.030 1.705 2.280 11 0.044*
CEA CAM5 2.552 4.682 1.352 -0.423 5.527 1.888 11 0.086
SCGB2A2 2.168 4.139 1.195 -0.462 4.797 1.814 11 0.097
MUC1 EMA 1.053 2.013 0.581 -0.225 2.332 1.813 11 0.097
MYL3 -0.078 0.149 0.043 -0.172 0.017 -1.797 11 0.100
TFF1 1.892 3.674 1.061 -0.443 4.226 1.784 11 0.102
IL17BR3 -0.734 1.435 0.414 -1.646 0.177 -1.773 11 0.104
DUSP4 1.750 3.430 0.990 -0.429 3.929 1.767 11 0.105
FOXA1 0.395 0.775 0.224 -0.098 0.888 1.765 11 0.105
IGFBP5 1.560 3.113 0.899 -0.418 3.538 1.736 11 0.110
DTX3 0.449 0.964 0.278 -0.163 1.061 1.615 11 0.135
FEN1 0.247 0.530 0.153 -0.090 0.583 1.614 11 0.135
AGR2 -1.474 3.314 0.957 -3.580 0.632 -1.541 11 0.152
TM4SF13 -0.668 1.513 0.437 -1.629 0.294 -1.528 11 0.155
COL2A1 -0.954 2.177 0.629 -2.338 0.429 -1.518 11 0.157
TWIS -1.018 2.355 0.680 -2.515 0.478 -1.498 11 0.162
CD44 0.421 1.006 0.290 -0.218 1.060 1.449 11 0.175
PLOD2 0.522 1.300 0.375 -0.304 1.347 1.391 11 0.192
CAV1 -0.918 2.407 0.695 -2.447 0.611 -1.322 11 0.213
CD24 0.743 2.081 0.601 -0.579 2.064 1.236 11 0.242
CCNE2 0.553 1.602 0.463 -0.465 1.570 1.195 11 0.257
SEPP1 0.466 1.409 0.407 -0.429 1.361 1.146 11 0.276
KIF11 0.468 1.431 0.413 -0.442 1.377 1.131 11 0.282
Supplemental Table 1. Continued.
 Paired differences    




Lower Upper T Df P-value 
(2-tailed)
PKP3 0.625 1.962 0.566 -0.622 1.872 1.103 11 0.293
KRT17 -0.419 1.328 0.383 -1.263 0.425 -1.093 11 0.298
PTRF -0.578 1.833 0.529 -1.743 0.586 -1.093 11 0.298
PTPRK -0.374 1.189 0.343 -1.130 0.381 -1.090 11 0.299
CTTN EMS1 0.363 1.176 0.339 -0.385 1.110 1.068 11 0.308
CD29 0.245 0.798 0.230 -0.262 0.752 1.063 11 0.310
CD45 0.364 1.218 0.352 -0.410 1.138 1.036 11 0.323
ERBB2 0.690 2.327 0.672 -0.788 2.168 1.027 11 0.326
GALGT 0.369 1.265 0.365 -0.434 1.173 1.011 11 0.334
CDH5 -0.625 2.218 0.640 -2.034 0.784 -0.976 11 0.350
SBEM -1.680 6.068 1.752 -5.536 2.176 -0.959 11 0.358
CLDN3 -0.433 1.569 0.453 -1.430 0.564 -0.957 11 0.359
ERBB3 0.216 0.783 0.226 -0.282 0.713 0.955 11 0.360
FGFR3 -0.758 2.969 0.857 -2.644 1.129 -0.884 11 0.396
MET -0.502 2.064 0.596 -1.813 0.810 -0.842 11 0.418
MKI67 0.189 0.826 0.238 -0.335 0.714 0.794 11 0.444
MELK 0.397 1.756 0.507 -0.719 1.512 0.783 11 0.450
VWF -0.469 2.097 0.605 -1.802 0.863 -0.775 11 0.455
IGFBP4 0.366 1.674 0.483 -0.698 1.429 0.757 11 0.465
MCAM -0.443 2.112 0.610 -1.784 0.899 -0.726 11 0.483
FGFR4 0.553 2.685 0.775 -1.154 2.259 0.713 11 0.491
GATA3 0.253 1.290 0.373 -0.567 1.073 0.68 11 0.511
S100A16 0.328 1.696 0.489 -0.749 1.406 0.671 11 0.516
LAD1 -0.284 1.518 0.438 -1.248 0.680 -0.649 11 0.530
LOXL2 0.258 1.431 0.413 -0.652 1.167 0.623 11 0.546
ITGA6 -0.246 1.395 0.403 -1.132 0.640 -0.611 11 0.554
KRT7 -0.494 2.811 0.811 -2.280 1.292 -0.609 11 0.555
IGFBP3 0.480 2.825 0.816 -1.315 2.275 0.589 11 0.568
PSMD10 0.280 1.737 0.501 -0.824 1.384 0.558 11 0.588
TOX3 0.389 2.541 0.734 -1.225 2.004 0.531 11 0.606
IGFBP2 -0.285 1.903 0.549 -1.494 0.924 -0.519 11 0.614
FGFR2 0.241 1.669 0.482 -0.819 1.301 0.500 11 0.627
TOP2A 0.265 2.182 0.630 -1.122 1.652 0.421 11 0.682
ESR1 -0.216 1.802 0.520 -1.361 0.929 -0.415 11 0.686
EPCAM -0.123 1.174 0.339 -0.869 0.623 -0.364 11 0.723
MSMB -0.204 1.949 0.563 -1.442 1.034 -0.363 11 0.724
CDH1 -0.159 1.596 0.461 -1.173 0.855 -0.345 11 0.736
CCNE1 0.139 1.470 0.424 -0.795 1.073 0.328 11 0.749
PIP 0.457 4.904 1.416 -2.659 3.573 0.323 11 0.753
TIMP3 0.176 1.933 0.558 -1.052 1.404 0.315 11 0.759
DTL 0.137 1.585 0.458 -0.870 1.144 0.299 11 0.771
BST1 0.150 1.763 0.509 -0.970 1.270 0.295 11 0.774
PLK1 -0.170 2.289 0.661 -1.624 1.284 -0.257 11 0.802
FKBP10 -0.111 1.608 0.464 -1.133 0.911 -0.239 11 0.816
NME1 0.058 0.898 0.259 -0.512 0.629 0.225 11 0.826
SELE -0.173 2.672 0.771 -1.871 1.525 -0.225 11 0.826
TFF3 -0.261 4.616 1.332 -3.194 2.672 -0.196 11 0.848
CCND1 0.095 1.700 0.491 -0.985 1.175 0.194 11 0.850
CRABP2 -0.236 4.267 1.232 -2.947 2.475 -0.191 11 0.852
KRT19 0.057 1.326 0.383 -0.786 0.899 0.148 11 0.885
CCNB1 0.055 1.326 0.383 -0.788 0.898 0.144 11 0.888
VEGFR2 -0.093 2.516 0.726 -1.692 1.505 -0.129 11 0.90
ERBB4 0.092 2.711 0.783 -1.631 1.814 0.117 11 0.909
KPNA2 -0.041 1.370 0.396 -0.911 0.830 -0.103 11 0.920
SPDEF -0.013 0.464 0.134 -0.308 0.283 -0.093 11 0.927
EEF1A2 -0.045 1.887 0.545 -1.244 1.154 -0.083 11 0.936
SMA 0.074 3.626 1.047 -2.230 2.378 0.071 11 0.945
CEP55 -0.013 1.500 0.433 -0.967 0.940 -0.031 11 0.976
*Based on T-test. genes that are significantly differed (P < 0.05)
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Table 2. Overview of genes with a significantly different expression between pure DCIS and DCIS with 
synchronous IBC.





Lower Upper T P-value 
(2-tailed)
PLAU Plasminogen activator, 
urokinase
1.178 1.020 0.294 0.529 1.827 3.998 0.002
COL1A1 Collagen, type I, alpha 1 2.164 2.179 0.629 0.779 3.548 3.440 0.006
KRT81 Keratin 81 2.346 2.563 0.740 0.717 3.975 3.171 0.009
EGFR Epidermal growth factor 
receptor (erythroblastic 
leukemia viral (v-erb-b) 
oncogene homolog, avian)
-1.075 1.289 0.372 -1.894 -0.256 -2.891 0.015
S100A7 S100 calcium binding  
protein A7
2.918 3.519 1.015 0.682 5.154 2.873 0.015
SCGB1D2 Secretoglobin, family 1D, 
member 2
3.227 4.224 1.219 0.543 5.911 2.647 0.023
CXCL14 Chemokine (C-X-C motif) 
ligand 14
-1.481 2.025 0.584 -2.768 -0.194 -2.534 0.028
KRT18 Keratin 18; keratin 18 
pseudogene 26; keratin 18 
pseudogene 19
0.499 0.688 0.198 0.061 0.936 2.511 0.029
NOTCH3 Notch homolog 3 
(Drosophila)
0.867 1.317 0.380 0.030 1.704 2.280 0.044
On the basis of these nine genes with a significantly different expression between both 
groups, a DCIS index score was calculated (Figure 1). The DCIS index value ranged 
from -2.31 to -86.84. The optimal cutoff value to discriminate pure DCIS samples from 
DCIS samples with synchronous IBC was -65.16 (Figure 1A). Supervised hierarchical 
clustering analysis based on these nine genes separated the most pure DCIS lesions 
from DCIS lesions with synchronous IBC (Figure 1B). However, three samples of pure 
DCIS clustered within the group of DCIS cases with synchronous IBC as a result of a 
high DCIS index score. Notably, two of these three samples were PR negative and/or 
HER2 positive and, therefore, categorized as luminal B.
Figure 1. DCIS-index scores of differently expressed genes between matched pairs of patients.
A. Box-plot with DCIS index-scores that significantly differentiate patients with pure DCIS from 
patients with DCIS and synchronous IBC.
B. Supervised-clustering analysis demonstrated distinct clustering of patients with pure DCIS and 
patients with DCIS and synchronous IBC. 
In this figure, samples are ranked from low to high according to their individual DCIS-index score. In addition, the 
Cq-values of each gene (horizontal) are shown for each individual sample (vertical). 
*DCIS with or without IBC; 0= without IBC, 1= with IBC.
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Immunohistochemistry
The identified nine genes with a significantly different gene expression between pure 
DCIS and DCIS with synchronous IBC were evaluated by immunohistochemistry. 
Figure 2 provides an overview of the immunohistochemical staining pattern. For 
each antibody, a representative case is shown.
As described above, seven of these nine genes showed a higher gene expression 
in cases with DCIS and synchronous IBC. Immunohistochemically, CK81 (catalog 
number H00003887-M01; Abnova, Taipei, Taiwan) and NOTCH3 (catalog number 
ab 23426; Abcam, Cambridge, UK) were only expressed in the myoepithelial cells, 
whereas the luminal cells were negative in both groups (Figure 2, A and B). COL1A1 
(catalog number NB600-408; Novus Biologicals, Littleton, CO) showed periductal 
stromal staining (Figure 2C) in six cases, but no significant difference (P = 0.317) was 
observed between both groups.
SCGB1D2 (lipophilin B; catalog number NBP1-81304; Novus Biologicals) was 
positive in the cytoplasm of neoplastic DCIS cells (Figure 2D) and was scored 
dichotomous (negative/weak or moderate/strong). There was a significantly higher 
expression in cases with DCIS and synchronous IBC as compared to the pure DCIS 
cases (P = 0.009), which was in line with the gene expression pattern of SCGB1D2.
S100A7 (catalog number NB100-56559; Novus Biologicals) was positive in the 
nucleus of the neoplastic DCIS cells (Figure 2E) and was also scored dichotomous 
(negative/ weak or moderate/strong). Although no significantly different expression 
was seen between both groups, there was a trend toward a higher expression in those 
cases with DCIS and synchronous IBC as compared to the pure DCIS cases (P = 0.150).
CK18 (catalog number HPA001605; Sigma-Aldrich, Darmstadt, Germany) and 
urokinase plasminogen activator (clone 150; Grünenthal, Stolberg, Germany) were 
expressed cytoplasmatically in the neoplastic DCIS cells (Figure 2, F and G). No 
difference was seen between both groups (P = 0.48 and P = 0.572, respectively).
Epidermal growth factor receptor (EGFR) and CXCL14 showed a higher gene 
expression in the group of patients with pure DCIS. Immunohistochemically, EGFR 
(3C6 790- 2988; Ventana) was only expressed in myoepithelial cells (Figure 2H). None 
of the cases showed expression in the luminal cells. Immunohistochemical evaluation 
of CXCL14 was not feasible because of a non-specific staining pattern. Figure 2. Staining pattern for each antibody.  
CK81 (A) and NOTCH3 (B) were positive in the myoepithelial cells and negative in the neoplastic DCIS 
cells. COL1A1 (C) showed periductal stromal staining. SCGB1D2 (D) was positive in the cytoplasm of 
neoplastic DCIS cells and S100A7 (E) showed nuclear staining. Both CK18 (F) and UPA (G) were positive 
in the cytoplasm of neoplastic DCIS cells.  EGFR (H) was positive in the myoepithelial cells and negative 
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Functional annotation of differently expressed genes according to Gene 
Ontology
According to Gene Ontology, a total of five genes (of the nine differently expressed 
genes) were annotated. These genes are involved in several biological processes, 
including signal transduction (EGFR, CXCL14, and PLAU), chemotaxis (CXCL14 and 
PLAU), angiogenesis (S100A7 and PLAU), cellular response to epidermal growth factor 
stimulus (EGFR and COL1A1), positive regulation of extracellular signal regulated 
kinase 1 and 2 cascade (EFGR and S100A7), response to hyperoxia (COL1A1 and 
PLAU), and cellular response to amino acid stimulus (EGFR and COL1A1). None of 
these functions were statistically significantly enriched (P > 0.05) compared to the 
functions annotated to the total list of 93 measured genes.
DISCUSSION
To achieve optimal individualized treatment for patients with DCIS, it is necessary 
to unravel the molecular events that contribute to DCIS progression. In this study, 
we identified significantly different gene expression profiles between patients with 
extensive pure DCIS (representing a group with a biologically indolent behavior) and 
patients with a limited amount of DCIS and synchronous IBC (representing a group 
with a biologically aggressive behavior). Most of these differently expressed genes 
(7/9) showed a higher expression in the DCIS group with synchronous IBC, including 
PLAU, COL1A1, KRT81, S100A7, SCGB1D2, KRT18, and NOTCH3. At the protein level, 
this could only be confirmed for SCGB1D2. The remaining two genes, EGFR and 
CXCL14, were upregulated in pure DCIS lesions at the transcriptional level. These 
findings are in line with previous studies that reported differences between pure 
DCIS lesions and DCIS with synchronous IBC based on gene copy number changes 
and whole exome sequencing.10,27
On the basis of these identified genes, supervised hierarchical cluster analysis 
showed distinct clustering for patients with pure DCIS (characterized by lower 
expression levels) and patients with DCIS and synchronous IBC (characterized by 
higher expression levels). However, three patients with pure DCIS clustered within the 
group of DCIS cases with synchronous IBC. Two of these three cases were classified 
as luminal B, which might explain a gene expression profile that is more similar to 
DCIS with synchronous IBC.15,28
The progression of in situ to invasive carcinoma is a multistep process that 
includes several biological processes (ie, regulation of transcription, cell adhesion, 
immune response, chemotaxis, apoptosis, and cell proliferation).8,29,30 According to 
Gene Ontology, the differently expressed genes in our study are involved in several of 
these processes, mainly signal transduction. This suggests that signal transduction 
might play an important role in the progression of DCIS. In our series, COL1A1 and 
NOTCH3 were up-regulated in cases with DCIS with synchronous IBC as compared to 
pure DCIS cases. This is in line with previous studies that reported that these genes 
have an important role in cell adhesion and migration.31,32 Furthermore, NOTCH3 plays 
an important role in cell growth by the inhibition of apoptosis and induction of cell 
proliferation, although the exact mechanism in breast cancer remains unknown.32 
Another gene with an important role in cell growth is CXCL14, although in contrast to 
NOTCH3, overexpression of this gene inhibits cell proliferation and invasion.33 In line 
with this, a recent study reported that this gene is a negative regulator of growth and 
metastases in breast cancer. This anticancer effect correlates with the upregulation 
of CXCL14 in pure DCIS samples in our study, where it might have contributed to the 
indolent behavior.33
Several previous studies reported that disruption of the myoepithelial cell layer 
is one of the critical events in DCIS progression.8,34 This is in line with the results 
of our study, in which several of the up-regulated genes (EGFR,COL1A1, KRT81, 
and NOTCH3) are involved in the myoepithelial cell layer.29,34,35 Our finding that up-
regulation of these genes was reported in both groups suggests that they could 
have both proinvasive and anti-invasive effects. Besides, it makes it unlikely that 
this finding was influenced by the amount of myoepithelial cells in the analyses. EGFR 
has been described as a specific marker in myoepithelial cells of the breast.35 COL1A1, 
together with other members of the collagenase family, was recently characterized 
as a myoepithelial-type gene in ER-positive breast cancer.29 Regarding KRT81 and 
NOTCH3, we could not find such data in the literature, although we identified this 
protein in the myoepithelial compartment by immunohistochemistry.
The strength of our study is that we matched for surrogate DCIS subtypes. This 
was assumed to be more reliable than matching on grade, which is known to be a 
subjective feature. Ideally, matching should also be based on other factors (including 
grade, PR status, and Ki-67 index) because these factors could affect biological 
behavior, but this was not feasible. Our study also has several other limitations, 
in particular the sample size, and as such, our work should be considered as a 
hypothesis-generating study. In addition, the presence of an invasive component 
cannot be ruled out in those cases classified as pure DCIS. However, because these 
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specimens were examined extensively, it is unlikely that a large invasive component 
was missed.
The immunohistochemical staining provided important information regarding 
the localization of the expression (neoplastic cells, myoepithelial cells, or periductal 
stroma), but the ability to detect different expression levels between pure DCIS and 
DCIS with synchronous IBC was limited by group size. Besides, we only evaluated a 
subset of luminal-like cases. Although this is the most common subtype, our data 
cannot be extrapolated to other DCIS subtypes (eg, ER-negative/HER2-positive 
cases and triple-negative cases). Furthermore, because we evaluated only a selected 
number of tumor-specific target genes, it is likely that some cancer genes and 
functional pathways have been missed.
In conclusion, we reported distinct gene expression profiles in cases with pure 
DCIS and cases with DCIS and synchronous IBC. If these results can be validated 
in independent and larger cohorts, these differently expressed genes could be 
used to predict progression in individual patients diagnosed with DCIS to facilitate 
individualized treatment. Besides, these genes may pinpoint potentially targetable 
driver pathway(s) that play an important role in the progression of DCIS to IBC, which 
could ultimately result in the prevention of progression.
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ABSTRACT
The underlying mechanism of the progression of ductal carcinoma in situ (DCIS), 
a non-obligate precursor of invasive breast cancer (IBC), has yet to be elucidated. 
In IBC, Apolipoprotein B mRNA Editing Enzyme, Catalytic Polypeptide-Like 3B 
(APOBEC3B) is upregulated in a substantial proportion of cases and is associated 
with higher mutational load and poor prognosis. However, APOBEC3B expression has 
never been studied in DCIS. We performed mRNA expression analysis of APOBEC3B 
in synchronous DCIS and IBC and surrounding normal cells. RNA was obtained 
from 53 patients. The tumors were categorized based on estrogen receptor (ER), 
progesterone receptor (PR), human epidermal growth factor receptor 2 (Her2) and 
phosphoinositide-3-kinase, catalytic, alpha polypeptide (PIK3CA) mutation status. 
APOBEC3B mRNA levels were measured by RT-qPCR. The expression levels of paired 
DCIS and adjacent IBC were compared, including subgroup analyses. The normal cells 
expressed the lowest levels of APOBEC3B. No differences in expression were found 
between DCIS and IBC. Subgroup analysis showed that APOBEC3B was the highest 
in the ER subgroups of DCIS and IBC. While there was no difference in APOBEC3B 
between wild-type versus mutated PIK3CA DCIS, APOBEC3B was higher in wild-type 
versus PIK3CA-mutated IBC. In summary, our data show that APOBEC3B is already 
upregulated in DCIS. This suggests that APOBEC3B could already play a role in early 
carcinogenesis. Since APOBEC3B is a gain-of-function mutagenic enzyme, patients 
could benefit from the therapeutic targeting of APOBEC3B in the early non-invasive 
stage of breast cancer.
INTRODUCTION
Ductal carcinoma in situ (DCIS) is a non-obligate precursor of invasive breast cancer 
(IBC).1 This is supported by previous studies that reported a high genomic concordance 
of synchronous DCIS and IBC.2–4 However, despite molecular similarities, recent in-
depth genetic studies also reported specific mutations that were either restricted to 
the in situ or the invasive component.3,5 Increased insight in the molecular changes 
during DCIS progression has the potential to reveal novel, potentially targetable 
drivers of progression.
A major role of Apolipoprotein B mRNA Editing Enzyme, Catalytic Polypeptide-
Like 3B (APOBEC3B) has been reported in breast cancer and several other cancers.6–9 
This enzyme is a member of the APOBEC family of deaminases and is involved in 
DNA cytosine deaminase activity, which has diverse biological functions, including 
activities in the innate immune system by restricting virus replication.10 The 
upregulation of APOBEC3B is correlated with increased C-to-T transitions and 
increased mutational load, including known driver mutations in PIK3CA and tumor 
protein 53 (TP53).10–12  APOBEC3B mRNA is upregulated in a substantial proportion of 
IBC cases and an association with poor clinical outcome has been reported in Estrogen 
receptor (ER)-positive subtypes.13 In addition, we recently reported higher mRNA 
levels of APOBEC3B in breast cancer metastasis as compared to the corresponding 
primary tumor, which implied that breast cancer progression is associated with the 
upregulation of APOBEC3B.14
In this study we investigated APOBEC3B mRNA expression levels in synchronous 
DCIS and IBC and correlated the expression with PIK3CA mutation status in order to 
increase our understanding regarding the expression levels of this enzyme during 
progression from the in situ to the invasive stage. We believe this could improve breast 
cancer care in the future since APOBEC3B is a gain-of-function mutagenic enzyme, 
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RESULTS
General Clinicopathological Data
In total, 53 patients were included. Table 1 provides an overview of the 
clinicopathological data of all patients. The overall median age was 53 years (range 
28–102 years). The majority of DCIS and IBC samples were high grade (62.3 and 54.7%, 
respectively). There was no difference in grade between DCIS and adjacent IBC (Fisher 
Exact Probability Test p = 0.92). Based on immunohistochemical staining, IBCs were 
categorized into the following five breast cancer subtype categories: ER+/PR high/
Her2− (n = 13), ER+/PR− or low/Her2− (n = 12), ER+/any PR/Her2+ (n = 11), ER−/PR−/
Her2+ (n = 8), or ER−/PR−/ Her2− (n = 9).
Table 1. Clinicopathological features of patients with ductal carcinoma in situ (DCIS) and adjacent 
invasive breast cancer (IBC) (n = 53).
Characteristic n (%)
Age at diagnosis 53
years, median (range) (28–102)
Type of surgery











≤ 2 cm 28 49.1
> 2–5 cm 21 39.6
> 5 cm 4 7.5
Missing 0 3.8
Subtypes based on immunohistochemistry
ER+/PR high/Her2− 13 24.5
ER+/PR− or low/Her2− 12 22.6
ER+/any PR/Her2+ 11 20.8
ER−/PR−/Her2+ 8 15.1
ER−/PR−/Her2− 9 17.0
APOBEC3B Expression in Synchronous Normal, DCIS and IBC Cells
Both the Kruskal-Wallis Test and the Median Test indicated that there was a significant 
difference (p < 0.001) in APOBEC3B mRNA levels between the normal controls, DCIS 
and IBC. APOBEC3B mRNA was lower expressed in the normal mammary epithelial 
tissue adjacent DCIS and IBC (unpaired Mann-Whitney U Test and paired Wilcoxon 
Signed Ranks Test p < 0.001) (Figure 1). There was no statistically significant difference 
in APOBEC3B mRNA expression between DCIS and IBC (unpaired Mann–Whitney U 
Test p = 0.065 (Figure 1), Wilcoxon Signed Ranks Test p = 0.082). (Figure 2).
Figure 1. Boxplots of APOBEC3B mRNA expression levels in paired normal, DCIS and IBC (n = 53). Differ-
ences between normal, DCIS and IBC were analyzed by the Mann-Whitney U test.
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APOBEC3B mRNA Subgroup Analysis
Previous studies reported elevated APOBEC3B mRNA levels in breast cancers with 
otherwise aggressive characteristics, including high histological grade and lack of 
estrogen expression.7,13,15 For both DCIS and IBC, there was no correlation between 
APOBEC3B expression levels and tumor diameter (Spearman Rank Correlation 
Test p > 0.05) or histological grade (Kruskal-Wallis Test p > 0.05). Our breast cancer 
subtype analysis showed that the expression of APOBEC3B was the highest in the 
ER− subgroup (Mann–Whitney U Test, p = 0.037) (Figure 3).
Figure 3. Boxplots of Apolipoprotein B mRNA Editing Enzyme, Catalytic Polypeptide-Like 3B (APOBEC3B) 
mRNA expression levels according to ER status. The difference between ER+ and ER− cases was analyzed 
by the Mann-Whitney U test.
APOBEC3B Expression in Epithelial Versus Inflammatory Cells
Based on the positive correlation between APOBEC3B and marker for epithelial 
content (EPCAM) mRNA levels (Spearman Rank Correlation test, p = 0.005 for DCIS, 
p = 0.001 for IBC), APOBEC3B mRNA was mostly expressed by epithelial cells. Of note, 
there was no significant difference in the levels of EPCAM mRNA between DCIS and 
synchronous IBC (Wilcoxon Signed Ranks Test, p = 0.18).
Since inflammatory cells also express APOBEC3B,16 we investigated whether the 
number of inflammatory cells could have biased our results by comparing Protein 
Tyrosine Phosphatase Receptor Type C (PTPRC, gene for the common leukocyte 
antigen CD45) mRNA levels from DCIS and IBC. There was no correlation between 
APOBEC3B and PTPRC mRNA levels (Spearman Rank Correlation test, p = 0.18 for 
DCIS and p = 0.29 for IBC). However, IBC expressed slightly higher levels of PTPRC 
when compared with DCIS (Wilcoxon Signed Ranks Test, p = 0.023).
APOBEC3B Expression and PIK3CA Mutation Status
In a recently published study,17 we detected a PIK3CA somatic hotspot mutation in 
24.7% (18 out of 73) patients. For these 18 PIK3CA-positive patients, a significantly 
higher PIK3CA variant allele frequency (VAF) was detected in the DCIS component 
(45.8%) when compared with the synchronous IBC component (31.7%) (p = 0.007). 
For the n = 14 PIK3CA mutation-positive patients (26.4%) included in the current 
study, a significantly higher PIK3CA VAF was also detected in the DCIS component 
(52.3%) when compared with the synchronous IBC component (37.2%) (p = 0.027). 
The correlation of PIK3CA VAF with APOBEC3B showed a negative Spearman Rank 
correlation in IBC (rs = −0.33, p = 0.001, n = 53). For the DCIS cases, there was no 
such correlation (rs = 0.02, p = 0.89, n = 53). Analyzing these data irrespective of the 
degree of the PIK3CA VAF levels revealed that for the 53 patients analyzed in this 
study, APOBEC3B mRNA levels in IBC were significantly lower in the eight patients 
with exon 9 (G to A)-mutated PIK3CA when compared with the n = 39 wild-type PIK3CA 
cases (Mann-Whitney U test p = 0.017). No such difference was observed for the DCIS 
cases (p = 0.28) (Figure 4). Albeit not statistically significant, APOBEC3B mRNA levels 
were higher overall in the n = 39 PIK3CA wild-type IBC samples when compared with 
the PIK3CA wild-type DCIS samples (Mean ± SEM: −4.54 ± 0.36 for IBC versus −5.38 
± 0.35 for DCIS) and lower in the n = 8 G-to-A PIK3CA-mutated IBC samples when 
compared with G-to-A PIK3CA-mutated DCIS samples (Mean ± SEM: −6.52 ± 1.66 for 
IBC versus −6.14 ± 0.74 for DCIS). Although the majority of samples with a PIK3CA 
mutation were ER+, there was no significant interaction effect between ER status 
and the absence or presence of the two types of tested PIK3CA mutations (p = 0.46 
for DCIS and p = 0.20 for IBC).
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Figure 4. Boxplots of APOBEC3B mRNA expression levels according PIK3CA mutation status. The dif-




Fifty-three patients with synchronous DCIS and IBC were enrolled. We used coded 
leftover patient material in accordance with the Code of Conduct of the Federation 
of Medical Scientific Societies in the Netherlands (http://www.federa.org/codes-
conduct). This article is approved by the Medical Ethics Committee of the Erasmus 
MC (approval number MEC 02.953). According to national guidelines, no informed 
consent was needed for this study.
Formalin-fixed-paraffin-embedded (FFPE) hematoxylin and eosin (H&E)-
stained whole sections of excision specimens were collected and reviewed by two 
pathologists (Carolien H. M. van Deurzen and Shusma C. Doebar). Histopathological 
features included the grade of IBC ,22 IBC diameter, ER, PR and Her2 status, and grade 
of DCIS.23 Tumors were divided into subtypes based on immunohistochemistry (ER, PR 
and Her2), including the following 5 categories: ER+/PR high/Her2−; ER+/PR− or low/
Her2−; ER+/any PR/Her2+; ER−/PR−/Her2+; ER−/PR−/Her2−. ER was considered positive 
when at least 10% of the tumor cells were positive, irrespective of intensity, according 
to national guidelines (https://richtlijnendatabase.nl). Low PR was defined as ≤ 20%.24 
Immunohistochemical HER2 expression was scored according to international 
guidelines.25 Equivocal cases were evaluated by silver in situ hybridization.
RT-qPCR
RNA was extracted from tissue areas composed of at least 50% IBC or DCIS cells and 
analyzed by RT-qPCR as described before.14,17 In brief, these cells were obtained by 
microdissection from FFPE tissue, which was performed with a sterile needle under 
a stereomicroscope. RNA was extracted from these cells using the Qiagen (Hamburg, 
Germany) AllPrep DNA/RNA FFPE Kit according the manufacturer’s instructions. RNA 
concentrations were measured with a Nanodrop 2000 system. cDNA was generated 
from 50 ng/µL cDNA and was generated for 30 min at 48 °C with the RevertAid H minus 
kit (Thermo Fisher Scientific, Breda, The Netherlands) and gene-specific pre-amplified 
with Taqman PreAmp Master mix (Thermo Fisher Scientific) for 15 cycles, followed 
by Taqman probe based real-time PCR according to the manufacturer’s instructions 
in a MX3000P Real-Time PCR System (Agilent, Amsterdam, The Netherlands). The 
following intron-spanning gene expression assays (all from Thermo Fisher Scientific) 
were evaluated: APOBEC3B, assay ID: hs00358981_m1; EPCAM, hs00158980_m1, and 
PTPRC, hs00236304_m1. Messenger RNA levels were quantified relative to the average 
expression of 2 reference genes (GUSB, hs9999908_m1 and HMBS, hs00609297_m1) 
using the delta Cq (average Cq reference genes −Cq target gene) method. According 
GeNorm and NormFinder, the average of these two reference genes was the most 
stable expressed across our samples (M-value = 0.59, SD = 0.29). Also, when taking 
the different groups into account, the inter and intra variation was the lowest for 
the average of our 2 reference genes (SD = 0.19 for the NormFinder analysis across 
the control, DCIS and IBC groups and SD = 0.24 for the NormFinder analysis across 
the ER/PR/Her2 groups). Samples with an average reference gene expression of Cq 
> 25 were considered to be of insufficient RNA quality and excluded from further 
analysis, together with their paired samples. A serially diluted RNA pool of FFPE breast 
tumor samples was included in each experiment to evaluate the linear amplification 
and efficiencies for all genes included in the panel and absence of amplification 
in the absence of reverse transcriptase. All gene transcripts were equally efficient 
amplified (range 94–106%) and were negative in the absence of reverse transcriptase. 
A summary of the performance of our assays on these serially diluted samples is 
shown in Supplementary Table S1.
PIK3CA Mutation Status
PIK3CA mutation status and VAFs were measured as described before.17 In brief, DNA 
was extracted from the same micro-dissected FFPE tissues used for RNA extraction 
using the Qiagen (Hamburg, Germany) AllPrep DNA/RNA FFPE Kit. The SNaPshot 
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Multiplex System for SNP Genotyping (Thermo Fisher Scientific) was used to identify 
samples positive for PIK3CA hotspot mutations in exon 9 and exon 20. Next, we used 
digital PCR (dPCR) to validate the SNaPshot results and quantify the relative number 
of PIK3CA-mutated copies (of E542K, E545K in exon 9 and H1047R and H1047L in exon 
20) in both the DCIS and IBC component of those patients with a PIK3CA mutation 
identified by SNaPshot analysis.
Statistical Analyses
GeNorm and NormFinder,26,27 present in GenEx qPCR data analysis software (version 
6.1, MultiD, Götenborg, Sweden), were used to assess the stability of our reference 
genes. SPSS version 24 was used for the statistical analyses. Because our APOBEC3B 
mRNA data were not normally distributed (skewness −1.01 ± 0.33 and −1.75 ± 0.33, 
kurtosis 0.80 ± 0.64 and 3.60 ± 0.64 for DCIS and IBC, respectively), we only used 
non-parametric tests. The Wilcoxon Signed Ranks Test was used to compare levels 
in paired DCIS and IBC and unpaired analyses were performed using the Wilcoxon or 
Mann-Whitney U Test or the Fisher Exact Probability Test for contingency tabled data. 
Continuous variables were analyzed by the Spearman Rank Correlation test. p-values 
≤ 0.05 were considered statistically significant.
DISCUSSION
APOBEC3B has been identified as an important factor in the evolution of breast 
cancer.8 In a recently published pan-tissue, pan-cancer analysis of RNA-seq data 
specific to the seven APOBEC3 genes in 8951 tumors, 786 cancer cell lines and 
6119 normal tissues, APOBEC3B consistently demonstrated its association with 
proliferative cells and processes, in contrast to other APOBEC3s, especially APOBEC3G 
and APOBEC3H, which were revealed as more immune cell related.9 Our current data 
showed that APOBEC3B mRNA is already upregulated in the in situ stage of breast 
cancer, which is in line with the high genomic resemblances between DCIS and IBC.18 
In a study we performed earlier, we observed higher mRNA levels of APOBEC3B 
in breast cancer metastasis as compared to the corresponding primary tumor,14 
supporting our hypothesis that, already starting from DCIS, breast cancer progression 
is associated with deregulated expression of APOBEC3B.
Tumors with upregulated APOBEC3B demonstrate a higher mutational load, which 
could explain the aggressive behavior of these tumors.7,12 Two hotspot G-to-A mutations 
in exon 9 of the—often mutated in breast cancer—PIK3CA gene (E542K and E545K) are 
thought to be generated by APOBEC3B induced C-to-T (G-to-A) transitions.11 Whether 
APOBEC3B is still needed once the mutations are present needs further investigation. 
In the study of Kosumi et al., APOBEC3B expression in esophageal squamous 
cell carcinoma was significantly correlated with PIK3CA mutations in exon 9.10 
However, no correlation was found between APOBEC3B expression and PIK3CA 
mutations status in a Japanese breast cancer cohort.15 Although PIK3CA mutations are 
known to be more prevalent in ER+ cases,19 and thus might have been a confounder 
in our analysis, we found no significant difference in the distribution of wild-type and 
mutated PIK3CA in ER+ and ER− cases. In our cohort, APOBEC3B levels were decreased 
in specifically the G-to-A PIK3CA-mutated IBC samples when compared with wild-type 
PIK3CA IBC tumors. In the synchronous DCIS counterpart, however, there was no 
difference in APOBEC3B levels between mutated and PIK3CA wild-type tumors. This 
might suggest that, in contrast to DCIS, the invasive tumors no longer need APOBEC3B 
to proliferate and metastasize. Previous studies reported elevated APOBEC3B mRNA 
levels in breast cancers with otherwise aggressive characteristics, including high 
histological grade and lack of estrogen expression.7,13,15 This is consistent with our 
subgroup analysis, which showed higher APOBEC3B levels in synchronous DCIS and 
IBC of ER− tumors as compared to ER+ tumors. However, in our study, no significant 
correlations were found between APOBEC3B levels and histological grade and/or 
tumor diameter. This could be due to the fact that the majority of our samples were 
high grade.
This is the first study evaluating APOBEC3B levels within DCIS and co-existing 
IBC, including different breast cancer subtypes. However, our study has several 
limitations, such as the relatively small size of our cohort and the analysis of a limited 
mRNA panel only, with the main focus on APOBEC3B. Since upregulated APOBEC3B 
is associated with higher mutational load, evaluation of the mutational status of 
additional markers besides PIK3CA will be interesting. Another limitation is that 
APOBEC3B is also expressed by inflammatory cells, which could have influenced our 
data because we performed manual microdissection, and thus contamination with 
inflammatory cells was not completely avoidable. Although IBC expressed slightly 
higher levels of PTPRC (the gene for leukocyte antigen CD45) than DCIS, there was 
no correlation between APOBEC3B and PTPRC mRNA levels. Based on this analysis, 
it seems unlikely that the number of inflammatory cells biased our data.
Increased insight in molecular mechanisms that contribute to DCIS progression 
will improve the development of a personalized treatment strategy for patients with 
DCIS. APOBEC3B could be a potential therapeutic target since it is non-essential, 
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but it has an active enzymatic activity that may be inhibited.7 Patients with DCIS 
could therefore benefit from such therapeutic molecules by inhibiting tumor 
evolution. Concept inhibitors have already been developed for the related enzyme 
APOBEC3G.20,21 Additional clinical and pharmaceutical assays are necessary to 
develop and explore the potential benefit of APOBEC3B inhibitors.
CONCLUSIONS
In conclusion, our results indicate that APOBEC3B mRNA is similarly upregulated in 
DCIS and IBC, but declines in PIK3CA-mutated IBC, which suggests that APOBEC3B 
plays a role in the early stages of breast carcinogenesis. Since APOBEC3B is a gain-
of-function mutagenic enzyme, it could be a candidate for therapeutic targeting in 
an early, non-invasive stage of breast cancer.
Supplementary Materials: The following are available online at http://www.mdpi.
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ABSTRACT
Several models have been described as potential mechanisms for the progression of 
ductal carcinoma in situ (DCIS) to invasive breast cancer (IBC). The aim of our study 
was to increase our understanding of DCIS progression by using massive parallel 
sequencing of synchronous DCIS and IBC. We included patients with synchronous 
DCIS and IBC (n = 4). Initially, IBC and normal tissue were subjected to whole exome 
sequencing. Subsequently, targeted sequencing was performed to validate those 
tumor-specific variants identified by whole exome sequencing. Finally, we analyzed 
whether those specific variants of the invasive component were also present in the 
DCIS component. There was a high genomic concordance between synchronous 
DCIS and IBC (52 out of 92 mutations were present in both components). However, 
the remaining mutations (40 out of 92) were restricted to the invasive component. 
The proportion of tumor cells with these mutations was higher in the invasive 
component compared to the DCIS component in a subset of patients. Our findings 
support the theory that the progression from DCIS to IBC could be driven by the 
selection of subclones with specific genetic aberrations. This knowledge improves our 
understanding of DCIS progression, which may lead to the identification of potential 
markers of progression and novel therapeutic targets in order to develop a more 
personalized treatment of patients with DCIS.
Ductal carcinoma in situ (DCIS) is a non-obligate precursor of invasive breast cancer 
(IBC). However, no reliable biomarkers or clinical tests are available to predict 
which DCIS cases are most likely to progress. In-depth genetic studies of DCIS 
and synchronous IBC reported intra-tumoral genetic heterogeneity and genetic 
differences between DCIS and synchronous IBC.1,2 Based on these findings, an 
evolutionary bottleneck selection model has been proposed.3,4 According to this 
theory, distinct subclones with specific genetic changes are selected during the 
transition from DCIS to invasive disease. This leads to differences in the prevalence 
of specific mutations between the neoplastic DCIS cells and invasive counterpart.3,5,6 
In contrast to this model, a multiclonal evolution theory has been proposed, which 
assumes that multiple subclones in DCIS co-migrate during the transition from DCIS 
to IBC.4,7 To increase our understanding of DCIS progression, we performed massive 
parallel sequencing of synchronous DCIS and IBC. We reported overlapping mutations 
between synchronous DCIS and IBC combined with the presence of invasive-specific 
mutations, which support the theory that the progression from DCIS to IBC could be 
driven by the selection of subclones with specific genetic aberrations.
We examined the exomes of four patients diagnosed with Estrogen receptor (ER) 
positive, Human Epidermal Growth Factor Receptor 2 (HER2) negative DCIS and 
synchronous IBC after surgical excision. All cases had an invasive ductal carcinoma 
that was graded in each case as grade 3. Regarding the in situ component, the DCIS 
grade was in all cases concordant with the grade of the invasive carcinoma. The 
proportion of DCIS in each case was ranging from 2cm to 5cm.
Figure 1 provides an overview of the workflow. Initially, fresh frozen (FF) tissue of IBC 
and normal cells were subjected to whole exome sequencing. The sequence reads 
were aligned to the human genome build 19 (hg19) using BW.8 For each sample, at least 
four gigabases of sequences were aligned to the genome with an average coverage 
of at least 120x for IBC and at least 70x for normal tissue samples. Subsequently, the 
aligned reads were processed using the Indel Realigner, Mark Duplicates and PHRED 
Recalibration tools from the Genome Analysis Toolkit (GATK )9 to remove systematic 
biases and to recalibrate the PHRED quality scores in the alignments. Genetic variants 
were called using the Unified Genotyper Tool from GATK.
Based on the selected invasive tumor-specific variants, a specific custom-made 
panel was designed per patient. This custom-made cancer panel was performed 
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on the Ion Torrent Personal Genome Machine (PGM) in order to validate whether 
those tumor-specific variants identified by whole exome sequencing could also be 
detected by targeted sequencing, using the same FF DNA samples, to ensure an 
accurate concordance between these two platforms. Subsequently, IBC-specific 
variants verified by Ion Torrent PGM were validated in DNA of formalin fixed paraffin 
embedded (FFPE) tissue of IBC, using a minimal genomic DNA input of 10 ng. In the 
final step we validated only those IBC-specific variants verified in both FF tissue and 
FFPE tissue of IBC on DNA extracted from FFPE tissue of DCIS.




Chapter 6Progression of ductal carcinoma in situ to invasive breast cancer
Library and template preparations were performed consecutively with the AmpliSeq 
Library Kit 2.0-384 LV and the Ion PGM Hi-Q Chef Kit. Templates were sequenced using 
the Ion PGM Hi-Q Chef Kit on an Ion 318v2 chip. Sequence information was analyzed 
with Variant Caller v4.4.2.1 (Life Technologies Carlsbad, CA, USA) and variants were 
annotated in a local Galaxy pipeline using ANNOVAR.10 Variants were called when the 
position was covered at least 100 times. Nonsynonymous somatic point mutations, 
insertions and deletions that change the protein amino acids sequence and splice 
site alterations were selected. Variants found in at least 5% of the called reads and ≥ 
10 variant-reads were considered reliable.
Based on whole-exome sequencing of the four IBC samples, a total number of 792 
tumor-specific variants were identified. Out of these 792 tumor-specific variants, 
primers were available for 585 variants. In total, 433 out of 585 tumor-specific variants 
could not be verified as a tumor-specific variant at the (ion-torrent) validation stage 
in FF tissue of IBC. Out of the remaining 152 tumor-specific variants, 60 variants 
could not be validated in FFPE tissue of IBC. These variants were excluded for further 
analysis.
This resulted in a total number of 92 tumor-specific variants that remained for 
targeted validation in the DCIS component. Within each patient, a proportion of 
tumor-specific variants overlapped between the DCIS component and the invasive 
counterpart (in total 52 out of 92). In patient 1, all tumor-specific variants (17 out 
of 17) that were identified in IBC were also detected in the DCIS component. In the 
remaining 3 patients, the number of tumor-specific variants detected in the DCIS 
component was lower compared to the number detected in the invasive component.
We also compared the frequencies of tumor-specific variants between DCIS and 
adjacent IBC, as shown in Figure 2. In patient 1, the frequency of tumor-specific variants 
was higher in the invasive component as compared to the DCIS component, which 
could not be explained by a difference in tumor cell percentage. This trend was also 
seen in patient 2, although less tumor-specific variants were detected as compared to 
patient 1. In patient 3, there was no consistent pattern with respect to differences in 
the distribution of tumor-specific variant percentages between the two components. 
For patient 4, there were only four overlapping tumor-specific variants between the 
invasive component and the in-situ component. This patient showed a higher frequency 
of tumor-specific variants in DCIS as compared to IBC for 3 out of the 4 mutations. 
Figure 2. Differences in tumor specific-variant percentages between DCIS (square) and adjacent IBC 
(rhomb) in all 4 patients.
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Taken together, our analyses confirmed a high genomic resemblance between 
synchronous DCIS and IBC; more than half (52 out of 92) of the mutations identified 
in the invasive component were also detected in the adjacent in situ component. 
However, a proportion of mutations (40 out of 92) identified in IBC were not detected 
in the adjacent DCIS component. In addition, in a subset of patients the frequencies 
of the mutations seemed to be higher in the invasive component as compared to 
DCIS, which could not be explained by the tumor cell percentages in the analyses.
It is important to note that these findings are based on a small number of patients and 
should be considered as hypothesis generating only. Besides, our study has several 
other limitations. First of all, we used two different platforms of massive parallel 
sequencing. At the validation stage major differences were observed between these 
two platforms, due to unreadable sequence regions by ion-torrent, an insufficient 
number of reads and false-positive tumor-specific variants (validated in normal tissue 
by ion-torrent sequencing). The latter might be the result of a lower sequence depth 
of whole exome sequencing as compared to ion-torrent sequencing. In addition, 
a substantial proportion of variants detected in FF tissue of IBC using Ion-torrent 
sequencing, could not be detected in FFPE tissue of the same tumor, which could 
be due to tumor heterogeneity. Another limitation of this study is the lack of whole 
exome data for DCIS, due to lack of available FF tissue of DCIS. Therefore, we could 
only perform a one-way evaluation of genetic alterations between synchronous DCIS 
and IBC; genetic alterations restricted to the DCIS component could not be evaluated. 
At last, we only included ER positive/ HER2 negative breast cancer.
In conclusion, we reported overlapping mutations between synchronous DCIS and IBC 
(with differences regarding the frequencies of mutations between both components), 
combined with the presence of invasive-specific mutations, which supports the 
theory that DCIS progression could be driven by the selection of subclones. This 
knowledge might facilitate future studies regarding potential progression markers 
and novel therapeutic targets in order to establish a more effective personalized 
treatment for patients with DCIS.
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ABSTRACT
In men, data regarding breast cancer carcinogenesis are limited. The aim of our study 
was to describe the presence of precursor lesions adjacent to invasive male breast 
cancer, in order to increase our understanding of carcinogenesis in these patients. 
Central pathology review was performed for 1328 male breast cancer patients, 
registered in the retrospective joint analysis of the International Male Breast Cancer 
Program, which included the presence and type of breast cancer precursor lesions. 
In a subset, invasive breast cancer was compared with the adjacent precursor lesion 
by immunohistochemistry (n=83) or targeted next generation sequencing (n=7). 
Additionally, we correlated the presence of ductal carcinoma in situ with outcome. 
A substantial proportion (46.2%) of patients with invasive breast cancer also had an 
adjacent precursor lesion, mainly ductal carcinoma in situ (97.9%). The presence of 
lobular carcinoma in situ and columnar cell-like lesions were very low (< 1%). In the 
subset of invasive breast cancer cases with adjacent ductal carcinoma in situ (n=83), 
a complete concordance was observed between the estrogen receptor, progesterone 
receptor, and HER2 status of both components. Next generation sequencing on a 
subset of cases with invasive breast cancer and adjacent ductal carcinoma in situ 
(n=4) showed identical genomic aberrations, including PIK3CA, GATA3, TP53, and 
MAP2K4 mutations. Next generation sequencing on a subset of cases with invasive 
breast cancer and an adjacent columnar cell-like lesion showed genomic concordance 
in two out of three patients. A multivariate Cox model for survival showed a trend that 
the presence of ductal carcinoma in situ was associated with a better overall survival, 
in particular in the Luminal B HER2+ subgroup. In conclusion, ductal carcinoma in 
situ is the most commonly observed precursor lesion in male breast cancer and its 
presence seems to be associated with a better outcome, in particular in Luminal B 
HER2+ cases. The rate of lobular carcinoma in situ and columnar cell-like lesions 
adjacent to male breast cancer is very low, but our findings support the role of 
columnar cell-like lesions as a precursor of male breast cancer.
INTRODUCTION
Male breast cancer is rare, with an estimated incidence of approximately 1.1 
per 100,000 a year, representing less than 1% of all breast cancer cases reported 
worldwide.1 Male breast cancer seems to resemble hormone receptor-positive 
postmenopausal female breast cancer, although there is a later age of onset, a more 
advanced stage at presentation, and consequently an overall worse prognosis.1–3 
Furthermore, there appears to be a markedly lower prevalence of invasive lobular 
carcinomas in men (1–2%) as compared with women (15%).4
In women, terminal ductal lobular units of the breast are regarded as the origin 
of invasive breast cancer.5 Ductal carcinoma in situ and lobular carcinoma in situ 
are seen as precursor lesions of invasive ductal carcinoma and invasive lobular 
carcinoma, respectively.6 Besides carcinoma in situ, columnar cell lesions are 
regarded as precursor lesions of (low-grade estrogen receptor positive) female breast 
cancer.7 Pure ductal carcinoma in situ accounts for up to 15–30% of all breast cancers 
detected in women nowadays and it is detected adjacent to invasive breast cancer in 
a substantial proportion of patients.8,9
In women, coexisting ductal carcinoma in situ has been reported to be associated 
with lower biological aggressiveness in luminal type breast cancer as compared with 
pure luminal breast cancer without coexisting ductal carcinoma in situ.10,11
Obviously, the anatomy of male breasts is different as compared with female 
breasts since male breasts tissues mainly consist of ducts without the formation 
of lobules. Based on this difference, one could hypothesize a different pattern of 
carcinogenesis in men as compared with women. In men, pure ductal carcinoma 
in situ accounts for about 10% of all breast cancers detected and we could find no 
published data regarding the frequency of carcinoma in situ adjacent to invasive 
breast cancer.12,13
Besides, there are also no published data regarding the biological significance 
of coexisting ductal carcinoma in situ in male breast cancer, which are estrogen 
receptor (ER) positive/HER2 negative breast cancers in the vast majority of cases. In 
literature, there is no consensus regarding the existence of columnar cell-like lesions 
in males.7,14 Verschuur- Maes et al.7 found no convincing columnar cell-like lesions 
at the periphery of 89 male breast cancer cases, but identified Keratine 5 clonally 
negative ducts, which might indicate that these lesions are breast cancer precursor 
lesions. In line with this, Ni et al.14 reported the presence of ducts with a columnar cell-
like morphology in a small subset of male breast cancer cases. However, both studies 
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were based only on morphology supplemented with immunohistochemistry, lacking 
additional molecular analyses to evaluate genomic aberrations in these potential 
male breast cancer precursor lesions.
In this study, we report the presence of various breast cancer precursor lesions 
in the largest male breast cancer series ever published, supplemented with next 
generation sequencing on a selected number of cases. Furthermore, we correlated 
the presence of these lesions with other clinicopathologic features and outcome, in 
order to increase our understanding of carcinogenesis in this population, which may 
facilitate future studies regarding prevention and early diagnosis.
MATERIALS AND METHODS
Patients
The International Male Breast Cancer Program is a worldwide collaborative effort, 
coordinated by the European Organization for Research and Treatment of Cancer 
(study number 10085), with the help of Translational Breast Cancer Research 
Consortium in the USA, and run under the Breast International Group and North 
American Breast Cancer Group networks. It is composed of three parts, where part 
1 was a retrospective joint analysis of all male breast cancer cases treated in the 
participating centers for a period of 20 years (1990–2010). In this part 1, 1822 male 
breast cancer cases were enrolled in 23 centers from nine countries. A subgroup of this 
initial population was selected based on eligibility for this male breast cancer program 
(22 excluded) and availability of a tumor tissue block for central pathology review 
(446 excluded) for which the precursor lesion status could be assessed (26 excluded). 
Therefore, the present analysis population consists of 1328 patients. Patient and 
tumor characteristics studied include age, stage, tumor size, and nodal status.
In this study we adhered to the Declaration of Helsinki and the Code of Conduct of 
the Federation of Medical Scientific Societies in the Netherlands (http://www.fmwv.
nl). Since this was a retrospective study with coded patient identification without 
risks, no informed consent was needed.
Pathologic evaluation
One representative formalin-fixed-paraffin-embedded, hematoxylin and eosin-
stained tumor tissue block was selected for central pathology review (performed 
by CvD or PvD). Tumor characteristics were evaluated, including histological type 
(according to the WHO), grade (according to the modified Bloom and Richardson 
grading system),15 and presence of a precursor lesion. The precursor lesions were 
categorized as columnar cell-like lesions (with or without atypia), atypical lobular 
neoplasia/lobular carcinoma in situ, atypical ductal hyperplasia or ductal carcinoma 
in situ. In cases where ductal carcinoma in situ was present, nuclear grade was 
recorded.16
ER, Progesterone receptor (PR), Ki67, and HER2 expression were assessed on a 
Tissue Micro Array in a different central lab. ER and PR were reported as Allred scores, 
using a cutoff point of 42 as positive. HER2 status was reported as per the ASCO-CAP 
guideline.17 Immunohistochemistry-based surrogate intrinsic breast cancer subtypes 
were defined according to the 2013 St Gallen consensus guidelines (referred to as 
surrogate breast cancer subtypes).18 A subset of 83 cases with invasive breast cancer 
and adjacent ductal carcinoma in situ was selected for additional immunostaining 
with ER, PR, and HER2 on whole sections. These cases were selected based on the 
presence of sufficient ductal carcinoma in situ for additional immunostaining.
Molecular analysis: microdissection, DNA extraction and Next Generation 
Sequencing
We selected four cases of male breast cancer with a sufficient amount of adjacent 
ductal carcinoma in situ and three cases with invasive breast cancer and an 
adjacent lesion resembling columnar cell-like lesions. These cases with a columnar 
cell-like lesion were selected based on the availability of a tissue block. Additional 
immunohistochemistry was performed on these three cases with a columnar cell-like 
lesion, using antibodies against Keratine 5 and ER. Microdissection was performed 
manually with a sterile scalpel under a stereomicroscope (Zeiss, Oberkochen, 
Germany). Normal tissue, columnar cell-like lesions, ductal carcinoma in situ, and 
invasive breast cancer cells were dissected from 10 to 15 hematoxylin-stained 
sections (6 μm) of formalin-fixed-paraffin-embedded tissue blocks. The percentage 
of the dissected tumor cells of invasive breast cancer and ductal carcinoma in situ 
was approximately 80–90%. Of all isolated lesions, DNA was extracted using a lysis 
buffer (Promega Benelux, Leiden, The Netherlands) with proteinase K and 5% Chelex 
100 resin. We started by analyzing DNA extracted from the invasive breast cancer 
regions. Next generation sequencing was performed on the Ion Torrent Personal 
Genome Machine with a broad breast cancer-related panel. Genes listed in this panel 
included 37 breast cancer-related genes and 9 hotspot-regions as described for 
female breast cancer, that is, PIK3CA, TP53, AKT1, GATA3, and MAP3K119–21 (details 
of genes listed in this breast cancer panel are available in Supplementary Table S1). 
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The minimal DNA input was 10 ng per primer pool. In brief, library and template 
preparations were performed consecutively with the Ampli- Seq Library Kit 2.0-384 
LV and the Ion PGM Hi-Q Chef Kit. Templates were sequenced using the Ion PGM 
Hi-Q Chef Kit on an Ion 318v2 chip. Sequence information was analyzed with Variant 
Caller v4.4.2.1 (Life Technologies, Carlsbad, CA, USA) and variants were annotated 
in a local Galaxy pipeline using ANNOVAR.22–24 Variants were called when the position 
was covered at least 100 times. Nonsynonymous somatic point mutations, insertions, 
and deletions that change the protein amino acid sequence and splice site alterations 
were selected. Variants found in at least 25% of the called reads were considered 
reliable. Non-reproducible sequence artifacts due to cytosine deamination, G>A, or 
C>T mutations, were excluded when not listed in the COSMIC database (http://cancer.
sanger. ac.uk/cosmic). To find genomic resemblances between breast cancer and 
the adjacent columnar cell-like lesion and/or ductal carcinoma in situ, we started 
with next generation sequencing analyses of the invasive component. Based on 
the selected invasive tumor-specific variants, a specific custom-made panel was 
designed per patient, which was used for targeted analyses in the adjacent columnar 
cell-like lesion and/or adjacent ductal carcinoma in situ component. Furthermore, 
the originally reported variants of the invasive component were validated with this 
custom-made panel.
Supplementary table S1. Details of genes listed in the breast cancer panel.










AKT1_ex17 chr14 105246500 105246625 1 126 126 0
GENOME 
REGION
BRAF_V600 chr7 140453099 140453224 1 126 126 0
GENOME 
REGION
CTNNB1_ex3 chr3 41266061 41266175 1 115 115 0
GENOME 
REGION
EGFR_ex18 chr7 55241596 55241779 1 184 184 0
GENOME 
REGION





chr12 25398183 25398310 1 128 128 0
GENOME 
REGION










chr3 178952001 178952103 1 103 103 0
GENE AKAP9 chr7 . . 119 12438 11913 525
GENE APC chr5 . . 62 8873 8841 32
GENE ARID1A chr1 . . 47 7330 7181 149
Supplementary table S1. Continued.








GENE ATM chr11 . . 108 9853 9365 488
GENE BRCA1 chr17 . . 46 6286 6209 77
GENE CDH1 chr16 . . 22 2825 2825 0
GENE CDK12 chr17 . . 34 5324 5267 57
GENE CHEK2 chr22 . . 19 1926 1777 149
GENE CREBBP chr16 . . 57 7670 7662 8
GENE ERBB2 chr17 . . 39 4211 4169 42
GENE FBXW7 chr4 . . 25 2675 2675 0
GENE GATA3 chr10 . . 10 1544 1534 10
GENE JAK1 chr1 . . 29 3729 3719 10
GENE KIT chr4 . . 27 3355 3355 0
GENE LRP2 chr2 . . 123 14837 14743 94
GENE MAP2K4 chr17 . . 13 1321 1306 15
GENE MAP3K1 chr5 . . 42 4759 4508 251
GENE MED12 chrX . . 55 7029 6813 216
GENE MLH1 chr3 . . 23 2581 2578 3
GENE MLL chr11 . . 83 12440 12149 291
GENE MLL2 chr12 . . 108 17208 16865 343
GENE MLL3 chr7 . . 135 15385 15237 148
GENE MLLT3 chr9 . . 16 1828 1828 0
GENE KAT6B chr10 . . 45 6398 6384 14
GENE NCOA3 chr20 . . 38 5314 5184 130
GENE NCOR1 chr17 . . 76 8748 8490 258
GENE NCOR2 chr12 . . 71 8438 8401 37
GENE NF1 chr17 . . 104 9310 9191 119
GENE PDE4DIP chr1 . . 84 9820 9603 217
GENE PIK3R1 chr5 . . 25 2524 2520 4
GENE PPP2R1A chr19 . . 18 1935 1935 0
GENE PTCH1 chr9 . . 36 4962 4927 35
GENE PTEN chr10 . . 15 1311 1311 0
GENE RB1 chr13 . . 41 3084 2874 210
GENE RNF213 chr17 . . 114 16821 16622 199
GENE RUNX1 chr21 . . 15 1852 1852 0
GENE RYR1 chr19 . . 150 16283 16020 263
GENE SMAD4 chr18 . . 19 1780 1758 22
GENE TP53 chr17 . . 14 1569 1510 59
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Statistics
The association between the presence of ductal carcinoma in situ and lobular 
carcinoma in situ with histological type of the tumor was assessed, as was the 
association between the presence of ductal carcinoma in situ and M stage, HER2 
status, breast cancer subtype, and nodal status (for patients who were free of 
metastases at diagnosis (M0 patients)). Also, the relationship between grade of the 
ductal carcinoma in situ component vs grade of the adjacent invasive breast cancer 
was explored. For all the aforementioned contingency tables, Fisher exact tests 
for association were performed. The relationship between the presence of ductal 
carcinoma in situ and outcome, as measured by relapse-free survival for M0 patients 
and overall survival, was investigated. Subgroup analyses were added for the three 
breast cancer subtypes with a prevalence of at least 50 patients: Luminal A, Luminal 
B (HER2 negative), and Luminal B (HER2 positive). A multivariate model for overall 
survival was fitted to assess the effect of the presence of ductal carcinoma in situ 
when adjusting for the baseline factors included in Table 3. Patients with missing 
information on one of the aforementioned factors, or with a different breast cancer 
subtype than the ones mentioned above were excluded from the analysis. Relapse-
free survival was defined as the time from diagnosis until one of the following 
events: local recurrence, distant relapse, or death due to any cause. Overall survival 
constitutes the time interval from diagnosis until death due to any cause. Patients 
without an event of interest for the above end points are censored at their last follow-
up date. Patients with missing data on (any of) the events of interest for relapse-free 
survival or overall survival are excluded from the analyses on that end point. Outcome 
data are analyzed per the Kaplan–Meier method, reported P-values correspond to the 
logrank test, and the hazard ratio was estimated from the Cox proportional hazards 
model (95% confidence intervals are per Wald test). The reported analyses should be 
considered exploratory. No multiple testing adjustments were implemented.
RESULTS
General Patient and Treatment Characteristics
We collected a total number of 1328 primary male breast cancers. Median age was 
67 years. The majority of patients were treated with a mastectomy (60.1%). A small 
subset of patients underwent either breast-conserving surgery (2.6%) or no surgery 
(0.6%). The remaining cases (36.6%) missed data regarding breast surgery. About half 
of the patients with known data regarding adjuvant radiotherapy received radiation 
(29.9% with radiation vs 29.7% without radiation). The majority of patients (43.2%) did 
not receive chemotherapy (only 16.6% of the patients did receive chemotherapy and 
40.2% of the patients had missing data). In contrast, the majority of patients (43.9%) 
received endocrine therapy (14.5% did not receive endocrine therapy and remaining 
data were missing). The majority of Her2-positive patients received Trastuzumab 
from 2006 onwards (43.3% vs 16.7% who did not receive Trastuzumab, remaining 
data were missing).
Patients with Precursor Lesions
Out of 1328 cases, 613 (46.2%) had a precursor lesion adjacent to the invasive 
component. In the remaining 715 cases (53.8%), no precursor lesion was detected 
within the selected tissue block. The majority of precursor lesions consisted of ductal 
carcinoma in situ (97.9%), mainly grade 2 (64%). The observed frequency of lobular 
carcinoma in situ, atypical ductal hyperplasia, and columnar cell-like lesions was very 
low (<1%). Table 1 provides an overview of subtypes of precursor lesions. A total of 13 
patients had a combination of precursor lesions. The majority of these cases (11 out of 
13) had a combination of ductal carcinoma in situ with a columnar cell-like lesion, one 
patient had atypical ductal hyperplasia with a columnar cell-like lesion and one case 
had a combination of lobular carcinoma in situ with ductal carcinoma in situ grade 1.




DCIS, all grades 599 (97.7)
DCIS grade 1 83 (13.9)
DCIS grade 2 384 (64.1)
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Presence of Precursor Lesions According to Other Clinicopathological Features
Table 2 provides an overview of patient and tumor characteristics by the presence 
of a precursor lesion. The majority of breast cancers were classified as invasive 
ductal carcinoma (84.6%), mainly grade 2 (49.8%). The prevalence of invasive lobular 
carcinoma was low (1.4%). Most carcinomas were classified by immunohistochemistry 
as luminal-like subtype, either luminal A (35.9%) or luminal B (49.3%). There was 
no significant association between surrogate breast cancer subtype or HER2 status 
and the presence of a precursor lesion (P = 0.14 and 0.31 respectively). More detailed 
patient and tumor characteristics were presented before.25
Table 2. Patient and tumor characteristics according to the presence of a precursor lesion.











≤ 50 57 (8.0) 74 (12.1) 131 (9.9)
51 - 65 211 (29.5) 212 (34.6) 423 (31.9)
66 - 75 237 (33.1) 172 (28.1) 409 (30.8)
> 75 210 (29.4) 155 (25.3) 365 (27.5)
Median 68.9 66.3 67.8
T status
T1 270 (37.8) 306 (49.9) 576 (43.4)
T2 256 (35.8) 199 (32.5) 455 (34.3)
T3 15 (2.1) 7 (1.1) 22 (1.7)
T4 115 (16.1) 52 (8.5) 167 (12.6)
Missing 59 (8.3) 49 (8.0) 108 (8.1)
Histological type
Ductal 595 (83.2) 528 (86.1) 1123 (84.6)
Lobular 11 (1.5) 7 (1.1) 18 (1.4)
Mixed 36 (5.0) 36 (5.9) 72 (5.4)
Other 73 (10.2) 42 (6.9) 115 (8.7)
Missing 0 (0.0) 2 (0.3) 2 (0.2)
Grade of invasive BC
1 161 (22.5) 131 (21.4) 292 (22.0)
2 356 (49.8) 305 (49.8) 661 (49.8)
3 193 (27.0) 166 (27.1) 359 (27.0)
Missing 5 (0.7) 11 (1.8) 16 (1.2)
Molecular subtypes *
Luminal A 268 (37.5) 209 (34.1) 477 (35.9)
Luminal B (HER2 negative) 323 (45.2) 270 (44.0) 593 (44.7)
Luminal B (HER2 positive) 26 (3.6) 36 (5.9) 62 (4.7)
HER2 positive (non-luminal) 1 (0.1) 1 (0.2) 2 (0.2)
Basal 9 (1.3) 4 (0.7) 13 (1.0)
Not classified (ER-, PgR+) 2 (0.3) 0 (0.0) 2 (0.2)
Missing 86 (12.0) 93 (15.2) 179 (13.5)
LN status (pN, but cN reported if pN is missing)
N- 356 (49.8) 321 (52.4) 677 (51.0)
N+ 222 (31.0) 177 (28.9) 399 (30.0)
Missing 137 (19.2) 115 (18.8) 252 (19.0)
*Subtypes according to St. Gallen consensus 2013, Ki67 high: %pos cells ≥ 20%, 
ER/PgR positive: allred > 2, PgR low: allred < 5
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Comparison of Ductal Carcinoma In Situ and Lobular Carcinoma In Situ with 
Adjacent Invasive Breast Cancer
We observed a significant correlation between the presence of ductal carcinoma in 
situ and the histology of the invasive breast cancer (P = 0.02). The prevalence of ductal 
carcinoma in situ adjacent to invasive ductal carcinoma was the highest (46.6%), as 
compared with lobular or other subtypes (27.8% and 36.8% respectively). Similarly, 
there was a significant correlation between the presence of lobular carcinoma in 
situ and histologic breast cancer subtype (P < 0.01). Although the prevalence of 
lobular carcinoma in situ was low (n = 5), it was mainly seen adjacent to invasive 
lobular carcinoma (3 out of 5). The remaining two cases with lobular carcinoma in situ 
were associated with a mixed ductal and lobular carcinoma. In cases with invasive 
breast cancer and adjacent ductal carcinoma in situ, there was a positive correlation 
between nuclear grade of ductal carcinoma in situ and nuclear grade of invasive 
breast cancer, where grade was frequently similar in both components (Trend test 
for association P < 0.01). In line with this, there was a strong correlation of ER, PR, 
and HER2 status between ductal carcinoma in situ and the adjacent invasive breast 
cancer where tested. Regarding ER, the majority of cases (82 out of 83 cases) were 
positive for ER in both the ductal carcinoma in situ and the invasive component. One 
case was negative in both components. PR status was positive in both components 
in 81 out of 83 patients. The remaining two cases were negative in both components. 
Regarding HER2 status, no discrepancies were detected between ductal carcinoma 
in situ and the adjacent invasive component. The majority of cases (78 out of 83) 
were not overexpressed in both components; the remaining cases (n = 5) were 
overexpressed in both components. For four patients, we performed targeted next 
generation sequencing of invasive ductal carcinoma and adjacent ductal carcinoma 
in situ. The results of these analyses are presented in Table 3. In three out of four 
patients, well-known breast cancer mutations noted in the COSMIC database were 
found in both the ductal carcinoma in situ component and the adjacent invasive 
component, which supports the hypothesis that ductal carcinoma in situ is indeed 
a precursor lesion of male breast cancer. In one out of these four cases, no specific 
somatic mutation was found in either the invasive or the in situ component within 
this focused panel of genes.
Table 3. Non-silent somatic mutations in 4 patients with invasive BC and adjacent DCIS.
Invasive BC- 
DCIS
Pathogenic somatic variants Percentage of variant 




Patient 1 Invasive BC





























Patient 4 Invasive BC




Presence of Columnar Cell-Like Lesions
In 13 patients, a lesion resembling columnar cell-like lesions in women was detected 
adjacent to invasive breast cancer. The majority of these cases (11 out of 13) also had 
adjacent ductal carcinoma in situ. These columnar cell-like lesions mainly consisted 
of dilated ducts with apical snouting and cytonuclear atypia. Notably, the cytonuclear 
aspects resembled the cellular aspects of the adjacent invasive component (Figure 1). 
However, a convincing morphologic architecture of these lesions, as seen in women, 
is missing. Next generation sequencing was performed for three of these cases. 
The selection was based on availability of tissue. In two out of three cases, we 
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Figure 1. Two cases with distended ducts lined by myoepithelial cells and an inner layer of columnar cells 
with apical snouting, rounded nuclei and prominent nucleoli (A and C), interpreted as a columnar cell-
like lesion, and an adjacent invasive component with similar cytonuclear features (B and D respectively) 
(original magnification x 40).
 In case 1 (Figure 2A–F), the invasive breast cancer was associated with both a ductal 
carcinoma in situ component and a columnar cell-like lesion. These three components 
showed similar mutations, including a PIK3CA and a GATA3 mutation. Case 2 (Figure 
2G–L) showed a PIK3CA mutation in both the invasive breast cancer and the adjacent 
columnar cell-like lesion. In the remaining case, we identified a TP53 mutation in the 
invasive component, which could not be found in the adjacent columnar cell-like 
lesion. These findings are in line with the overlapping morphology and support the 
hypothesis that columnar cell-like lesions are a putative precursor lesion of male 
breast cancer.
Figure 2. Two cases (A-F: case 1, G-L: case 2) with a CCL-like lesion and adjacent invasive BC. H&E staining 
of the CCL-like lesions adjacent to invasive BC in A and G (original magnification 20x). A detailed H&E 
staining of CLL-like ducts (B and H) and an adjacent invasive component with similar cytonuclear features 
(C and I) (original magnification 40x). The luminal columnar cells show strong nuclear staining with ER (D 
and J) while only a few cells are positive for CK5 (E and K). NGS showed identical mutations in both the 
CCL-like lesion and the adjacent invasive component (F: GATA3 deletion mutation and a PIK3CA missense 
mutation, L: PIK3CA missense mutation).
Association Between the Presence of Ductal Carcinoma In Situ and Clinical 
Outcome
There was no significant association between the presence of ductal carcinoma in 
situ and metastatic or nodal status (P = 0.17 and P = 0.41, respectively). Relapse-
free survival for M0 patients with ductal carcinoma in situ vs patients without ductal 
carcinoma in situ was not statistically different (HR = 0.84; 95% CI 0.65, 1.08; P = 0.18). 
Subgroup analyses for Luminal A, Luminal B HER2 − , and Luminal B HER2+ did also 
not indicate an effect for ductal carcinoma in situ vs no ductal carcinoma in situ 
(Luminal A: HR= 0.81, 95% CI 0.52–1.24, P = 0.33; Luminal B HER2 − : HR = 0.96, 95% CI 
0.67–1.37, P = 0.80; Luminal B HER2+: HR = 0.43, 95% CI 0.09– 2.07, P = 0.29). For overall 
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survival, however, there was a difference between patients with ductal carcinoma in 
situ as compared with patients without ductal carcinoma in situ (HR = 0.74, 95% CI 
0.63– 0.87, P < 0.01; Figure 3a). Subgroup analyses showed that this effect is mainly 
driven by the Luminal A cases (HR = 0.64, 95% CI 0.49–0.84, P < 0.01; Figure 3b) and 
Luminal B HER2+ patients (HR = 0.34, 95% CI 0.15-0.79, Po0.01; Figure 2d) and was not 
seen in the Luminal B HER2 − cases (HR = 0.91, 95% CI 0.72–1.16, P = 0.44; Figure 2c).
Figure 3. Kaplan-Meier curves for Overall Survival of all M0 patients with DCIS versus patients without 
DCIS (figure A) and subgroup analyses for Luminal A (figure B), Luminal B HER2- (figure C) and luminal B 
HER2+ (figure D) cases.
A multivariate Cox model for overall survival was fitted including potential 
confounding covariates (Table 4). After adjusting for these factors in this model, there 
was a trend that the presence of ductal carcinoma in situ was associated with a better 
overall survival, in the Luminal A but in particular in the Luminal B HER2+ subgroup.
Table 4. Multivariate Cox model for Overall Survival (N=749) for Luminal A-like and Luminal B-like cases.
Multivariate Cox Model for Overall Survival
Parameter Hazard
Ratio
95% Hazard Ratio 
Confidence Limits
p-value
Age at diagnosis <.0001
≤ 40 (reference) 1
41 - 50 0.94 0.26 3.37
51 - 65 1.38 0.43 4.45
66 - 75 2.35 0.73 7.56
> 75 4.70 1.47 15.12
M status <.0001
M0 (reference) 1
M1 3.58 2.22 5.77
LN status 0.118
Negative (reference) 1
Positive 1.22 0.95 1.56
T status <.0001
T1 (reference) 1
T2 1.67 1.28 2.18
T3 2.44 1.19 5.02
T4 2.19 1.55 3.09
BC subtype 0.052
Luminal A (reference) 1
Luminal B (HER2 negative) 1.18 0.84 1.66
Luminal B (HER2 positive) 0.28 0.09 0.93
DCIS by BC subtype 0.062
DCIS (yes vs no) lum A 0.85 0.58 1.24
DCIS (yes vs no) lum B HER2- 1.17 0.85 1.61
DCIS (yes vs no) lum B HER2+ 0.21 0.06 0.77
Histological type 0.14
Invasive ductal (reference) 1
invasive lobular 1.64 0.75 3.58
Other 0.76 0.52 1.11
Grade of Invasive BC 0.54
1 (reference) 1
2 1.14 0.83 1.57
3 1.24 0.85 1.81
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DISCUSSION
In our series, a substantial proportion (46%) of patients with invasive breast cancer 
also had adjacent ductal carcinoma in situ. Although we cannot draw conclusions 
regarding the exact frequency of ductal carcinoma in situ adjacent to male breast 
cancer (since we only received one block/ patient), we can conclude that ductal 
carcinoma in situ is present in a large proportion of male breast cancer. There was 
a strong positive correlation between nuclear grade, ER, PR, and HER2 status of 
ductal carcinoma in situ and the adjacent invasive breast cancer. In line with this, 
molecular analysis confirmed similarities on the genomic level, including identical 
PIK3CA, GATA3, TP53, and MAP2K4 mutations in both components. These data are 
supportive but not definitive evidence that ductal carcinoma in situ represents a 
precursor lesion of male breast cancer.
The frequency of lobular carcinoma in situ in our series was very low (< 1%), 
which is in line with the very low incidence of invasive lobular carcinoma previously 
reported in male breast cancer patients. No classic columnar cell-like lesions were 
reported in this large series of male breast cancer patients, which is in line with a 
previous smaller series.7 However, we reported a few cases with columnar cell-like 
lesions adjacent to invasive breast cancer, including dilated, twisted ducts with apical 
snouts, and morphological resemblance with the adjacent invasive component. 
These ducts lacked the classical morphology of female columnar cell-like lesions, 
including rounded ducts with intraluminal calcifications, which limits the ability to 
recognize these lesions. Therefore, since distinct morphological criteria to define 
columnar cell-like lesions in male are lacking, the incidence remains unknown. In 
our series, we reported several identical genomic alterations, including PIK3CA and 
GATA3 mutations, in two out of three patients with a columnar cell-like lesion and an 
adjacent invasive component.
A limitation of this study is that next generation sequencing analysis was 
performed on only a small subset of cases with a columnar cell-like lesion, due to 
the low detection rate and the lack of available tissue blocks to perform additional 
analyses. Regarding ductal carcinoma in situ, there was not such a restriction 
regarding availability of tissue, but performing next generation sequencing on 
more samples would not have changed the conclusion that ductal carcinoma in 
situ is indeed a precursor of male breast cancer. Another limitation is that we only 
sequenced a panel of selected tumor-specific variants and, therefore, we were not 
able to evaluate the full spectrum of mutational events. A larger panel could have 
identified additional genes. However, the goal of this part of the study was to support 
the morphological finding of resemblance of the columnar cell-like lesions and the 
adjacent invasive component by providing additional information on the genetic level, 
rather than providing an overview of all mutations present in these lesions.
 In women, ductal carcinoma in situ is more often detected adjacent to ER, PR, 
and/or HER2 positive invasive breast cancer. In this male breast cancer series, there 
was no significant association between the presence of ductal carcinoma in situ and 
surrogate breast cancer subtype. A potential explanation for this difference is the 
different distribution of breast cancer surrogate subtypes in men as compared with 
women, including a low frequency of HER2+ and triple negative cases.
In the literature, no data exist regarding the association between the presence of 
ductal carcinoma in situ and outcome of male breast cancer. In our series, Luminal A 
and Luminal B HER2+ patients with an adjacent ductal carcinoma in situ component 
were observed to have a better overall survival compared with those without a 
ductal carcinoma in situ component, also after adjustment for potential confounders, 
which suggests that coexisting ductal carcinoma in situ could represent an earlier 
or biologically less aggressive form of disease. However, the observed associations 
between the presence of ductal carcinoma in situ with clinical outcome in this study 
should be interpreted cautiously since the treatments these patients received were 
not highly standardized and not controlled by protocols. Therefore, the reported 
analysis is informative and hypothesis generating but cannot be considered a classical 
prognostic factor analysis.
In conclusion, this is the first and largest study describing the presence and 
significance of breast cancer precursor lesions in male breast cancer, supplemented 
with next generation sequencing. Ductal carcinoma in situ seems to be the most 
common precursor lesion in male breast cancer, as in female patients. The frequency 
of lobular carcinoma in situ was very low, which is in line with the low frequency 
of lobular carcinomas in male patients. Based on our data, no definite conclusion 
can be drawn regarding the prevalence of columnar cell-like lesions in men, but the 
morphological and genetic overlap between columnar cell-like lesions and adjacent 
invasive breast cancer suggest a possible causal relationship between these lesions.
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ABSTRACT
Characterizing male breast cancer (BC) and unraveling male breast carcinogenesis 
is challenging because of the rarity of this disease. We investigated copy number 
status of 22 BC-related genes in 18 cases of pure ductal carcinoma in situ (DCIS) and 
in 49 cases of invasive carcinoma (IC) with adjacent DCIS (DCIS-AIC) in males using 
multiplex ligation-dependent probe amplification (MLPA). Results were compared to 
female BC and correlated with survival. Overall, copy number ratio and aberration 
frequency including all 22 genes showed no significant difference between the 3 
groups. Individual unpaired analysis revealed a significantly higher MTDH copy 
number ratio in IC compared to DCIS-AIC and pure DCIS (P = 0.009 and P = 0.038, 
respectively). ADAM9 showed a significantly lower copy number aberration frequency 
in male BC, compared to female BC (P = 0.020). In DCIS-AIC, MTDH, CPD, CDC6 and 
TOP2A showed a lower frequency of copy number increase in males compared to 
females (P < 0.001 for all 4 genes). In IC, CPD gain and CCNE1 gain were independent 
predictors of poor overall survival. In conclusion, male DCIS and IC showed a similar 
copy number profile for 21 out of 22 interrogated BC-related genes, illustrating their 
clonal relation and the genetically advanced state of male DCIS. MTDH showed a 
higher copy number ratio in IC compared to adjacent and pure DCIS and may therefore 
play a role in male breast carcinogenesis. Differences were detected between male 
and female DCIS for 4 genes pointing to differences in breast carcinogenesis between 
the sexes.
INTRODUCTION
Breast carcinogenesis is a multi-step process involving accumulation of DNA 
alterations and epigenetic changes. An important event during cancer development 
is oncogene amplification. Several genes have been described to be frequently 
amplified in female breast cancer (BC), of which the best-known example is the human 
epidermal growth factor receptor 2 (HER2). HER2 is amplified in 10–20% of female BC 
and is correlated to overall survival, time to relapse and response to trastuzumab, a 
humanized monoclonal anti-HER2 antibody (Slamon et al. 1987, Hudis 2007, Moelans 
et al. 2009). Other oncogenes that have been described to have clinical implications in 
female BC include the estrogen receptor (ESR1), epidermal growth factor receptor 1 
(EGFR), MYC, topoisomerase IIa (TOP2A), fibroblast growth factor receptor 1 (FGFR1), 
cyclin E (CCNE1) and cyclin D1 (CCND1) (Holst et al. 2007, Rodriguez-Pinilla et al. 2007, 
Turner et al. 2010, Holm et al. 2012, Masuda et al. 2012, Almeida et al. 2014, Lundgren 
et al. 2015).
Invasive ductal type cancers (IDC) of the breast are thought to arise from ductal 
carcinoma in situ (DCIS) via parallel breast cancer progression pathways in which 
low-grade DCIS progresses to low-grade IDC and high-grade DCIS to high-grade IDC. 
These parallel pathways have been postulated to have distinct genomic aberrations 
(Hwang et al. 2004, Moelans et al. 2010a, Burger et al. 2013). Progression through 
grade is a phenomenon that has been rarely observed in BC (Schymik et al. 2012).
The final step in breast carcinogenesis, where the basement membrane of the 
ducts is breeched and the malignant epithelial cells infiltrate the surrounding stroma, 
is poorly understood. Several female BC studies have shown similar levels of gene 
amplification in DCIS and adjacent IC, indicating that these genes play an early role 
in breast carcinogenesis, but not in the progression from DCIS to invasive carcinoma 
(Aubele et al. 2000, Burkhardt et al. 2010, Moelans et al. 2010a). Furthermore, not 
all patients diagnosed with pure DCIS show progression to IC when left untreated. 
A previous study showed progression from low-grade DCIS to IC in 11/28 cases, 
the remaining cases showing an indolent course (Sanders et al. 2005). Therefore, 
unraveling the drivers that control the progression of DCIS to IC has proved to 
be challenging in female BC, let alone in male BC, where the rarity of the disease 
hampers thorough investigation. This knowledge is however needed to understand 
the biological course of male DCIS, to predict patients’ outcome and to optimize DCIS 
treatment strategies. In this study, we compare pure DCIS, DCIS adjacent to IC (DCIS-
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AIC) and IC, as differences at molecular level have been described between these two 
types of DCIS in females, using RT-PCR (Doebar et al. 2017).
Male BC is a rare disease, accounting for approximately 1% of all BC (Siegel et 
al. 2015). Pure DCIS represents approximately 5% (range 1–17%) of all cancers in the 
male breast (Pappo et al. 2005). In female BC, the diagnosis of pure DCIS is made in 
approximately 20% of all BC, and this difference in DCIS frequency between male and 
female BC can perhaps be explained by the participation of women in BC screening 
programs (Leonard & Swain 2004).
There are many similarities but also important differences between male and 
female BC. There are differences in distribution of histologic subtypes as well as 
molecular subtypes; men tend to be older at the time of diagnosis and have more 
advanced disease at presentation compared to women (Giordano et al. 2004, Ge et 
al. 2009, Anderson et al. 2010, Kornegoor et al. 2012b). Also, there is some evidence 
suggesting differences in gene amplification frequencies (Kornegoor et al. 2012a). 
In a previous male BC study, gain of CCND1 and EGFR was more frequent in male 
BC compared to female BC, and amplification of TRAF4 and EMSY was more often 
observed in female BC in comparison to male BC (Kornegoor et al. 2012a). In the 
present study, we used multiplex ligation-dependent probe amplification (MLPA) to 
investigate DNA copy number changes of 22 breast cancer-related genes in a group 
of male IC with adjacent DCIS and in a group of male pure DCIS. We correlated these 
copy number aberrations with clinicopathologic features and 10-year survival data 
and compared our results to a previous female BC study using a similar MLPA kit 
(Moelans et al. 2010a).
MATERIALS AND METHODS
Patient material
Patients with DCIS and adjacent IC or pure DCIS were enrolled from a previously 
selected large male BC cohort (Cardoso et al. 2015, Vermeulen et al. 2017). A subgroup 
of this initial population was selected based on availability of a tumor tissue block for 
central pathology review and sufficient tissue for DNA isolation. This resulted in a total 
of 51 cases with IC and adjacent DCIS and 20 cases of pure DCIS. Patient and tumor 
characteristics including age at diagnosis and 10-year overall survival status (defined 
as death due to any cause) were recorded. Data concerning BRCA1/2 testing was 
not available. Hematoxylin and eosin (H&E) slides were reviewed by an experienced 
pathologist to confirm the diagnosis and to type and grade the IC according to the 
World Health Organization and modified Bloom and Richardson score (Elston & Ellis 
1991). DCIS was graded according to the classification by Holland and coworkers 
(1994). ER, PgR and HER2 were evaluated using immunohistochemistry and scored 
according to the Allred score (Allred et al. 1998) and ASCO-CAP guidelines (Wolff et al. 
2013). The areas of interest (pure DCIS, DCIS-AIC and IC) were dissected either manually 
with a sterile scalpel when big enough or by laser capture microdissection using a 
Zeiss PALM MD3 laser microdissection system, from 5 sections (4 μm) of formalin-fixed 
paraffin-embedded (FFPE) tissue blocks. Laser capture microdissection was done in 
cases with only small areas of DCIS or with abundant inflammatory cells surrounding 
the area of interest. The DNA was extracted by overnight incubation in proteinase K 
(10 mg/mL; Roche) at 56°C, followed by boiling for 10 min and centrifugation. Normal 
male breast tissue was taken along as control. Results from a previous female BC 
study comparing DCIS and adjacent IC (N = 39) using a similar MLPA kit were used to 
compare copy number status in female and male BC (Moelans et al. 2010a).
Clinicopathological data are shown in Table 1. Hormone receptor status showed a 
high concordance (100%) between DCIS and adjacent IC.
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Table 1. Clinicopathological data of all male breast cancer cases (invasive carcinoma (IC), male pure 
ductal carcinoma in situ (pure DCIS) and DCIS adjacent to invasive carcinoma).
Invasive carcinoma Adjacent DCIS Pure DCIS
Age (years)
Mean (range) 63.2 (37-85) 63.2 (37-85) 62.3 (37-76)
Histologic subtype IC
Ductal type carcinoma 46 (90.2 %)
Mucinous carcinoma 1 (2 %)
Micropapillary carcinoma 1 (2 %)





1 14 (27.5 %) 11 (21.6 %) 3 (15 %)
2 22 (43.1 %) 32 (62.7 %) 16 (80 %)
3 15 (29.4 %) 8 (15.7 %) 1 (5 %)
ER
Positive 51 (100 %) 51 (100 %) 20 (100 %)
Negative 0 (0 %) 0 (0 %) 0 (0%)
PR
Positive 49 (96.1 %) 49 (96.1 %) 20 (100 %)
Negative 2 (3.9 %) 2 (3.9 %) 0 (0%)
HER2
Positive 2 (3.9 %) 2 (3.9 %) 1 (5.3 %)
Negative 49 (96.1 %) 49 (96.1 %) 18 (94.7 %)
Missing 0 0 1
Multiplex Ligation-dependentProbe Amplification (MLPA)
MLPA analysis was performed on all isolated DNA using the P078-C1 kit (MRC Holland, 
Amsterdam, The Netherlands), containing 41 probes targeting 22 breast cancer-related 
genes (Supplementary Table 1, see section on supplementary data given at the end of 
this article). MLPA was performed according to the manufacturer’s instructions (MRC 
Holland), using an ABI 9700 PCR machine (Applied Biosystems). All tests were done 
in duplicate, and each MLPA run included 7 negative reference samples (3 healthy 
blood samples, 3 normal male breast FFPE samples and 1 normal female breast FFPE 
sample). The PCR products were separated by capillary electrophoresis on a 3730 DNA 
analyzer (Applied Biosystems). Gene copy numbers were analyzed using GeneScan 
analysis (Applied Biosystems) and Coffalyser. net software (MRC-Holland). For genes 
targeted by more than one probe, the mean of all probe ratios was calculated. Four 
of the 12 reference probes showed above average copy number variations and were 
excluded from further analyses (NRAP located at 10q25.3, TGIF1 located at 18p11.31, 
CETN3 located at 05q14.3 and SNCA located at 04q22.1).
Cut-off values were set as described previously with a copy number ratio of <0.7 for 
gene loss, 1.3–2.0 for copy number gain and >2.0 for amplification (Moelans et al. 
2010a, Kornegoor et al. 2012a). Values between 0.7 and 1.3 were considered copy 
number neutral.
Statistics
Statistical calculations were done using SPSS, version 21.0. The Kruskal–Wallis test 
was used to compare the overall copy number ratio including all 22 genes between 
the 3 groups and to compare copy number ratios between the 3 groups for the 22 
individual genes. After dichotomization, the chi-square test was used to compare 
the frequency of gains, amplifications or losses between groups. Mean copy number 
aberration frequency, for gains, amplifications and losses, including all genes was 
analyzed using the Kruskal– Wallis test. Individual genes in pure DCIS and DCIS-AIC 
were compared using Mann–Whitney test for copy number ratio and chi-square for 
dichotomized results. For paired data (IC and DCIS-AIC) the Wilcoxon signed-rank 
test was used to compare mean copy number ratio, and McNemar’s test was used to 
compare copy number aberration frequency for the 22 individual genes. The overall 
copy number ratios between low/ intermediate-grade and high-grade DCIS, as well as 
between low/intermediate-grade and high-grade IC were compared by Mann–Whitney 
test. Dichotomized data per grade category were evaluated by chi-square. P values 
less than 0.05 were considered significant and correction for multiple comparisons 
was done using the Holm–Bonferroni method. Survival data were available for all IC 
and DCIS-AIC cases with a median follow-up of 8.1 years (range 0.86–19.56 years). 
For univariate survival analysis, Kaplan– Meier curves were plotted and analyzed 
with the log-rank test. Multivariate survival analysis was done with Cox regression 
(backward LR) and included age, mitosis and grade. Finally, unsupervised hierarchical 
clustering (Euclidian distance method) of copy number ratios was performed using 
the statistical program R (www.r-project.org).
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RESULTS
Copy number ratio and aberration frequencies in DCIS and invasive carcinoma
One case of invasive carcinoma, one case of DCIS-AIC and two cases of pure DCIS had 
an insufficient DNA yield and were excluded from further analysis, leaving 49 cases 
of DCIS with adjacent IC and 18 cases of pure DCIS suitable for copy number analysis. 
Supplementary Table 2 shows raw MLPA copy number data.
Table 2 summarizes copy number status for all 22 analyzed genes in each 
subgroup and Fig. 1 illustrates the copy number aberration frequency for each studied 
gene. The frequencies of losses, gains and amplifications were similar between the 
three groups (P = 0.167, P = 0.132 and P = 0.361, respectively). Copy number gain/
amplification (cut-off >1.3) was most frequently observed for ZNF703, CCND1 and 
MYC, but none of these genes showed a significant difference between the groups.
Table 2. Frequencies of losses, gains and amplifications in 22 genes for male pure ductal carcinoma in situ 
(pure DCIS), DCIS adjacent to invasive carcinoma (DCIS-AIC) and invasive carcinoma (IC) including the p-value 
for gain/amplification (copy number ratio >1.3), amplification (copy number ratio >2.0), and the average copy 
number aberration frequency for all 22 genes.
Frequencies (%)





















































































































ESR1 6q25.1 0 0 0 1 (2%) 5 (10%) 0 0 5 (10%) 0 0.362 .
EGFR 7p11.2 0 2 (11%) 1 (6%) 0 5 (10%) 1 (2%) 0 8 (16%) 1 (2%) 0.697 0.701
ZNF703 8p11.23 0 11 (61%) 5 (28%) 0 22 (45%) 12 (24%) 1 (2%) 25 (51%) 10 (20%) 0.267 0.395
FGFR1 8p11.22 0 2 (11%) 1 (6%) 1 (2%) 11 (22%) 7 (14%) 1 (2%) 13 (27%) 7 (14%) 0.162 0.443
ADAM9 8p11.22 5 (28%) 0 1 (6%) 8 (16%) 7 (14%) 3 (6%) 9 (18%) 5 (10%) 4 (8%) 0.426 0.901
IKBKB 8p11.21 0 4 (22%) 0 0 7 (14%) 2 (4%) 0 15 (31%) 1 (2%) 0.252 0.682
PRMD14 8p13.3 0 4 (22%) 0 0 7 (14%) 1 (2%) 3 (6%) 12 (24%) 1 (2%) 0.375 0.817
MTDH 8q22.1 0 3 (17%) 2 (11%) 0 9 (18%) 1 (2%) 0 22 (45%) 1 (2%) 0.018 0.237
MYC 8q24.21 0 4 (22%) 2 (11%) 0 17 (35%) 3 (6%) 3 (6%) 14 (29%) 9 (18%) 0.429 0.137
CCND1 11q13.3 0 7 (39%) 1 (6%) 0 18 (37%) 8 (16%) 0 24 (49%) 9 (18%) 0.166 0.241
C11ORF30 11q13.5 0 1 (6%) 0 2 (4%) 3 (6%) 1 (2%) 5 (10%) 3 (6%) 1 (2%) 0.897 0.814
CDH1 16q22.1 0 4 (22%) 0 1 (2%) 9 (18%) 1 (2%) 2 (4%) 8 (16%) 2 (4%) 0.992 0.618
CPD 17q11.2 1 (6%) 0 0 7 (14%) 0 0 5 (10%) 4 (8%) 0 0.061 .
MED1 17q12 0 2 (11%) 1 (6%) 0 11 (22%) 2 (4%) 1 (2%) 10 (20%) 7 (14%) 0.295 0.148
ERBB2 17q12 0 5 (27%) 1 (6%) 0 7 (14%) 2 (4%) 0 9 (18%) 3 (6%) 0.423 0.857
CDC6 17q21.2 0 1 (6%) 0 1 (2%) 2 (4%) 1 (2%) 6 (12%) 4 (8%) 2 (4%) 0.376 0.532
TOP2A 17q21.2 0 0 0 1 (2%) 2 (4%) 2 (4%) 2 (4%) 5 (10%) 3 (6%) 0.109 0.483
MAPT 17q21.31 0 2 (11%) 0 1 (2%) 4 (8%) 0 1 (2%) 6 (12%) 1 (2%) 0.628 0.486
PPM1D 17q23.2 0 1 (6%) 0 1 (2%) 3 (6%) 2 (4%) 1 (2%) 4 (8%) 2 (4%) 0.715 0.672
BIRC5 17q25.3 0 3 (17%) 0 0 8 (16%) 0 1 (2%) 9 (18%) 2 (4%) 0.682 0.231
CCNE1 19q12 0 0 0 1 (2%) 1 (2%) 0 1 (2%) 3 (6%) 0 0.366 .
AURKA 20q13.2 1 (6%) 0 0 2 (4%) 8 (16%) 1 (2%) 3 (6%) 8 (16%) 2 (4%) 0.166 0.566
Total 7 56 15 27 166 50 45 216 68 0.133 0.012
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Figure 1. Frequencies of gain/amplification by MLPA for all 22 analyzed genes in male pure ductal car-
cinoma in situ (pure DCIS), DCIS adjacent to invasive carcinoma (DCIS-AIC) and invasive carcinoma(IC).
Overall, the copy number ratio including all 22 genes showed no significant difference 
between pure DCIS, DCIS-AIC and IC. At the individual gene level, MTDH showed a 
significantly higher copy number ratio in IC as compared to DCIS-AIC and pure 
DCIS (P = 0.009 and P = 0.038, respectively). Using a cut-off of >1.3, MTDH showed 
a significantly higher aberration frequency in IC (46.9%) as compared to DCIS-AIC 
(20.4%) (P = 0.005).
The copy number ratio for PRDM14, C11ORF30 and FGFR1 was higher in DCIS-AIC 
compared to pure DCIS (P = 0.007, P = 0.027 and P = 0.042, respectively). However, 
these genes lost their significance after dichotomization.
No significant differences were found when comparing copy number aberration 
frequency (gain and amplification) with histologic subtype in IC, although these 
results should be interpreted with caution due to small sample sizes.
Paired comparison of DCIS-AIC and adjacent IC showed a high concordance of copy 
number status for all interrogated genes, with no significant differences present. The 
highest concordance rates were seen for the genes CCNE1 (95.9%) and CDC6 (93.9%). 
Copy number ratio was significantly higher in IC compared to the paired DCIS-AIC 
for MTDH (P < 0.001), MYC (P = 0.039), CPD (P = 0.015), TOP2A (P = 0.043) and PPM1D 
(P = 0.036). Figure 2 shows the median copy number ratio for the 22 analyzed genes 
and Fig. 3 the copy number ratio for MTDH, MYC, CPD, TOP2A and PPM1D in paired 
IC and DCIS-AIC.
Figure 2. Median copy number ratio for all 22 analyzed genes in male invasive carcinoma (IC) and adja-
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Figure 3. Copy number ratios for MTDH, MYC, CPD, TOP2A and PPM1D in male invasive carcinoma (IC) and 
adjacent ductal carcinoma in situ (DCIS-AIC).
Correlation between copy number and grade in DCIS-AIC and invasive 
carcinoma
Copy number ratios and aberration frequencies were compared for DCIS-AIC and IC 
between low/ intermediate-grade and high-grade lesions. The mean copy number 
ratio was 1.17 ± 0.22 vs 1.32 ± 0.25 for low/ intermediate-grade vs high-grade DCIS-
AIC (P = 0.165), and 1.15 ± 0.16 vs 1.42 ± 0.44 for low/intermediate grade vs high grade 
IC (P = 0.040). The average number of gains/ amplifications in the 22 analyzed genes 
was 3.7 vs 8.4 for low/intermediate-grade vs high-grade DCIS-AIC (P = 0.019) and 4.8 
vs 8.3 for low/intermediate-grade vs high-grade IC (P = 0.037).
DCIS-AIC showed a significantly higher copy number ratio in high-grade lesions for 
the genes ESR1 (P = 0.047), PPM1D (P = 0.004), BIRC5 (P = 0.002) and CCNE1 (P = 0.005). 
After dichotomization (cut-off >1.3), these differences remained significant (P < 0.001, 
P = 0.002, P = 0.040 and P = 0.014, respectively). In addition, PRDM14 (P = 0.040), CDC6 
(P = 0.003), TOP2A (P = 0.018) and AURKA (P = 0.006) showed a significantly higher copy 
number aberration frequency in high-grade DCIS-AIC lesions. Only MTDH showed a 
significantly higher frequency of amplification in high-grade DCIS-AIC (P = 0.007).
IC showed a significantly higher copy number ratio in high-grade lesions for the genes 
EGFR (P = 0.005) and CCND1 (P = 0.005). Dichotomized data (cut-off >1.3) showed 
a significantly higher aberration frequency for ESR1 (P = 0.007), EGFR (P = 0.047), 
C11ORF30 (P = 0.001), CDC6 (P = 0.022) and PPM1D (P = 0.020) in high-grade lesions. 
ADAM9 (P = 0.029), MYC (P = 0.031), CCND1 (P = 0.005), CDH1 (P = 0.029), CDC6 
(P = 0.013), TOP2A (P = 0.004) and PPM1D (P = 0.012) showed significant amplification 
more often in high-grade lesions.
After correction for multiple comparisons, only BIRC5 in DCIS-AIC remained significant 
with regard to copy number ratio difference (1.068 in low/intermediate grade vs 1.353 
in high grade). For the dichotomized data, C11ORF30 in IC (17.1% in low/intermediate 
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Comparison of DCIS-AIC and IC copy number status between male and female 
breast cancer
Results from a previous female BC study including 39 patients (IC and adjacent DCIS) 
were used to compare copy number status between female and male BC (Moelans et 
al. 2010a). This previous study used a prior version of the MLPA kit used here. Twenty 
genes were similar in both MLPA kits, with some differences in the probes used for 
the genes and were used for analysis. In IC, ADAM9 showed a significantly lower copy 
number aberration frequency (cut-off >1.3) in male BC (22.5%) compared to female BC 
(56.4%) (P = 0.020). In DCIS, MTDH, CPD, CDC6 and TOP2A showed a lower frequency of 
copy number increase in male compared to female BC (P < 0.001 for all 4 genes) (Fig. 
4). The frequencies of amplifications (cut-off >2.0) and losses were similar between 
female and male BC.
Figure 4. Frequency of copy number increase (cut-off >1.3) in female and male ductal carcinoma in situ 
(DCIS). Genes with a diamond show a significantly higher frequency of copy number gain in female BC.
In addition, we compared copy number aberration frequencies of 21/22 interrogated 
genes (EMSY data not available) with a large public female breast cancer 
cohort (METABRIC, www.cbioportal.org, (Curtis et al. 2012, Pereira et al. 2016)). 
Supplementary Table 3 shows a high amplification frequency similarity for all genes 
except for PRDM14 and MTDH, which both showed a difference of at least 10% in 
amplification frequency, with a higher amplification percentage in the METABRIC 
population (N = 2173).
Supplemental table 3.
    METABRIC MALE BC METABRIC MALE BC
Gene N Missing Total gain (%) gain (%) amplification(%) amplification(%)
ESR1 2509 336 2173 6,44 10,0 2,30 0,0
EGFR 2509 336 2173 14,13 16,0 2,39 2,0
ZNF703 2509 336 2173 12,10 51,0 14,27 20,0
FGFR1 2509 336 2173 12,47 27,0 13,12 14,0
ADAM9 2509 336 2173 12,33 10,0 11,23 8,0
IKBKB 2509 336 2173 15,14 31,0 10,26 2,0
PRDM14 2509 336 2173 21,58 24,0 15,74 2,0
MTDH 2509 336 2173 22,46 45,0 19,24 2,0
MYC 2509 336 2173 22,09 29,0 25,49 18,0
CCND1 2509 336 2173 11,18 49,0 16,29 18,0
EMSY 2509 2509 0  6,0 2,0
CDH1 2509 336 2173 2,95 16,0 0,18 4,0
CPD 2509 336 2173 8,10 8,0 2,76 0,0
MED1 2509 336 2173 8,51 20,0 11,92 14,0
ERBB2 2509 336 2173 8,42 18,0 15,74 6,0
CDC6 2509 336 2173 8,65 8,0 6,53 4,0
TOP2A 2509 336 2173 8,74 10,0 4,92 6,0
MAPT 2509 336 2173 8,70 12,0 1,10 2,0
PPM1D 2509 336 2173 14,17 8,0 10,08 4,0
BIRC5 2509 336 2173 16,57 18,0 5,71 4,0
CCNE1 2509 336 2173 7,87 6,0 2,81 0,0
AURKA 2509 336 2173 20,66 16,0 6,35 4,0
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Correlation between copy number alterations and survival
CPD and CCNE1 gain (no amplifications were observed) in IC were predictors of 
poor 10-year overall survival (P = 0.050 and P = 0.001) and remained independent 
prognosticators when grade, mitoses and age were included in multivariable analysis 
(P = 0.017 (HR 5.1) and P = 0.003 (HR 6.9)). Kaplan–Meier curves are presented in Fig. 
5. None of the other interrogated genes were associated with survival.
Figure 5. K Kaplan-Meier 10-year overall survival plots for CCNE1 gain and CPD gain.
Cluster analysis of all male pure DCIS, DCIS-AIC and IC lesions
Unsupervised hierarchical cluster analysis of all pure DCIS, DCIS-AIC and IC showed 2 
main clusters that differed significantly according to grade (grade 1/2 vs grade 3) with 
more high-grade lesions in cluster B (n = 29) compared to cluster A (n = 20) (P = 0.001) 
(Fig. 6). In addition, all genes showed a higher copy number ratio in cluster B. Of the 
49 paired DCIS-AIC and IC samples in the cluster analysis, 40 samples (81.6%) were in 
the same cluster, and of these, 17 pairs (34.7%) clustered closely together indicating 
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DISCUSSION
To discover drivers that may control the progression of DCIS to IC and to establish 
the precursor role of DCIS in male breast carcinogenesis, we studied copy number 
status of 22 breast cancer-related genes in IC, DCIS-AIC and pure DCIS of the male 
breast by MLPA. Overall, in line with previous studies on their female counterparts, 
there were only few copy number differences between male DCIS and IC (Aubele 
et al. 2000, Burkhardt et al. 2010, Moelans et al. 2010a). Copy number ratios were 
similar in pure DCIS, DCIS-AIC and IC for most of the studied genes, indicating that 
copy number gain of the majority of these genes does not seem to play a significant 
role in the transition from male DCIS to IC. This finding is in line with a previous copy 
number and gene expression study in female BC (Moelans et al. 2010a). There was 
however one gene, MTDH, that showed a significantly higher copy number ratio and 
frequency of gain in IC as compared to DCIS-AIC. This implies that gain of MTDH 
could play a role in the progression of DCIS to IC. In a previous MLPA-based male 
BC study, MTDH showed gain/amplification in 46% of the IC samples, similar to our 
results (Kornegoor et al. 2012a). MTDH is located on chromosome 8 and encodes 
Metadherin, a transmembrane protein that plays a key role in the activation of several 
signaling pathways including PI3K/Akt, NFκβ, Wnt/βcatenin and the MAPK pathways 
(Shi & Wang 2015). These pathways play a role in cell proliferation, apoptosis, invasion, 
angiogenesis and metastasis. Metadherin is frequently overexpressed in female BC 
and overexpression correlates with advanced clinical stage, distant metastasis and an 
aggressive phenotype (Tokunaga et al. 2014). Moelans and coworkers compared MTDH 
copy number in 39 paired cases of female DCIS-AIC and IC but found no significant 
differences in copy number ratio, suggesting that this event may be specific for male 
breast carcinogenesis (Moelans et al. 2010a).
Interestingly, almost all of the analyzed genes showed copy number changes 
in DCIS, indicating that copy number gain is a relatively early event in male 
breast carcinogenesis. Paired analysis of IC and DCIS-AIC samples showed a high 
concordance of gain/amplification status between individual patients, supported by 
cluster analysis. This confirms the clonal relation between male DCIS and IC, as has 
also been accepted in female breast carcinogenesis (Moelans et al. 2010a). CCND1, 
a cell cycle regulatory protein, showed a high copy number aberration frequency in 
all three groups with 49% CCND1 gain and 18% CCND1 amplification in IC. CCND1 
amplification is more frequent in ER-positive and PR tumors, so these high frequencies 
can be explained by the high rate of ER positivity (all cases being ER positive) and PR 
positivity (96% of DCIS-AIC/IC cases and 100% of pure DCIS cases being positive) in 
our male BC cohort (Reis-Filho et al. 2006).
Several genes showed a higher aberration frequency in high-grade lesions compared 
to low-grade lesions (ESR1, PPM1D, BIRC5, CCNE1, PRDM14, CDC6, TOP2A and AURKA 
for DCIS-AIC and ESR1, EGFR, C11ORF30, CDC6 and PPM1D for IC). Also, the average 
copy number ratio was higher in high grade IC compared to low/ intermediate-grade 
IC. After correction for multiple comparisons, BIRC5 copy number ratio and ESR1 
gain in DCIS-AIC and C11ORF30 gain in IC were significantly higher/more frequent 
in high-grade lesions. Although the sample sizes of high-grade DCIS-AIC and high-
grade IC were small (n = 7 and n = 14, respectively), this does suggest that tumors 
with a higher copy number gain have a tendency to have higher histological grade, 
as previously demonstrated in male BC (Kornegoor et al. 2012a). BIRC5 codes for the 
protein Survivin, a regulatory protein involved in cell proliferation and apoptosis. It 
has been extensively studied in female BC where an increased expression of Survivin 
was correlated with a higher risk of recurrence and with a decreased overall survival 
rate (Davis et al. 2007, Li et al. 2014). ESR1 codes for estrogen receptor alpha, a 
transcription factor located on chromosome 6q25 and an important therapeutic 
target in female BC with tamoxifen being the standard endocrine therapy for ER-
positive breast cancers (Holst et al. 2007). In a previous study using MLPA, ESR1 
amplification and gain were shown in 2% and 6% of 135 female breast tumors, 
respectively (Moelans et al. 2011). C11ORF30 (also known as EMSY) is a transcription 
regulatory protein that can compromise BRCA2 function in sporadic breast cancer 
and ovarian cancer (Hughes-Davies et al. 2003). In female BC, it has been associated 
with a reduced overall survival in ER-positive patients (Kirkegaard et al. 2008).
Upon comparison of our findings with female BC, a high concordance was evident, 
especially for IC. For DCIS, 4 genes (MTDH, CPD, CDC6 and TOP2A) showed a higher 
frequency of gain in female BC, although no differences in amplification frequency 
were observed. Copy number aberration frequencies for 21 genes were also compared 
with a large female breast cancer cohort (METABRIC, www.cbioportal.org, (Curtis et 
al. 2012, Pereira et al. 2016)), showing a high amplification frequency similarity.
Two of the 22 studied genes showed a correlation with overall survival. CCNE1 and 
CPD gain were both indicative of a decreased 10-year overall survival; however, the 
number of cases showing gain of these genes (n = 3 and n = 4, respectively) were 
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small and none of the cases showed amplification. Also, treatment regimens and 
lymph node status were not known so could not be included in the survival analysis. 
Therefore, results should be interpreted with caution. High levels of Cyclin E have 
been described to have prognostic value in female breast cancer, especially as a 
predictor of endocrine therapy failure (Keyomarsi et al. 2002, Span et al. 2003).
CPD has been investigated in breast cancer cell lines (MCF-7 cells), where prolactin/17β-
estradiol-induced cell surface CPD increased intracellular NO production, which 
increased the survival and inhibited apoptosis (Abdelmagid & Too 2008).
Although a limitation of this study is the relatively small study population, it should 
be noted that male BC is rare, male DCIS is even rarer, and our DCIS samples have 
been extracted from a large cohort study and were enriched for tumor cells by scalpel 
or laser microdissection. We used MLPA for copy number analysis, a multiplex PCR-
based method that simultaneously assesses relative copy numbers of a variety of 
genes in a quantitative way. The major advantage of this technique is that it requires 
only minimal amounts of small DNA fragments, which makes it very suitable to 
study small lesions in paraffin-embedded tissue, such as DCIS (Moelans et al. 2009). 
The MLPA kit used was pre-designed by the manufacturer and contains 22 cancer-
related genes that often show copy number aberrations in female BC (Moelans et al. 
2010a,b). Although there are some genetic differences between male and female BC, 
we expected the bigger part of these genes to play a role in male breast carcinogenesis 
as well (Moelans et al. 2010b). We did not include PIK3CA, TP53 and GATA3, possible 
important genomic drivers in female BC and described to be frequently mutated 
in female BC (2012). In this study, we only focused on copy number variations and 
not on specific mutations. In conclusion, this MLPA-based study showed a similar 
copy number status for 21 out of 22 studied breast cancer-related genes in male DCIS 
and IC, illustrating the clonal relation between male DCIS and adjacent IC, and the 
genetically advanced state of male DCIS. MTDH showed a higher copy number ratio 
and aberration frequency in IC compared to DCIS and could therefore play a role in 
the transition of male DCIS to IC.
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This thesis describes several clinical and molecular aspects of DCIS and provides 
potential progression markers that could contribute to the development of 
personalized treatment strategies in patients with DCIS.
Chapter 1 provides an introduction on several histological, molecular and clinical 
DCIS characteristics, including an outline of this thesis. Chapter 2 describes a study 
aiming to find novel markers for upstaging to IBC in the surgical resection specimen, 
after having a diagnosis of pure DCIS based on needle biopsy, since this could aid in 
the selection of patients for nodal staging. According to current Dutch guidelines, 
several risk factors for upstaging have been proposed (i.e. palpable mass, young 
age (<55 years), enhancement on MRI, high grade DCIS and tumor size > 25 mm),1 
but these factors are suboptimal in daily clinical practice. This results in the use of 
a sentinel node biopsy (SNB) in patients with DCIS without clinical benefit and, in 
addition, secondary nodal staging for patients who did not undergo a SNB during the 
initial surgical procedure. In our study, we analyzed micro-environmental changes 
and epithelial characteristics of DCIS in needle-biopsies with DCIS only. Overall, 
the upstaging rate to IBC in our cohort was 22%. We reported several factors that 
were significantly associated with upstaging to invasive cancer in the final excision: 
palpability of the lesion, young age (≤ 40 years), mass lesion on imaging, peri-ductal 
changes such as inflammation and loss of Decorin expression. The upstaging-risk 
correlated with the number of risk factors present: i.e. 9% for patients without risk 
factors, 29% for patients with 1 risk factor, 37% for patients with 2 risk factors and 
54% for patients with ≥3 risk factors. Therefore, these factors may be helpful to 
select patients with a high upstaging-risk for nodal staging during the initial surgical 
procedure. Primary nodal staging could be avoided in low-risk patients undergoing 
breast-conserving surgery (BCS).
In chapter 3, the presence and extent of DCIS was evaluated within breast cancer 
subtypes in a large national population-based cohort of women treated for IBC. 
Substantial differences in clinical and pathological characteristics of DCIS were 
found within the breast cancer subtypes, including the resection margin status for 
patients treated with BCS. HER2+ IBC subtypes showed a higher prevalence and a 
larger extension of adjacent DCIS. In addition, this subgroup showed a higher rate 
of irradicality of the DCIS component as compared to HER2- IBC subtypes. This 
finding is consistent with previous studies reporting higher local recurrence rates 
after BCS of patients with HER2+ IBC, which might be due to an extensive DCIS 
component.2-4 Pre-operative knowledge regarding the extent of DCIS according to 
breast cancer subtype could support clinicians in adjusting local therapy control. 
In chapter 4, the biological behavior of DCIS was further evaluated by gene expression 
profiling. For this study, we hypothesized that extensive DCIS without any sign of 
invasion represents an indolent lesion with a limited invasive potential, harboring 
less molecular alterations, in comparison to small DCIS lesions adjacent to IBC, 
representing lesions with a high invasive potential. Our gene expression analysis 
indeed identified significant differences in the in situ component between patients 
with extensive pure DCIS versus patient with a limited DCIS component adjacent to 
IBC. Most of these differently expressed genes showed a higher expression in the DCIS 
component adjacent to IBC, including genes involved in several biological processes: 
signal transduction, chemotaxis, angiogenesis, cellular response to epidermal growth 
factor stimulus, positive regulation of extracellular signal regulated kinase 1 and 2 
cascade, response to hyperoxia and cellular response to amino acid stimulus. Based 
on these identified genes, it was possible to create a distinct gene expression pattern 
that discriminates DCIS lesions with invasion from pure DCIS lesions. Our findings 
were in line with previous studies that reported differences between pure DCIS lesions 
and DCIS with synchronous IBC based on gene copy number changes and whole 
sequencing.10,27 However, validation of these results in an independent larger cohort 
is required to validated whether these differently expressed genes could be used to 
predict progression in individual patients diagnosed with DCIS. This might improve 
individualized treatment strategies for these patients, in which the identified genes 
(involved in potentially targetable driver pathway(s) that play an important role in 
the progression of DCIS to IBC) might be inhibited in an early stage of breast cancer, 
which could ultimately result in the prevention of progression. Chapter 5 elaborates 
on gene expression differences between DCIS and paired IBC by evaluating APOBEC3B 
levels. Additionally, we correlated APOBEC3B levels with PIK3CA mutational status. 
Upregulated APOBEC3B plays an important role in several human cancers, which 
is associated with a high mutational load, including PICK3CA and TP53 mutations.5 
This enzyme is non-essential (not expressed in normal tissue) and therefore 
upregulation could be inhibited by small molecules. In our analysis, APOBEC3B mRNA 
levels were upregulated in both DCIS and adjacent IBC. No difference was measured 
in APOBEC3B between wild-type versus mutated PIK3CA DCIS, while APOBEC3B 
was higher in wild-type versus PIK3CA-mutated IBC. This might imply that once the 
invasive stage has been reached, PIK3CA is less important for further progression. 
Higher APOBEC3B levels were found in synchronous DCIS and IBC in ER- tumors as 
9
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compared to ER+ tumors. This is in line with previous studies that found upregulated 
APOBEC3B levels in breast cancer with aggressive characters.6,7-9 This chapter 
suggests that APOBEC3B could be a potential therapeutic target in patients with 
DCIS, although the development of inhibitors for related enzymes is still in progress 
and additional research is necessary to develop and explore the potential benefit of 
APOBEC3B inhibitors. In chapter 6 we described the results of in depth- sequencing 
of synchronous DCIS and IBC to find answers regarding the mechanism of DCIS 
progression. We found overlapping mutations between synchronous DCIS and IBC, 
which was consistent with previous molecular studies that found similar alterations 
between these two components.10,11 However, a proportion of mutations was only 
found in the invasive component, which implies that DCIS progression could be 
driven by the selection of subclones.10,12 In other words, DCIS evolution might follow 
a Darwinian evolution; distinct subclones with specific genetic changes are selected 
during invasion. This leads to differences in the prevalence of specific mutations 
between the neoplastic DCIS cells and the invasive counterpart. This knowledge might 
facilitate future studies in the search of potential markers that play an important role 
in the transition from DCIS to IBC.
In chapter 7 we evaluated the presence, characteristics and prognostic relevance 
of pre-cursor lesions adjacent to invasive cancer of the male breast in a large 
international cohort, supplemented with NGS data. In this cohort, male breast cancer 
showed a high prevalence of adjacent DCIS (46% of cases) while the frequency of 
other pre-cursor lesions (lobular carcinoma in situ, atypical ductal hyperplasia, 
and columnar cell-like lesions) was very low (< 1%). DCIS and adjacent invasive 
cancer showed a strong positive correlation for nuclear grade (p= <0.001) and a 
high concordance in receptor status of ER, PR and HER2. These strong similarities 
between synchronous DCIS and IBC, which is already known in female breast cancer, 
imply that DCIS is indeed a precursor lesion of male breast cancer. This was further 
supported by molecular analysis in a small subset of cases (n=4) that confirmed 
resemblances on the genomic level of well-known breast cancer mutations in both 
components (including identical PIK3CA, GATA3, TP53, and MAP2K4 mutations). In 
literature, the presence of columnar cell-like lesions in the male breast, as described 
in female breast, is controversial. In male, distinct morphological criteria to define 
columnar cell-like lesions are lacking and therefore the incidence remains unknown 
since the ability to recognize these lesions is limited. In our series, we recognized 
ducts with overlapping features as described for female columnar cell lesions. In a 
small subset of those lesions, NGS showed identical genomic alterations (including 
PIK3CA and GATA3 mutations) between the columnar cell-like lesion and adjacent 
invasive component. These similarities on the genomic level suggest a possible 
causal relationship between these lesions and support the role of columnar cell-like 
lesions as a precursor of male breast cancer. Our analysis regarding the presence 
of DCIS and clinical outcome showed that Luminal A and Luminal B HER2+ patients 
with an adjacent DCIS component had a better overall survival compared with those 
without an adjacent DCIS component. This suggests that IBC with coexisting DCIS 
of the luminal A and B subtype could represent a biologically less aggressive form 
of disease. In chapter 8, a subset of male breast cancer cases extracted from the 
same male breast cancer series as described in the previous chapter was further 
evaluated. For this analysis, male breast cancer, DCIS adjacent to MBC and pure male 
DCIS lesions were subjected to multiplex ligation-dependent probe amplification 
(MLPA) to investigate DNA copy number changes of 22 breast cancer-related genes. 
These results were compared to a previous analysis of copy number changes in female 
breast cancer using a similar MLPA kit. In addition, copy number aberrations were 
correlated with clinicopathologic features and 10-year survival data. This analysis 
demonstrated a similar copy number status of 21 out of 22 genes in MBC, synchronous 
DCIS adjacent to male breast cancer and pure male DCIS. This finding supports the 
clonal relation between male breast cancer and adjacent DCIS. Furthermore, it 
demonstrates the genetically advanced state of male DCIS; copy number changes are 
early events in male breast carcinogenesis. However, one gene, MTHD, involved in the 
activation of several signaling pathways including PI3K/Akt, NFκβ, Wnt/βcatenin and 
the MAPK pathways,13 showed a higher copy number ratio in the invasive component 
as compared to synchronous DCIS. In literature, this gene is also expressed in female 
breast cancer where it is associated with aggressive tumor behavior,14 suggesting that 
this gene might play an important role in the carcinogenesis of male breast cancer. 
Some genes showed a higher frequency of copy number aberrations in high-grade 
lesions as compared to low-grade lesions, including BIRC5 and ESR1 for DCIS adjacent 
to male breast cancer and C11ORF30 for male breast cancer. Although sample sizes 
were small, this suggests that a high frequency of copy number aberrations is seen 
in lesions of higher grade. Two out of the 22 studied genes, CCNE1 and CPD gain, 
were associated with a decreased 10-year overall survival. However, the numbers of 
cases with gain of these genes were small and should be interpreted with caution. 
The results of Chapter 7 and 8 contribute to a better understanding of early events 
in male breast carcinogenesis.
9
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PERSPECTIVES
Over the past years, DCIS and its progression to IBC has been an emerging field 
of research. There is a general consensus that current treatment guidelines for 
patients with DCIS are not specific enough, leading to overtreatment of a substantial 
proportion of patients. On the other hand, IBC remains the most common (1 out of 
8 women) and deadliest cancer in women worldwide, despite major global efforts 
to treat this disease. Therefore, the urgency is high to invest in research programs 
focusing on early therapeutic/preventive strategies, since only early intervention 
has the potential to substantially reduce breast cancer mortality and morbidity by 
decreasing the incidence. In this thesis, we demonstrated that DCIS is a heterogeneous 
disease including several subtypes with a different biological behavior and different 
underlying genetic changes. These features involve changes of the neoplastic DCIS 
cells, but also DCIS-associated micro-environmental changes, including stromal and 
inflammatory cells. This could be relevant since recent developments of immune 
therapies are rapidly progressing.
Many publications reported identical genomic profiles between DCIS and adjacent 
IBC. This finding makes it challenging to filter specific genetic changes that are 
related to invasive progression. However, novel molecular approaches such as in-
depth sequencing could enable us to identify predictive markers. This technique 
has already extensively been used to study IBC, which dramatically increased our 
knowledge regarding its mutational landscape and subclonal evolution. However, 
in-depth analysis of DCIS by NGS is still relatively sparse since several limitations 
were encountered such as insufficient input material and lack of fresh frozen tissue. 
In the last few years, innovative improvement increased the possibility to perform 
certain massive parallel sequence techniques (i.e. whole exome sequencing) on 
paraffin-embedded tissue blocks. In this thesis, we reported preliminary data of intra-
tumor heterogeneity of synchronous DCIS and IBC; specific genetic aberrations are 
restricted to the invasive component, which might be responsible for progression 
to invasive cancer. However, we are still in the beginning of this process, which will 
ultimately lead towards a more individual treatment for patients with DCIS.
There is a strong need for a risk stratification tool that distinguishes indolent DCIS 
from potentially hazardous DCIS. To develop and validate such a predictive tool, a 
strong collaborative approach between medical centers is necessary to obtain large 
cohorts of patients (including clinical, radiological and pathological data). Besides, 
it requires a multidisciplinary approach, including i.e. clinicians, pathologists, 
molecular biologists and bio-informaticians. Current histopathological grading 
of DCIS based on nuclear atypia is suboptimal due to inter-observer variability, 
resulting in suboptimal reproducibility. Since DCIS is a heterogeneous lesion and 
the full molecular portrait is not yet known, there should also be an emphasis on its 
molecular characterization, including the DCIS-associated microenvironment. For this 
matter, it is necessary to perform molecular assays on tissue blocks with sufficient 
DCIS and a high purity of DCIS and surrounding cells. This could contribute to an 
accurate interpretation of molecular data in which a full molecular portrait of DCIS 
can be obtained, which could be related to clinical outcome such as progression to 
IBC or DCIS recurrence. Ultimately, in the future, specific genetic signatures could 
be used to develop a targeted inhibition therapy contributing to the prevention of 
progression to IBC. Currently, prospective trials are ongoing in which patients with 
low and intermediate grade DCIS are subjected to active surveillance. Although this 
could provide important information regarding the biological behavior of low-grade 
DCIS based on histopathologic grading, there is a large need to have more robust and 
reproducible progression markers.
Collaborative efforts should lead to a multidisciplinary predictive stratification 
tool in which clinical and pathological parameters are integrated with molecular 
approaches. The clinical implementation of this algorithm could contribute to the 
selection of patients who can benefit from less invasive treatment. 9
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Dit proefschrift richt zich op klinische en moleculaire kenmerken van DCIS en beschrijft 
potentiele markers voor progressie die kunnen bijdragen aan de ontwikkeling van een 
meer gerichte behandelstrategie voor patiënten met DCIS.
Hoofdstuk 1 omvat een introductie over histologische, moleculaire en klinische 
karakteristieken van DCIS, inclusief de inhoudsopgave van dit proefschrift. 
Hoofdstuk 2 richt zich op het vinden van nieuwe markers die de aanwezigheid van 
invasief borstkanker kunnen voorspellen in het mamma resectiepreparaat bij een 
preoperatieve naaldbiopt diagnose van puur DCIS. Dit kan in deze groep patiënten 
namelijk bijdragen aan een betere selectie voor lymfklierstagering. De huidige 
nationale richtlijn beschrijft verschillende risicofactoren voor opwaardering naar 
invasief borstkanker (palpabele laesie, jonge leeftijd (< 55 jaar), versterkte opname 
van signaal op MRI, hooggradig DCIS en een diameter > 25 mm).1 Echter, in de 
dagelijkse praktijk is de toepassing van deze risicofactoren suboptimaal. Dit resulteert 
in een inadequate voorspelling van borstkanker, hetgeen leidt tot een overbodige 
schildwachtklier procedure bij patiënten met puur DCIS. Tegelijktijdig worden 
patiënten met een preoperatieve diagnose van puur DCIS, waarbij na de operatie toch 
een invasieve component gevonden wordt, onderworpen aan secundaire chirurgie 
om alsnog de lymfklieren te stageren. In dit hoofdstuk beschrijven we verschillende 
karakteristieken van zowel DCIS cellen als peri-ductale omgevingsfactoren in 
naaldbiopten met de diagnose van puur DCIS. In deze studie had 22% van de patiënten 
met een preoperatieve naaldbiopt diagnose van DCIS uiteindelijk toch invasief 
borstkanker in het resectiepreparaat. Verschillende risicofactoren waren significant 
geassocieerd met invasief borstkanker: palpabele laesie, jonge leeftijd (< 40 jaar), 
massa op beeldvorming, peri-ductale veranderingen zoals inflammatie en verlies 
van Decorine expressie. Het risico voor invasief borstkanker na chirurgie correleerde 
met het aantal aanwezige risicofactoren: 9% voor patiënten zonder risicofactoren, 
29% voor patiënten met 1 risicofactor, 37% voor patiënten met 2 risicofactoren en 
54% voor patiënten met ≥3 risicofactoren. Deze risicofactoren kunnen dus bijdragen 
aan een betere preoperatieve selectie van patiënten met een verhoogd risico voor 
invasief borstkanker, waarbij lymfklierstagering overwogen kan worden gedurende 
initiële chirurgie. Dit in tegenstelling tot patiënten met een laag risico voor invasief 
borstkanker waarbij primaire lymfklierstagering juist achterwege gelaten kan worden 
bij borst sparende chirurgie.
In hoofstuk 3 hebben we de uitgebreidheid van de DCIS component onderzocht bij 
verschillende borstkanker subtypes in een groot nationaal cohort, gebruik makend 
van een retrospectief landelijk cohort van patiënten die zijn geopereerd i.v.m. 
borstkanker. Er waren significante verschillen tussen de DCIS karakteristieken binnen 
de borstkanker subtypes. HER2 positieve borstkanker was vaker geassocieerd met 
een aanwezige DCIS component en deze DCIS component had een grotere omvang 
vergeleken met de overige borstkanker subtypes. Deze subgroep toonde ook een 
hoger percentage van een irradicaal gereseceerde DCIS component in vergelijking 
met HER2 negatieve subtypes. Deze bevindingen zijn consistent met voorgaande 
studies die een hoger lokaal recidief percentage rapporteerden na borst sparende 
chirurgie bij patiënten met een HER2 positieve borstkanker, waar een uitgebreide 
DCIS component de oorzaak zou kunnen zijn.2-4 Preoperatieve kennis omtrent de 
uitgebreidheid van de DCIS component bij verschillende types invasief borstkanker 
kan clinici ondersteunen bij de optimalisatie van lokale behandeling. In hoofdstuk 4 
wordt het biologische gedrag van DCIS verder onderzocht door gebruik te maken 
van genexpressie profielen. Onze hypothese was dat uitgebreide DCIS zonder invasie 
een indolente laesie vertegenwoordigt en waarschijnlijk minder onderliggende 
moleculaire afwijkingen heeft vergeleken met kleine DCIS laesies aangrenzend aan 
invasief borstkanker, dat een hoge potentie heeft op invasieve groei en waarschijnlijk 
meer onderliggende moleculaire afwijkingen. Deze hypothese werd ondersteund 
door onze genexpressie analyse waarbij significante verschillen werden gevonden 
tussen patiënten met een uitgebreide DCIS (zonder invasie) versus patiënten met 
een kleine DCIS component naast invasief borstkanker. De meeste van deze genen 
toonden een hogere expressie in DCIS aangrenzend aan invasief borstkanker. Deze 
genen zijn betrokken bij diverse biologische processen als signaal transductie, 
chemotaxie, angiogenese, cellulaire reactie op epidermale groei factor stimulus, 
positieve regulatie van extracellulaire signaal gereguleerde kinase 1 en 2 cascade, 
respons op hyperoxie en cellulaire respons op aminozuur stimulus. Op basis van de 
geïdentificeerde genen was het mogelijk een genexpressie patroon te genereren die 
puur DCIS laesies onderscheidt van DCIS met invasief borstkanker. Onze resultaten 
kwamen overeen met eerdere moleculaire studies (gen copy number en whole exome 
sequence data) welke verschillen rapporteerden tussen puur DCIS en synchroon 
DCIS met invasief borstkanker.10,27 Echter, validatie van onze studie resultaten is 
nodig om te verifiëren of de geïdentificeerde genen geschikt zijn voor predictie op 
progressie naar invasief borstkanker in individuele patiënten met DCIS. Dit zou voor 




behandelstrategie, waar een gerichte inhibitie van de geïdentificeerde genen in 
een vroeg stadium van borstkanker zou kunnen plaatsvinden, hetgeen uiteindelijk 
resulteert in preventie van progressie. In hoofdstuk 5 onderzochten we verschillen 
tussen DCIS en synchroon borstkanker aangaande APOBEC3B genexpressie. Deze 
levels werden ook gecorreleerd met PIK3CA mutatie status. Verhoogde APOBEC3B 
expressie speelt een belangrijke rol bij verschillende soorten kanker, waar het is 
geassocieerd met proliferatie, inclusief PIK3CA en TP53 mutaties.5 Dit enzym is niet-
essentieel (komt niet tot expressie in normaal weefsel), waardoor het mogelijk is 
om verhoogde APOBEC3B levels te remmen met kleine moleculen. In onze analyse 
detecteerden we verhoogde APOBEC3B mRNA levels in zowel DCIS als synchroon 
invasief borstkanker. Er werden geen verschillen gemeten in APOBEC3B levels tussen 
wild-type versus gemuteerde PIK3CA DCIS. Dit in tegenstelling tot de aangrenzende 
invasieve component waar APOBEC3B hoger tot expressie kwam in wild-type 
PIK3CA in vergelijking met gemuteerde PIK3CA. Dit impliceert dat, wanneer het 
invasieve stadium is bereikt, PIK3CA mogelijk een minder belangrijke rol speelt bij 
tumorprogressie. Hogere APOBEC3B levels werden gemeten in synchroon DCIS en 
invasief borstkanker met een ER negatieve receptorstatus vergeleken met ER positieve 
tumoren. Deze bevinding werd ook beschreven in eerdere studies waar verhoogde 
APOBEC3B levels in borstkanker zijn geassocieerd met agressieve kenmerken.6,7-9 
De bevindingen beschreven in dit hoofdstuk suggereren dat APOBEC3B als een 
potentieel therapeutisch doelwit kan fungeren in patiënten met DCIS, echter 
dergelijke enzymatische therapeutische interventie is nog steeds in ontwikkeling. 
Additioneel onderzoek is nodig voor verdere ontwikkeling en exploratie van het 
potentiele voordeel van APOBEC3B blokkers.
Hoofdstuk 6 beschrijft de resultaten van diepgaande sequentie analyse in 
synchroon DCIS en invasief borstkanker met als doel antwoorden te vinden naar het 
onderliggende mechanisme van DCIS progressie. Onze analyse toonde overlappende 
mutaties tussen synchroon DCIS en invasief borstkanker, hetgeen ook eerder werd 
gerapporteerd door voorgaande studies.10,11 Echter, een deel van de geïdentificeerde 
mutaties werd alleen in de invasieve component gedetecteerd, hetgeen impliceert 
dat DCIS progressie wordt gedreven door een selectie van subklonen.10,12 In andere 
woorden, de evolutie van DCIS zou gebaseerd kunnen zijn op het Darwiniaanse 
principe; bepaalde subklonen met specifieke genetische veranderingen worden 
geselecteerd gedurende invasieve groei. Dit resulteert in verschillen in prevalentie 
van specifieke mutaties tussen de neoplastische DCIS cellen en de aangrenzende 
invasieve component. Deze kennis zou toekomstige studies kunnen faciliteren in het 
identificeren van potentiele markers die een belangrijke rol spelen in de transitie van 
DCIS naar invasief borstkanker.
In hoofdstuk 7 evalueerden we de aanwezigheid, karakteristieken en prognostische 
relevantie van voorloper laesies aangrenzend aan invasief borstkanker bij mannen in 
een groot internationaal cohort, aangevuld met moleculair onderzoek. In dit cohort 
van mannen met invasief borstkanker werd bij een aanzienlijk deel van de patiënten 
een aangrenzende DCIS component aangetroffen (46% van de casus), terwijl de 
frequentie van andere voorloper laesies (lobulair carcinoom in situ, atypische ductale 
hyperplasie en cilinder cel laesies) erg laag was (< 1%). Er was een sterke positieve 
correlatie tussen DCIS en de naastgelegen invasieve component voor kerngradering 
(p= <0.001) en een hoge concordantie van ER, PR en HER2 receptorstatus. Deze 
sterk overeenkomende kenmerken tussen synchroon DCIS en invasief borstkanker 
bij mannen, hetgeen ook uitvoerig is beschreven bij vrouwen, impliceert dat DCIS 
inderdaad een voorloper laesie is van borstkanker bij mannen. Dit werd verder 
ondersteund door onze moleculaire analyse in een deel van de casus (n=4), waarbij 
in beide componenten identieke mutaties werden gedetecteerd (PIK3CA, GATA3, TP53 
en MAP2K4). In de literatuur is het bestaan van cilinder cel laesies in de mannelijke 
borst, zoals beschreven bij vrouwen, controversieel. Bij mannen ontbreken specifieke 
morfologische criteria om cilinder cel laesies te definiëren, waardoor het herkennen 
ervan lastig is. In deze grote serie werden echter ducti herkend met overlappende 
kenmerken met cilinder cel laesies zoals beschreven bij vrouwen. NGS toonde 
identieke genetische afwijkingen (inclusief PIK3CA en GATA3 mutaties) tussen de 
cilinder cel laesie en de aangrenzende invasieve component. Deze overeenkomsten op 
zowel morfologisch als genomisch niveau suggereren een mogelijk causaal verband 
tussen deze laesies en ondersteunen de rol van cilinder cel laesies als een voorloper 
laesie in borstkanker bij mannen. Onze analyse betreffende de associatie tussen de 
aanwezigheid van DCIS en prognose toonde dat patiënten met luminaal A en luminaal 
B HER2+ type borstkanker met een aangrenzende DCIS component een betere 
overleving hadden dan patiënten zonder DCIS component. Dit suggereert dat invasief 
borstkanker met een aangrenzende DCIS component bij deze subtypes mogelijk een 
biologisch minder agressieve vorm van borstkanker betreft. In hoofdstuk 8 werd een 
selectie van mannen met borstkanker geëvalueerd waarvan het cohort deels overlapt 
met het cohort beschreven in het vorige hoofdstuk. Voor deze analyse werden invasief 




op DNA copy number veranderingen van 22 borstkanker-gerelateerde genen met 
behulp van multiplex ligatie-afhankelijke probe amplificatie (MLPA). Deze resultaten 
werden vergeleken met een voorgaande analyse van copy nummer veranderingen bij 
vrouwen met borstkanker. Verder werden de copy number afwijkingen gecorreleerd 
met clinicopathologische kenmerken en 10-jaars overleving data. Deze analyse 
toonde een concordante copy nummer status van 21 van de 22 genen tussen invasief 
borstkanker, synchroon DCIS aangrenzend aan invasief borstkanker en puur DCIS. 
Deze bevinding ondersteunt de klonale relatie tussen mannelijke borstkanker en 
aangrenzende DCIS. Verder benadrukt het de genetisch gevorderde status van 
DCIS; copy number veranderingen zijn een vroeg event in de carcinogenese van de 
borst bij mannen. Echter, 1 gen, MTHD, betrokken bij de activatie van verschillende 
signaal cascades inclusief PI3K/Akt, NFκβ, Wnt/βcatenin en de MAPK cascade,13 
demonstreerde een hogere copy number ratio in de invasieve component vergeleken 
met de synchrone DCIS component. In de literatuur wordt dit gen ook beschreven bij 
vrouwelijke borstkanker waar het is geassocieerd met een agressief gedrag,14 hetgeen 
suggereert dat dit gen een belangrijke rol zou kunnen spelen bij de carcinogenese 
van borstkanker bij mannen. Verder toonden enkele genen een hogere frequentie van 
copy nummer afwijkingen in hooggradige laesies vergeleken met laaggradige laesies 
(BIRC5, ESR1 en C11ORF30). In totaal waren 2 van de 22 onderzochte genen, CCNE1 
en CPD gain, geassocieerd met een verlaagde 10-jaars overleving. Echter, het aantal 
casus met deze genetische afwijkingen was klein dus voorzichtigheid is geboden bij 
de interpretatie van deze data. De resultaten van hoofdstuk 7 en 8 dragen bij aan een 
betere kennis van vroegtijdige events bij borstkanker bij mannen.
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DUCTAL CARCINOMA IN SITU: THE JOURNEY TO INVASIVE BREAST CANCER
1. DCIS is een heterogene ziekte
2. Synchroon DCIS en invasief borstkanker hebben veel moleculaire overeen-
komsten, maar zijn niet identiek 
3. Individuele risicoschatting zou een geïntegreerd onderdeel moeten zijn van 
het behandeltraject van patiënten met DCIS
4. DCIS bij mannen is anders dan DCIS bij vrouwen 
5. Onzekerheid leidt tot overbehandeling
6. An ounce of prevention is worth a pound of cure - Benjamin Franklin
7. The more you know, the less you need - Yvon Chouinard
8. You are unique, and if that is not fulfilled, then something has been lost - 
Martha Graham
9. He will manage the cure best who has foreseen what is to happen from the 
present state of matters - Hippocrates
10. You can’t make decisions based on fear and the possibility of what might 
happen - Michelle Obama
11. Een ziekte spreekt voor ieder zijn eigen taal
